GeDIG Legislation and the Sovereignty of the German Digital Health Front Door The Strategic Displacement of Private Platforms: The GeDIG Legislation and the Sovereignty of the German Digital Health Front Door The German digital health landscape is undergoing a structural reconfiguration that threatens to marginalise private intermediaries while centralising patient navigation within a state-governed digital ecosystem. At the center of this transformation is the Gesetz für Daten und digitale Innovation im Gesundheitswesen (GeDIG), a legislative initiative that redefines the electronic patient record (ePA) not merely as a clinical repository, but as the mandatory "digital front door" for the national healthcare system. This policy shift represents a deliberate effort by the Federal Ministry of Health (BMG) to reclaim "digital sovereignty" from commercial platforms like Doctolib and Jameda, which have effectively filled the void left by a decade of stagnation in the official Telematics Infrastructure (TI). The GeDIG Referentenentwurf, or discussion draft, published in early April 2026, codifies a vision where the patient’s entry into care, ranging from initial symptom assessment to specialist appointment booking, is facilitated through an insurer-managed ePA app. This "digital supply entry point" (Digitaler Versorgungseinstieg) is strategically designed to shift patient streams away from commercial search engines and booking platforms toward a regulated, public-sector routing mechanism. For commercial entities, the legislation introduces a dual threat: the direct competition from a state-sponsored front door with a captive user base of 70 million insured citizens, and a new suite of restrictive regulations under 370c SGB V that curtail the monetisation and operational flexibility of private booking services. The Institutional Pivot: From Gematik to the Health Digital Agency The failure of the previous governance model, characterised by the sluggishness of Gematik GmbH, necessitated a radical centralisation of power. The GeDIG facilitates the transformation of Gematik into the Digitalagentur Gesundheit (Digital Health Agency), an entity endowed with sovereign (hoheitliche) powers to dictate standards, certify applications and even enter the market as a provider of critical TI components. This shift is intended to overcome the "veto culture" of the semi-public shareholders that historically hampered digital progress in Germany. Under the new framework, the BMG maintains a 51% majority, ensuring that digital health strategy remains a tool of public policy rather than a consensus-driven compromise between insurers and medical associations. The Agency’s mandate includes the removal of "usage hurdles" and the enforcement of interoperability standards, which are viewed as the necessary infrastructure for the 2030 target of 20 million active ePA users. Governance Dimension Previous Model (Gematik) New Model (Digitalagentur Gesundheit) Legal Status Private Limited Company (GmbH) Public-Law Agency with sovereign powers. Role Coordinator and platform operator Regulator, certifier, and potential provider. Power Structure Consensus-based shareholder model Centralized BMG control (51% majority). Standardization Voluntary adoption of specifications Mandatory "Usability Standards" and orders. Market Entry Strictly neutral infrastructure Can procure and operate services directly. The transformation signifies a move toward a "platform-state" model where the government does not just provide the rails (the TI) but also the trains (the applications) and the stations (the digital front door). The Federal Medical Board (Bundesärztekammer) has expressed significant criticism of this dual role, arguing that an agency that both sets the rules and acts as a market participant creates an inherent conflict of interest that may stifle private innovation. The ePA as the Digital Front Door: Routing, Triage, and the 2030 Vision The most disruptive element of the GeDIG for commercial platforms is the evolution of the ePA into a "Digitaler Versorgungseinstieg." By February 1st, 2028, health insurance companies are required to integrate comprehensive care routing functions into their ePA apps. This is not merely an optional feature; it is intended to become the primary gateway for patients seeking care within the statutory system. Triage Integration and the 116117 Backbone The "digital front door" leverages existing public infrastructure, specifically the 116117 hotline’s triage logic, to provide standardised initial assessments of acute symptoms. This integration aims to steer patients to the most appropriate level of care, whether self-treatment, a general practitioner, or an emergency department, thereby reducing the inefficiency of spontaneous visits to specialists or clinics. While this approach is logically sound for system-wide load balancing, the technical execution faces the skepticism of a user base accustomed to the high-performance UI/UX of private apps. The track record of the ePA, which took nearly two decades to reach basic functionality, suggests that the 2028 deadline for a "smooth" triage experience is ambitious.Furthermore, the system must navigate the "AI-native" expectations of modern patients. While commercial providers like Doctolib are already deploying AI-driven assistants to manage documentation and patient queries, the government-managed system relies on standardised procedures that may lack the flexibility and responsiveness of modern AI implementations. The 2030 Adoption Targets The BMG has set a target of 20 million active ePA users by 2030. This goal is predicated on the shift from an opt-in to an opt-out model, which has already created e-files for approximately 70 million individuals. However, active engagement remains the critical metric. To achieve this, the ePA must move beyond being a "document storage" tool and become a "daily companion" that handles appointment booking and electronic referrals (e-Überweisungen). Functional Milestone Target Date Significance Opt-Out ePA Rollout 2025 Universal creation of digital records for the insured. Digital Identity (EUDI) January 1, 2027 Mandatory use of the EU digital wallet for health ID. Care Routing/Booking February 1, 2028 Mandatory "front door" functions in insurer apps. E-Referral Mandate September 1, 2029 Mandatory digital routing from GP to specialist. Active User Target 2030 Goal of 20 million patients actively using the system. Regulatory Constraints on Private Booking Platforms: Analysis of 370c SGB V The GeDIG does not merely compete with commercial platforms; it actively regulates their business models through the newly proposed 370c of the Fifth Social Code (SGB V). This section targets the specific mechanisms that allowed platforms like Doctolib to dominate the market: convenience, speed and visibility. The Five Prohibitions of 370c The legislation imposes a set of "fairness and neutrality" requirements that strike at the heart of commercial monetisation strategies for appointment booking. These restrictions are designed to ensure that the statutory health system’s resources are allocated based on medical necessity rather than commercial influence. Prohibition of Payment-Influenced Allocation: Platforms are barred from offering any mechanism where healthcare providers can pay for "premium" placement or where patients can pay to be seen faster. This effectively eliminates the "pay-to-play" model that has been a staple of digital marketplaces. Ban on Commercial Third-Party Data Use: The law strictly forbids the sale or utilization of booking data for any purpose other than the booking itself. This prevents platforms from building secondary revenue streams through data analytics or pharmaceutical marketing. Mandatory Ad-Free Environments: Commercial providers cannot "inject" advertisements into the booking process. This ensures that the patient’s path to care remains unbiased and focused purely on medical routing. Transparency of Allocation Logic: Platforms must publicly disclose the algorithms and rules they use to rank providers and allocate appointments. This is a move toward algorithmic accountability, aimed at preventing "dark patterns" that favour specific corporate interests. Official Attestation and Oversight: Compliance with these rules is not self-declared; platforms must undergo verification and attestation by an official body, likely the Digitalagentur or the BSI. The AOK-Bundesverband has strongly welcomed these restrictions, arguing that they correct a historical disadvantage faced by statutory health insurance (GKV) patients who were often bypassed in favour of private patients or those using "premium" digital services. From a competitive standpoint, these rules level the playing field but also significantly reduce the profitability of operating a digital booking service in Germany. Doctolib’s Strategic Response: Pivot to AI and Deep Integration The pervasive question in the German market is whether these legislative pressures will force Doctolib to exit. While the threat to their consumer-facing "front door" dominance is real, the company’s recent activities suggest a pivot toward becoming an "indispensable infrastructure provider" rather than just a booking portal. The "Operating System for the Practice" Doctolib’s "Digital Health Report 2026" outlines a strategic shift toward solving the "administrative burnout" of healthcare professionals (HCPs). With the ambulant care coverage expected to drop to 74% of current levels by 2040 due to physician aging, the company is positioning its AI-native tools as the only viable solution for practice survival. The company has introduced a suite of AI-native products designed to operate "behind the front door": AI Consultation Assistants: These tools are reported to save 70% of documentation time, potentially returning 10–20 hours of time per week to medical staff. AI Phone Assistants: Aimed at reducing reception interruptions by 60%, these tools address the "lost call" problem that plagues German medical practices. ISO and BSI Compliance: By securing C5 attestation from the BSI and ISO 27701 certifications, Doctolib has built a "compliance moat" that makes it difficult for the state to exclude them from the TI ecosystem on security grounds. Regional and Institutional Partnerships Doctolib is also moving toward deep institutional integration. In March 2026, the company announced a partnership with the "Modellregion Gesundheit Lausitz" to act as the digital backbone for a leading hospital system. This "bottom-up" integration strategy, where the platform becomes the essential workflow tool for large clinics and regional health clusters, provides a hedge against the "top-down" pressure from the BMG’s ePA front door. A "second-order" insight here is that while the BMG can mandate the entry point (the ePA app), it has less control over the internal workflows of medical practices. If Doctolib remains the primary tool for managing calendars, patient records, and documentation within the practice, the ePA app will ultimately have to "hand off" the patient to Doctolib’s backend. This makes an exit unlikely; instead, Doctolib is transforming from a public-facing portal into a specialised medical B2B software provider. Insurer Empowerment: Data Proactivity and Reallabore The GeDIG significantly expands the operational mandate of health insurers, allowing them to move from passive payers to proactive health managers. This shift is enabled by two key legal mechanisms: the expansion of § 25b SGB V and the creation of "experimental labs" under 284a. Predictive Analytics and Preventive Outreach Insurers are now permitted to use their vast billing datasets and, with one-time consent, ePA data to identify patients at high risk for chronic conditions such as cardiovascular disease or dementia. They can then issue digital invitations for early screening or offer individualized care services via the ePA app. This proactively bypasses the traditional "wait-and-see" model of care, but it also places the insurer in a more direct, steering relationship with the patient—a role historically reserved for the primary care physician. Experimental Labs (Reallabore) The introduction of "Reallabore" (Section 284a) allows insurers to test innovative data processing techniques for up to nine years. These labs provide a legal "sandbox" where data usage can exceed the standard restrictions of the SGB V, provided there is coordination with supervisory authorities. This represents a significant concession to the "Big Data" ambitions of the Krankenkassen, who aim to use machine learning to predict health risks and optimise resource allocation. Policy Feature Legal Basis Objective Expanded Prevention § 25b SGB V Data-based outreach for cardiovascular/dementia risks. Experimental Labs § 284a SGB V 9-year sandbox for innovative data processing. Clinical Trial Alerts § 345b SGB V Notifying patients of eligible clinical trials via ePA data. Data Enrichment SGB V (GeDIG) Insurers can add non-clinical data (smoking status, exercise) to ePA. The Implementation Challenge: Interoperability and the GP Gatekeeper The success of the "digital front door" relies on two factors that have historically been weak in the German system: technical interoperability and the capacity of general practitioners (GPs) to act as digital gatekeepers. Interoperability and TI 2.0 The Bvitg (Federal Association of Health IT) has repeatedly emphasized that the transition to "TI 2.0" must move away from hardware-based connectors toward cloud-based, provider-independent solutions. The GeDIG grants the Digitalagentur the power to mandate international standards like FHIR and HL7, but the legacy systems in thousands of medical practices remain a significant bottleneck. If the e-referral from the ePA app cannot be seamlessly read by the specialist's local practice management system (PVS), the "digital front door" will lead to a dead end. The GP Bottleneck The GeDIG vision is intrinsically linked to a "primary care physician system" where the GP serves as the central hub for all specialist referrals. Starting in September 2029, the system will mandate that specialised care is only accessible via digital referrals issued by the GP. While this is intended to reduce "over-care" and duplication, it risks overwhelming GPs who are already facing a workforce crisis. Without the integration of AI tools, the very tools the private sector is currently developing, the GP gatekeeper model could lead to longer wait times and decreased patient satisfaction, undermining the goal of 20 million active users. Financial and Economic Implications The transformation of the ePA into a functional front door is a multi-billion euro undertaking. The BMG estimates that the move to an opt-out ePA alone will cost insurers €114 million per year, with additional millions required for telemedicine development and the management of the Innovationsfonds. Furthermore, the "bureaucratic debt" of the analog era must be paid. The GeDIG requires medical practices to digitize legacy paper records for their patients, an effort projected to cost the system roughly €1.5 million in the initial phase alone. For the broader economy, however, the BMG predicts a net relief of €4.2 million per year through the reduction of administrative effort, provided the digital systems work as intended. Financial Category Estimated Cost / Impact Source of Funding / Impact ePA Yearly Operation €114 Million Statutory Health Insurance Funds. Telemedicine (2026-28) €24 Million Performance-based insurer spending. Innovationsfonds €200 Million/year 50% GKV, 50% Liquidity Reserve. Economic Relief €4.2 Million/year Reduced administrative burden on the economy. Legacy Digitization €1.5 Million (initial) One-time effort for providers/insurers. Synthesis and Strategic Outlook The GeDIG represents a "hard reset" of the German digital health strategy. By centralising governance in the Digitalagentur Gesundheit and mandating the ePA as the "digital front door," the BMG is attempting to bypass the slow-moving consensus models of the past. For commercial booking platforms, the era of unregulated growth in the German market is over. The 370c restrictions will force a transformation of their business models, likely leading them away from consumer-facing search and toward deep, AI-driven practice management software. The primary risk remains the "UX gap." If the public-sector ePA app remains a clunky, bureaucratic tool, the 20 million active user target will remain out of reach, regardless of the legal mandate. The government’s challenge is to build a "front door" that is not just a regulatory requirement, but a superior product. Conversely, private players like Doctolib must innovate faster than the state can regulate, finding value in the "back-office" complexities that the centralised ePA is not yet equipped to handle. In the long term, the GeDIG may not result in an "exit" for private platforms, but in a "forced convergence." We are likely to see a tiered ecosystem where the public "front door" (the ePA) provides the basic routing and triage services, while private "clinical operating systems" (Doctolib, Jameda) provide the AI-powered productivity tools that allow the medical practices behind those doors to function in an era of extreme personnel shortages. The battle for the German patient is no longer about who has the best booking button, but who controls the data-driven intelligence that makes care possible. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors 20 Future European HealthTech and MedTech Series 2026 Nelson Advisors have researched 20 future Healthtech and MedTech leaders in 20 European countries, highlighting the founders, scientists and technologists building innovative solutions and companies. In addition to the 20 x 20 Series, we have also predicted 3 HealthTech and MedTech hubs across Europe with the potential to become centres of excellence. Ghent, Porto, Wroclaw: Future European HealthTech and MedTech Hubs https://www.healthcare.digital/single-post/ghent-porto-wroclaw-future-european-healthtech-and-medtech-hubs The European medical technology and healthcare innovation landscape is currently traversing a period of profound structural realignment, characterised by a transition from speculative digital fragmentation toward a model of industrial maturity and regulatory rigor. As the global MedTech market is projected to expand from a valuation of $549.5 Billion in 2025 to approximately $853.4 Billion by 2035, growing at a compound annual growth rate (CAGR) of 4.5%, the European theatre is emerging as a critical frontier for high-conviction investment and clinical validation. This transformation is driven by a convergence of high medical trend rates, which are expected to reach 11.68% globally in 2025, and a persistent workforce crisis that has seen burnout rates among medical staff climb to 63% in regions like Spain and 36% in France. Consequently, three specific European hubs, Ghent in Belgium, Porto in Portugal, and Wroclaw in Poland are manifesting as primary centres of excellence, leveraging unique combinations of institutional heritage, sovereign funding and technological specialisations in robotics, genomic data and artificial intelligence (AI). 20 Future Slovakian HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-slovakian-healthtech-and-medtech-leaders The Slovakian healthcare technology ecosystem has transitioned from a period of nascent development into a sophisticated phase of global integration and scientific leadership. This evolution is not a localised phenomenon but rather a strategic realignment of Central and Eastern Europe (CEE) as a hub for high-precision biotechnology and digital health. At the heart of this transformation are 20 key individuals, founders, researchers and institutional leaders, whose work in artificial intelligence, molecular diagnostics and therapeutic platforms is redefining the boundaries of clinical medicine. This report examines these leaders not merely as successful entrepreneurs but as the architects of a data-driven, patient-centric healthcare infrastructure that leverages Slovakia's deep academic heritage in biochemistry and engineering. 20 Future Hungarian HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-hungarian-healthtech-and-medtech-leaders The landscape of Hungarian healthcare innovation has transitioned from a historical foundation of pharmaceutical excellence into a dynamic, multi-disciplinary ecosystem defined by medical deep tech, artificial intelligence and sophisticated biotechnology. This transformation is anchored by a strategic shift in the country’s academic and financial infrastructure, moving toward a "fourth-generation" research model where knowledge transfer and commercialization are prioritized alongside academic inquiry. Between 2015 and 2025, over €925 million in venture capital flowed into the Hungarian startup ecosystem, with the life sciences sector, encompassing pharmaceuticals, biotechnology and MedTech, securing a significant portion of this investment. This growth is not accidental but is the result of a coordinated effort by state agencies, university-led technology transfer centres and a new generation of scientists-turned-entrepreneurs who are bridging the gap between the laboratory bench and the patient's bedside. 20 Future Greek HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-greek-healthtech-and-medtech-leaders The Greek innovation ecosystem has entered a period of structural maturation, characterised by a transition from nascent digital adoption to the creation of globally competitive deep-tech enterprises. As of 2025, the Greek startup ecosystem is valued at approximately $4.2 billion, with Athens emerging as a significant node in the global innovation network, ranking 120th worldwide and 26th in Western Europe. This evolution is underpinned by the "Digital Transformation Bible 2020–2025," a foundational policy framework that has prioritised the modernisation of public health services through the deployment of "digital rails," such as the national e-Prescription system and the MyHealth mobile application operated by IDIKA S.A.. Furthermore, the 2024 National AI Strategy, "A Blueprint for Greece’s AI Transformation," has established a dedicated layer for artificial intelligence in healthcare, fostering an environment where scientific excellence from institutions like the Foundation for Research and Technology-Hellas (FORTH) and the National Centre for Scientific Research "Demokritos" can be commercialised effectively. The financial engine driving this transformation is increasingly robust. In 2025, total capital raised by Greek startups exceeded €732 million, representing a 35% increase over 2024 levels. Within this landscape, HealthTech has emerged alongside AI and SaaS as a primary vertical for investment, attracting over 143 unique investors from around the globe.The rise of growth-stage capital, exemplified by the €130 million Big Pi Growth fund, has begun to address the historical "growth gap," allowing promising Greek ventures to scale their operations internationally while maintaining significant R&D and operational bases within the country. This report identifies twenty future leaders, startups, spin-offs and visionary researchers, who are currently defining the frontiers of Greek healthtech and medtech. 20 Future Estonian HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-estonian-healthtech-and-medtech-leaders The emergence of Estonia as a preeminent global centre for health technology and medical engineering is a phenomenon predicated on the strategic synthesis of high-fidelity genomic data, a sophisticated digital identity infrastructure and a robust entrepreneurial ecosystem that prioritises clinical validation alongside technological scalability. The transition from traditional reactive medical models, often characterised as "sick-care", toward a proactive, personalised, and predictive health economy is driven by a cohort of leaders who bridge the gap between academic rigour and commercial viability. As the Estonian healthtech sector moves toward its "Vision 2035," which anticipates a high-density environment of science-based startups and a significant increase in healthy life years for the population, twenty specific individuals have surfaced as the architects of this transformation. This report provides an analysis of these twenty future leaders, their technical contributions and the strategic implications of their work for the global healthcare landscape. 20 Future Czech HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-czech-healthtech-and-medtech-leaders The healthcare technology and medical device sectors in the Czech Republic have reached a critical inflection point in 2026, transitioning from a regional innovation hub into a sophisticated global contender. This evolution is defined by a shift in capital allocation strategies, moving away from fragmented, early-stage experimentation toward a disciplined focus on profitability, clinical validation and scalable business models. As of early 2026, the European healthtech market, valued at approximately $96.68 billion, is navigating a period of strategic evolution influenced by a reorientation of investor priorities. Within this context, the Czech ecosystem, centred largely in the innovation corridors of Prague and Brno, has distinguished itself through a high concentration of deep tech expertise, robust academic spin-off frameworks, and a successful navigation of the rigorous European Medical Device Regulation (MDR). The resilience of the Czech sector is evidenced by its ability to secure significant funding rounds despite a 7.7% year-on-year decline in total investment for Czech founded startups in 2025, which totalled approximately €540 million. Notably, the healthtech vertical remained a cornerstone of this activity, with high-conviction "mega-deals" and strategic pre-seed rounds signaling a maturation of the ecosystem. This report identifies and analyses 20 pivotal leaders whose vision and technical execution are shaping the future of Czech healthtech and medtech, categorised by their impact on diagnostic intelligence, chronic disease management, advanced biotechnology and the burgeoning field of digital resilience. 20 Future Portuguese HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-portuguese-healthtech-and-medtech-leaders The Portuguese healthtech and medtech landscape has reached a state of systemic maturity, transitioning from a localized cluster of academic spin-offs to a formidable international player in precision medicine, digital surgery, and biotechnology. By the mid-2020s, the national startup ecosystem recorded a 16% increase in active ventures, totalling over 4,700 companies, of which nearly 70% were founded within the preceding five-year window. This acceleration is not merely numerical but represents a qualitative shift toward high-complexity "Deep Tech" and "Fusion Research," where the barriers between laboratory investigation and clinical implementation are systematically dismantled. The influx of venture capital, reaching €886 million in 2024, a 55% increase over previous years, has provided the necessary liquidity for Portuguese leaders to compete on a global stage, particularly in AI-driven care and sustainable biotechnology. 20 Future Swiss HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-swiss-healthtech-and-medtech-leaders The Swiss life sciences sector has entered a transformative era in 2025 and 2026, characterised by a fundamental shift from traditional pharmaceutical dominance toward a highly integrated "deep tech" health ecosystem. This evolution is underpinned by a robust venture capital environment that saw high-tech investments rise by 23.9% to CHF 2.9 billion in 2025, despite broader global economic uncertainties and sluggish growth in export-oriented industries. Within this capital influx, the medtech and biotech sectors have emerged as the most resilient pillars, driven by the unparalleled efficiency of the Swiss academic engine, specifically the Swiss Federal Institutes of Technology in Zurich (ETH Zurich) and Lausanne (EPFL). The record-breaking creation of 46 new ventures from ETH Zurich in 2025 serves as a testament to the maturation of the university spin-off model. This model is no longer merely about patent licensing but represents a comprehensive institutional commitment to commercializing research through formalized pathways like the ETH Pioneer Fellowship and the newly launched "Express Licensing" procedure. This procedure, which provides a standardized, negotiation-free license within six to eight weeks in exchange for a modest 2% equity stake, has drastically reduced the barriers to entry for scientific founders. Consequently, Swiss academic institutions now rank among the top ten globally for spin-off value creation, outperforming larger economies on a per-capita basis. However, the ecosystem faces a structural "late-stage gap," where approximately 96% of late-stage capital originates from international sources. This has necessitated a strategic focus on global expansion, particularly into the United States market. The Venture Leaders Medtech program, which selects the "Swiss National Startup Team" for an intensive roadshow in Boston, serves as a critical bridge for these 20 leaders as they transition from pre-clinical prototypes to market-ready clinical solutions. 20 Future Belgian HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-belgian-healthtech-and-medtech-leaders The Belgian healthcare innovation landscape has undergone a tectonic shift over the last decade, evolving from a traditional pharmaceutical stronghold into a globally recognised "Health and Biotech Valley". This maturation is not merely a product of historical legacy but the result of a deliberate, multi-layered strategy involving institutional catalysts, regional specialisation and a robust venture capital framework that prioritises deeptech inter-d isciplinarity The convergence of biotechnology, medical devices (MedTech) and digital health solutions has created an environment where the boundaries between hardware, software and biology are increasingly porous. 20 Future Norwegian HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-norwegian-healthtech-and-medtech-leaders The Norwegian life sciences landscape is currently undergoing a systemic transition, evolving from a research-intensive academic environment into a globally integrated commercial powerhouse. This metamorphosis is facilitated by a unique confluence of high-trust public health data, a robust sovereign wealth environment and a maturing infrastructure of specialised clusters such as Norway Health Tech, the Oslo Cancer Cluster and Aleap. As the global healthcare market increasingly demands precision medicine, decentralised care models and AI-augmented diagnostics, Norway has positioned itself as a "forerunner" region. This status is characterised by a "human scale" that allows for rapid testing and validation of sophisticated technologies within a public healthcare system, often referred to under the regional identity of "HealthFjords". The following report provides an analysis of twenty future leaders within this sector, the technological breakthroughs they oversee and the second-order socio-economic impacts of their work on the global stage. 20 Future Romanian HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-romanian-healthtech-and-medtech-leaders The technological landscape of Romania has experienced a seismic shift between the fiscal years of 2024 and 2026, transitioning from a secondary outsourcing destination into a primary forge for high-valuation HealthTech and MedTech intellectual property. This metamorphosis is not merely anecdotal; it is substantiated by a radical escalation in capital inflow and a strategic pivot toward "Born Global" enterprises that prioritise international scalability from their inception. The year 2025 stands as a historical inflection point for the region, where a single landmark financing event, the $165 Million Series C round for the robotics firm Dexory, nearly equaled the entire venture capital output of the Romanian ecosystem in 2024. This surge in liquidity, backed by global institutional heavyweights such as Atomico, Eurazeo and Lakestar, signals that the operational ceiling for Romanian-founded companies has been permanently elevated, transitioning the narrative from a regional hub to a consistent producer of global category leaders in medical and assistive technologies. The maturation of the sector is further evidenced by the increasing density of DeepTech and AI-native startups. By early 2026, the Romania Tech Startup Association (ROTSA) and accelerators like Techcelerator had mapped over 100 artificial intelligence startups with Romanian roots, many of which are dedicated to solving high-complexity problems in oncology, radiotherapy, microbiome analysis and feline longevity. This report analyses 20 such leaders, representing a mix of high-growth scale-ups, innovative pre-seed ventures and visionary individuals who are redefining the intersection of healthcare and technology. Nelson Advisors 20 Future European HealthTech and MedTech Series 2026 20 Future Finnish HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-finnish-healthtech-and-medtech-leaders The Finnish healthcare technology sector has undergone a profound transformation, evolving from a niche engineering discipline into the nation's most significant high-tech export industry. By early 2026, the sector has established itself as a global paradigm for how a small, digitally advanced nation can leverage longitudinal data and institutional trust to solve systemic global healthcare challenges. This transition is anchored in a unique structural advantage: a century of digitised health data and a legislative framework that permits the ethical, secondary use of this data for research and development. As global healthcare systems grapple with acute staffing shortages, aging populations, and rising costs, the Finnish ecosystem offers a blueprint for data-driven, human-centric innovation. 20 Future Irish HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-irish-healthtech-and-medtech-leaders The Republic of Ireland has established a formidable global position within the medical technology and digital health sectors, characterised by a unique synthesis of indigenous entrepreneurial agility and high-density multinational presence. As of 2025, the sector generates approximately €16 Billion in annual exports, representing 14% of the nation’s total export economy. With over 700 life sciences and health technology firms, more than 400 of which are homegrown, Ireland has successfully leveraged its academic research infrastructure and favourable venture capital environment to become the largest employer of MedTech professionals per capita in Europe. In 2024, the ecosystem reached a decade-high record in venture capital investment, securing €491.3 million across 89 deals, even as global life sciences funding experienced a dramatic contraction. This resilience is largely attributed to the maturing profile of the cluster, where late-stage and venture-growth deals now constitute 46% of total volume, reflecting a shift from speculative early-stage ventures to clinically validated, scalable platforms. This report analyses the twenty leaders and organisations at the vanguard of this evolution, examining the technological mechanisms, leadership backgrounds and market dynamics that define the next wave of Irish healthcare innovation. 20 Future Polish HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-polish-healthtech-and-medtech-leaders The Polish healthcare technology ecosystem has transitioned from a localised secondary market into a primary driver of European deep-tech innovation as of the first quarter of 2026. This transformation is underpinned by a structural shift from traditional software development to the application of advanced artificial intelligence, multimodal biological simulations, and high-precision medical hardware. Currently, Poland hosts over 3,300 active startups, with the Warsaw and Kraków hubs serving as the principal gravity centers for venture activity and technical talent. The sector's expansion is validated by significant capital inflows; in 2025, venture capital investment reached approximately PLN 3.4 Billion (~EUR 800 Million) across 180 distinct transactions, a momentum that has rallied into the current fiscal year. The institutional backbone of this growth is reinforced by the launch of "Future Tech Poland," a €350 Million fund-of-funds initiative spearheaded by the European Investment Fund (EIF) and Bank Gospodarstwa Krajowego (BGK). This program provides critical liquidity for high-tech ventures at various stages of growth, emphasising the Polish government’s commitment to establishing the nation as a global tech hub and enhancing the competitiveness of the European Union’s fifth-largest economy. Within this fertile landscape, a cadre of twenty leaders and their respective organisations have emerged as the vanguard of the Polish HealthTech and MedTech renaissance. 20 Future Icelandic HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-icelandic-healthtech-and-medtech-leaders The Icelandic healthcare technology (HealthTech) and medical device (MedTech) sectors have entered a period of unprecedented expansion, transitioning from a localised research infrastructure into a globally competitive innovation hub. This evolution is fundamentally rooted in the unique intersection of Iceland’s high-fidelity genomic data, a single-payer nationalised healthcare system, and a robust academic-clinical nexus centered at the University of Iceland and Landspítali University Hospital. Historically known for pioneering work in population genetics through deCODE genetics, the contemporary Icelandic ecosystem has matured, giving rise to a new generation of leaders who are leveraging artificial intelligence (AI), advanced biotechnology and digital health platforms to address global medical challenges. The emergence of Kerecis as the nation’s first "unicorn", achieving a $1.3 Billion valuation upon its acquisition by Coloplast, serves as a definitive proof-of-concept for the Icelandic model of innovation, catalysing increased venture capital interest and proving that a small-market environment can produce world-leading medical solutions. 20 Future Italian HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-italian-healthtech-and-medtech-leaders The Italian life sciences ecosystem has entered a period of profound structural transformation, transitioning from a cluster of high-quality specialised manufacturers into a primary engine of European medical innovation. Historically recognised as the fourth-largest medical device market in Europe, Italy is now characterised by a surge in venture capital activity, strategic international partnerships and a regulatory environment that is increasingly favourable to high-growth scale-ups. The convergence of the National Recovery and Resilience Plan (PNRR), which allocates significant capital to healthcare digitalisation and the emergence of institutional investors such as CDP Venture Capital and Angelini Ventures, has created a fertile ground for "soonicorns" positioned for high-value exits or massive fundraising rounds. As of early 2026, the Italian market size for medical devices and technology stands at approximately $13.04 Billion, with a robust local production value exceeding $10.3 Billion. However, the real story lies in the shift toward "intelligent" healthcare: surgical robotics, gene therapies, neurotechnology, and AI-driven preventative platforms. This report identifies 20 companies that represent the vanguard of this shift, each demonstrating the technical defensibility and commercial traction required to attract global strategic acquirers and institutional growth capital. 20 Future Spanish HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-spanish-healthtech-and-medtech-leaders The Spanish healthcare technology landscape entering 2026 is defined by a transition from a nascent, fragmented ecosystem into a phase of "industrial maturity". This evolution is characterised by a disciplined approach to capital allocation, a focus on measurable clinical outcomes and the emergence of regional hubs that are increasingly competitive on a global scale. While historically overshadowed by the larger hubs of London, Paris and Berlin, the Spanish market, led by Catalonia, Madrid, and Valencia, has demonstrated a unique resilience and a high capacity for scientific production, particularly in biotechnology and advanced therapies. In 2025, the sector reached a milestone with €517 Million invested in health startups and scale-ups in Catalonia alone, reflecting a 43% year-on-year increase and signalling a robust resurgence in investor confidence following the post-pandemic correction. This maturity is further underscored by the shifting patterns of funding. While the absolute number of deals may have stabilised or slightly declined in certain subsectors, the average ticket size has increased dramatically. In 2025, venture capital remained the primary engine of growth, yet the market saw the return of "mega-deals" and concentrated late-stage rounds, where nearly 47% of total capital was raised by just three standout operations. This concentration suggests that investors are no longer making speculative bets across a wide range of early-stage ventures but are instead doubling down on "soonicorns" that have successfully built "compliance moats" around their core technologies, particularly in response to the full enforcement of the EU AI Act in March 2026. The strategic importance of the Spanish ecosystem is also tied to the broader European goal of "strategic autonomy" in health and life sciences. With the pharmaceutical industry committing to €9 Billion in investments in Spain between 2023 and 2025, the synergy between established multinational corporations and agile technology startups has become a critical driver for clinical research and production leadership. Spain now ranks first in Europe in the percentage of high-impact scientific articles and fourth in Europe for the number of active clinical trials, providing a fertile ground for companies focused on clinical trial optimisation and data-driven drug discovery. 20 Future Swedish HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-swedish-healthtech-and-medtech-leaders The Swedish medical technology and digital health ecosystem is currently navigating a pivotal transition from early-stage innovation toward global commercial scale. As of 2025, the sector is defined by a robust convergence of computational biology, artificial intelligence, and decentralised care models, positioning Sweden as a primary engine of the European "TechBio" movement. The industry comprises over 2,100 medtech companies, which, alongside the broader life science sector, generated approximately $46.8 Billion in net turnover in 2022, a 54 % increase compared to 2014. This growth is supported by a highly specialised workforce that has expanded by 18% since 2019, reflecting the sector's resilience and its role as the second-largest export sector in Sweden, accounting for nearly 10 percent of total product exports. The national strategic framework is anchored by "Vision for eHealth 2025," an ambitious government initiative aimed at making Sweden the world leader in leveraging digitalization to provide equitable, high-quality healthcare. This vision is underpinned by substantial regional investments in IT infrastructure, totalling approximately $1.22 Billion annually.Furthermore, the decentralisation of care is accelerating, with the home healthcare market projected to reach $8.1 Billion by 2030, representing a compound annual growth rate (CAGR) of 10.3 percent from 2025 to 2030. While digital services currently represent the largest revenue segment, equipment and remote monitoring technologies are identified as the most profitable and fastest-growing categories. 20 Future Austrian HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-austrian-healthtech-and-medtech-leaders The European healthcare technology and medical technology sectors enter 2026 at a profound inflection point, moving from a period of post-pandemic recalibration to what market analysts describe as an era of "industrial maturity". Within this broader continental shift, Austria has emerged as a particularly disciplined and resilient hub for innovation. While the speculative fragmentation of the early 2020s led to detached valuations, the current vintage of Austrian startups is defined by a rigorous focus on unit economics, clinical validation and regulatory foresight. This report provides an analysis of the Austrian healthtech and medtech ecosystem, identifying twenty specific companies that are uniquely positioned for high-growth trajectories, significant venture capital infusions, or strategic acquisition by global incumbents. 20 Future Danish HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-danish-healthtech-and-medtech-leaders The Danish healthtech and medtech sectors have entered 2026 as the primary engine of Northern Europe’s innovation economy, characterised by a transition from the speculative fragmentation of the early 2020s toward a period of profound industrial maturity. This evolution is underpinned by a robust national infrastructure, most notably the Medicon Valley cluster, which spans Eastern Denmark and Southern Sweden and houses one of the most concentrated life science ecosystems globally. In 2026, the sector is defined by a rigorous focus on "Industrialisation," where venture capital and private equity firms have moved beyond "growth at all costs" metrics toward the "Rule of 40 + Data," prioritising assets that balance scale with unit-level profitability and defensible, proprietary clinical datasets. The institutional backbone of this ecosystem has been further fortified by massive capital injections. The Novo Nordisk Foundation’s allocation of DKK 5.5 billion (approximately EUR 736 million) to the BioInnovation Institute (BII) through 2035 represents a generational commitment to scaling deep-tech and life science startups into global category leaders. This funding frame specifically prioritises the intersection of biotechnology with artificial intelligence and quantum technologies, fields where Denmark maintains a disproportionate competitive advantage due to its unique health data infrastructure. As of early 2026, Denmark leads Europe in digital public services and research and development (R&D) intensity, facilitated by the universal application of the personal identifier (CPR number) which allows for cradle-to-grave longitudinal health data linkage—a critical asset for AI-driven diagnostic and therapeutic platforms. 20 Future Dutch HealthTech and MedTech Leaders https://www.healthcare.digital/single-post/20-future-dutch-healthtech-and-medtech-leaders The Dutch healthcare technology and medical technology landscape entering 2026 stands at a profound inflection point, characterised by a definitive transition from the speculative fragmentation of the early 2020s toward a disciplined era of industrial maturity. Following a period of structural recalibration in 2024 and a tentative recovery in 2025, the market is currently experiencing a robust, albeit structurally transformed, resurgence in capital deployment and mergers and acquisitions. The defining thesis for 2026 is the concept of "Industrialisation," which signifies a departure from the "growth at all costs" paradigm that defined the Zero Interest Rate Policy era. In this current cycle, the cost of capital remains elevated, forcing a rigorous recalibration of investment criteria toward unit economics and measurable clinical impact. The Netherlands has positioned itself as a top-tier hub for innovation, yet it faces a rapidly changing global environment where ambition alone is no longer sufficient to maintain a leading position. Deeptech remains the Dutch ecosystem's powerhouse, producing 41% of all scaleups and attracting the majority of venture capital in 2025. However, a significant "AI Paradox" persists; despite having the highest density of AI talent in Europe, the Dutch conversion rate of AI startups to scaleup status is only a quarter of the rate seen in the United States. This gap is a primary focus of national strategic initiatives aimed at securing the country's long-term growth through 2035. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Slovakian HealthTech and MedTech Leaders The Vanguard of Central European Healthcare: An Analysis of 20 Future Slovakian HealthTech and MedTech Leaders The Slovakian healthcare technology ecosystem has transitioned from a period of nascent development into a sophisticated phase of global integration and scientific leadership. This evolution is not a localised phenomenon but rather a strategic realignment of Central and Eastern Europe (CEE) as a hub for high-precision biotechnology and digital health. At the heart of this transformation are 20 key individuals, founders, researchers and institutional leaders, whose work in artificial intelligence, molecular diagnostics and therapeutic platforms is redefining the boundaries of clinical medicine. This report examines these leaders not merely as successful entrepreneurs but as the architects of a data-driven, patient-centric healthcare infrastructure that leverages Slovakia's deep academic heritage in biochemistry and engineering. The Intersection of Clinical Cardiology and Computational Intelligence Cardiovascular diseases remain the primary driver of global mortality, and the Slovakian ecosystem has emerged as a specialised center for solving the "time-to-intervention" problem through artificial intelligence. This specialisation is represented by a cluster of leaders who have successfully bridged the gap between the cardiology ward and the software laboratory. 1) Martin Herman and Robert Herman: The Architects of PMcardio The most visible figures in the current Slovakian MedTech landscape are Martin Herman and Robert Herman, the co-founders of Powerful Medical. Their leadership has propelled the company from a domestic startup into a formidable international entity with operations in 16 European markets. Robert Herman, serving as the Chief Medical Officer, provides the clinical and scientific ballast for the organisation. His role on the Research, Digital and Innovation Committee for the European Society of Cardiology underscores the high-level integration of the company into the continent’s medical policy-making bodies. Their flagship product, PMcardio, represents a paradigm shift in emergency diagnostics. As a CE-certified Class IIb EU MDR medical device, it utilizes deep learning algorithms trained on millions of clinical outcomes to interpret electrocardiograms (ECGs) across 39 different indications. The clinical impact of their leadership is quantifiable; the implementation of their care coordination platform has demonstrated a 13-hour reduction in door-to-balloon time for heart attack patients and a 67% decrease in false-positive catheterisation laboratory activations. These metrics are not merely operational efficiencies; they represent a fundamental improvement in patient survival rates and a reduction in the economic burden of unnecessary procedures. The financial trajectory of Powerful Medical further illustrates the maturity of their leadership. In 2024, they secured a €2.5 million grant and a €5 million follow-on investment from the European Innovation Council (EIC), followed by a massive €40 million IPCEI grant. This capital injection is being utilised to fund multi-centre randomised controlled trials (RCTs) across three countries, providing the high-level clinical validation required for a planned entry into the United States market. The Hermans have demonstrated that Slovakian MedTech can compete for the most prestigious and competitive innovation funding in the European Union, positioning Bratislava as a primary node in global AI cardiology. 2) Dr. Roman Bohac: Digitising the Acute Care Pathway While Powerful Medical focuses on diagnostic interpretation, Dr. Roman Bohac, the founder of STEMIglobal, has focused on the operational and communicative gaps in emergency medicine. Founded in 2017, STEMIglobal addresses the critical "golden hour" in cardiovascular and stroke care. Bohac’s leadership has been characterised by a focus on "democratising" access to specialists. The STEMI platform enables paramedics in rural or pre-hospital settings to share real-time ECG data and clinical information with specialised cardiology or stroke centres. This intervention addresses a systemic causal relationship between geographical location and clinical outcomes. By ensuring that a specialist can review a patient’s status before they arrive at the hospital, Bohac has effectively shifted the triage process from the emergency room to the ambulance. This digitisation of the acute care pathway is a necessary precursor to the widespread adoption of AI tools like PMcardio, as it builds the tele-medical infrastructure required for real-time data exchange. 3) Allan Böhm and Nikola Jajcay: The Personalisation of Preventive Cardiology The work of Allan Böhm and Nikola Jajcay at Seerlinq represents the third pillar of the Slovakian cardiovascular cluster: long-term, personalised monitoring. While the Hermans and Bohac focus on acute events, Seerlinq utilises machine learning to analyse photoplethysmogram (PPG) signals, the pulse data captured by ubiquitous wearable devices, to personalise the treatment and diagnostics of cardiovascular diseases. The strategic implication of Seerlinq’s work is the transition of cardiology from a reactive to a proactive specialty. By identifying subtle changes in PPG signals that may precede a clinical event, Böhm and Jajcay are providing tools that allow for medication adjustments and lifestyle interventions in a home-care setting. This aligns with broader European health trends toward "bringing care home," a priority identified by EIT Health as occupying $46\%$ of recent innovation submissions. Leader(s) Organisation Primary Technology Market Focus Funding / Recognition Martin & Robert Herman Powerful Medical AI-ECG Analysis Global (EU/US) €47.5M+ (EIC/IPCEI) Dr. Roman Bohac STEMIglobal Tele-Medical Triage CEE / Middle East EIT Health RIS Participant Allan Böhm & Nikola Jajcay Seerlinq ML PPG Analysis Personalized Care Seed Stage Pioneers in Molecular Diagnostics and Precision Oncology The Slovakian scientific community has long excelled in chemistry and molecular biology, a heritage that is now being commercialised through a new generation of leaders focusing on non-invasive cancer diagnostics. These individuals are moving beyond the traditional reliance on tissue biopsies toward a "liquid biopsy" paradigm that utilises advanced proteomics and glycomics. 4) Pavol Cekan: The Global-Local Catalyst for Precision Oncology Dr. Pavol Cekan, the founder and CEO of MultiplexDX, is perhaps the most influential bridge between the global scientific community and the Slovakian innovation ecosystem. With over 15 years of experience at institutions such as Rockefeller University and the National Cancer Institute, Cekan brought world-class expertise in nucleic acid chemistry back to Bratislava. His work is centred on eliminating cancer misdiagnosis through a dual-technology approach that combines RNA fluorescence in situ hybridisation (RNA FISH) and RNA sequencing (RNAseq). This cross-validation method provides oncologists with a 98% accurate, quantitative profile of a patient's cancer markers, enabling the prescription of highly personalized treatment regimens. Beyond his work in oncology, Cekan’s leadership during the COVID-19 pandemic demonstrated the strategic importance of domestic diagnostic capabilities. MultiplexDX developed nine different RT-PCR and LAMP tests, which were registered and distributed in 26 countries. His public service, recognised by the Order of Ľudovít Štúr II. class, has elevated the profile of Slovakian science to a level of national priority. 5) Jan Tkac and Tomas Bertok: Deciphering the Glycocode Drs. Jan Tkac and Tomas Bertok, the founders of Glycanostics, represent the pinnacle of academic-to-commercial translation in Slovakia. Both recipients of the "Scientist of the Year" award, they established Glycanostics in 2017 to bring their research on glycobiology to the diagnostic market. Their work focuses on glycan changes, complex carbohydrate structures, attached to specific proteins such as the Prostate-Specific Antigen (PSA). The significance of their technology lies in its ability to overcome the limitations of the current PSA screening paradigm, which frequently results in unnecessary biopsies due to low specificity. The Glycanostics GIA (Glycobiopsy ImmunoAssay) test utilises a unique magnetic bead-based protocol to enrich proteins from human serum and perform glycoprofiling. In clinical validation studies, their "prostate glycan index" (PGI) outperformed the standard Prostate Health Index (PHI), achieving an Area Under the Curve (AUC) of 0.821 for discriminating between the presence and absence of cancer, and 0.90 for therapy monitoring. By providing a more precise "second opinion" test, Tkac and Bertok are directly reducing the physical and psychological burden of cancer screening on the male population. 6) Lukáš Alner: Democratising Specialist Access While Cekan and Tkac focus on the biological detection of disease, Lukáš Alner, the founder of Diagnose.me , has focused on the informational democratisation of the diagnostic process. Diagnose.me operates a global platform that connects patients with world-leading medical specialists for second opinions. In a region where access to highly specialised medical expertise may be geographically concentrated, Alner’s platform provides a vital layer of diagnostic assurance. This service is particularly relevant in complex oncological cases where a second opinion can alter the entire course of treatment, preventing medical errors and improving long-term outcomes. Leader Organization Core Innovation Diagnostic Metric Funding / Stage Pavol Cekan MultiplexDX RNA FISH + RNAseq 98% Accuracy Seed A (€1.2M) Jan Tkac / Tomas Bertok Glycanostics Glyco-profiling AUC 0.82-0.90 EIC Accelerator / ERC Lukáš Alner Diagnose.me Tele-Specialist Network N/A Seed / Series Unknown The Platform Revolution: Synthetic Biology and Genomic Intelligence As healthcare moves toward the molecular level, Slovakian leaders are developing foundational platforms for the next generation of therapeutics and personalised wellness. This involves the integration of high-performance computing with biological manufacturing. 7) Miroslav Gasparek: Pioneering Cell-Based mRNA Manufacturing Miroslav Gasparek, the CEO and co-founder of Sensible Biotechnologies, is addressing one of the most critical bottlenecks in contemporary pharmacology: the manufacturing of mRNA. Traditional mRNA production relies on In Vitro Transcription (IVT), a cell-free method that often fails to meet the quality and purity requirements for chronic therapeutic applications. Gasparek’s leadership is defined by the development of a cell-based platform that utilises precision fermentation and computational biology to produce non-immunogenic, highly functional mRNA inside living cells. A major milestone in Gasparek's strategic vision was the integration of NVIDIA's accelerated computing and AI into their molecular design process. By utilising NVIDIA DGX Cloud and H100 GPUs, Sensible Biotechnologies has reduced its mRNA optimisation cycles by over 90%, cutting the time required from 15 days to just 24 hours. With over $13 million in funding from elite investors such as Y Combinator and BlueYard Capital, Gasparek is positioning Sensible Biotechnologies not just as a biotech firm, but as a critical infrastructure provider for the future of programmable medicine. 20 Future Slovakian HealthTech and MedTech Leaders 8) Michaela Šišková and Jakub Šiška: Genomic Literacy and Preventive Health In the consumer-facing segment of genomics, Michaela Šišková and Jakub Šiška have established DNA ERA as the leading provider of personalized genetic testing in the region. Their work involves the analysis of metabolic, athletic, and nutritional predispositions through non-invasive DNA tests. The underlying trend reflected in DNA ERA’s success is the shift toward "proactive health management" among the general population. By translating complex genetic data into actionable insights, the Šiškás are fostering a cultural shift toward preventive lifestyle interventions, which is essential for mitigating the long-term impact of non-communicable diseases on the public healthcare system. 9) Filip Nemcko: The Next Generation of Gene Function Research Representing the high-potential academic pipeline is Filip Nemcko, a Research Associate at the Research Institute of Molecular Pathology (IMP) and a member of the Forbes Slovakia "30 Under 30" class of 2024. Nemcko was recognised for his role in developing methods that significantly accelerate the understanding of human gene functions. His early achievements, including a second-place finish in the iGEM synthetic biology competition for a yeast-based cancer detection prototype, signal a future leader capable of bridging advanced research with clinical application. Nemcko’s work holds the potential to unlock new therapeutic targets for genetic diseases, providing the basic science that will power the MedTech startups of the 2030s. Operational Excellence and Healthcare Infrastructure The efficiency of a healthcare system is often determined by its administrative and logistical "plumbing." Several Slovakian leaders have identified and solved these systemic inefficiencies, creating scalable solutions for clinical management and trial logistics. 10) Peter Zajac: Digitising Compliance in the Surgery Center Peter Zajac, co-founder of Surglogs, has tackled the pervasive issue of administrative burden in surgical environments.Surglogs provides a digital platform that automates the management of regulatory compliance logbooks, medication supplies, and safety drills. By replacing antiquated paper systems, Zajac’s team is not only improving operational efficiency but also enhancing patient safety. In a high-stakes surgical environment, the ability to instantaneously verify compliance and supply levels reduces the risk of medical errors. Surglogs’ successful Series A funding and its expansion into the US market demonstrate that Slovakian entrepreneurs can solve universal operational challenges in global healthcare systems. 11) Martin Winkler: The Logistical Backbone of Clinical Trials The complexity of clinical trials is a major barrier to drug development. Martin Winkler, the founder of Meliovit, addresses this through a specialised logistics platform for clinical trials. Meliovit focuses on the secure, direct-to-patient delivery of materials and the efficient handling of clinical data. As clinical trials become increasingly decentralised and personalised, Winkler’s leadership in logistical optimisation ensures that the underlying data remains robust and that patients in remote locations can participate in groundbreaking research. This is a critical enabler for the biotech startups like Sensible Biotechnologies that require high-velocity trial cycles to validate their platforms. 12) Miroslav Kočan: Optimising the Ambulatory Workflow Miroslav Kočan, alongside founders Martin Minka and Daniel Dzurov, developed CURO to solve the administrative bottlenecks faced by primary and ambulatory care physicians. The CURO system streamlines the process of insurance performance checks and clinical documentation. While less prominent than AI-driven surgery, these innovations are vital for preserving the human resources of the healthcare system. By reducing the time doctors spend on paperwork, Kočan and his team are effectively increasing the clinical capacity of the ambulatory sector, a crucial intervention in the face of widespread medical staff shortages. 13) Patrik Kmeč and Roman Kučera: The Hilbi Health Ecosystem One of the most significant recent financial milestones in the Slovakian HealthTech sector was the €8 million strategic investment secured by Hilbi, led by founders Patrik Kmeč and Roman Kučera. Hilbi is a patient-centric platform that unifies electronic health records (EHR), transactional management, and AI-driven analytics into a borderless ecosystem. The innovation of Kmeč and Kučera lies in their decentralized architecture, which treats patients as "clients" who have ownership over their health data. The impact of this approach is measurable; clinics using Hilbi have reported a 20% increase in workflow efficiency and a revenue boost of up to 35%. By facilitating the monetisation of anonymous health data via blockchain, Hilbi is creating a new economic model for healthcare that incentivises data sharing for the benefit of global research. Their recent expansion into the Indian market highlights the global scalability of Slovakian health data platforms. Leader Organization Focus Area Funding / Impact Peter Zajac Surglogs Surgical Compliance Series A / US Market Martin Winkler Meliovit Trial Logistics Seed / Data Integrity Miroslav Kočan CURO Ambulatory Efficiency N/A / Workflow Optimization Patrik Kmeč / Roman Kučera Hilbi Health Data/Blockchain €8M Investment / 100k+ users Wellness, Nutrition and the Digitalisation of Mental Health The boundary between medical treatment and proactive wellness is blurring, and Slovakian leaders are at the forefront of this "preventive revolution," utilising digital tools to address nutrition and mental health at scale. 14) Michal Palenik: Scientific Nutrition at Scale Michal Palenik, the founder of Planeat, has transformed nutritional science into a scalable digital application. Recognising that nutrition is a fundamental determinant of health outcomes in chronic conditions such as diabetes and cardiovascular disease, Palenik developed a platform that creates personalised meal plans based on individual clinical profiles and dietary goals. Planeat’s integration into the medical workflow allows healthcare professionals to prescribe nutritional interventions with the same precision as pharmaceuticals, bridging the gap between clinical advice and daily behavioural execution. The Mentegram Team: Digitising Behavioral Health Mental health has long been underserved by traditional MedTech, but the team behind Mentegram is changing this through AI-driven assessment tools. Mentegram provides a platform for clinicians to conduct mental health assessments and monitor patient progress in real-time. By utilising AI to suggest personalised treatment plans for conditions like depression and substance abuse, Mentegram is effectively increasing the "reach" of a limited number of mental health specialists. Their work is critical for destigmatising mental healthcare and making it a standard component of integrated medical care. Institutional Research and Academic Excellence The long-term viability of the Slovakian MedTech sector is anchored by its academic institutions, where researchers are developing the biological and engineering frameworks for future innovations. 15) Andrea Lauková: A Leader in Postbiotic Science Dr. Andrea Lauková of the Centre of Biosciences at the Slovak Academy of Sciences (SAS) was awarded the SISA Scientist of the Year 2025 for her pioneering work in microbiology and biological sciences. Her research focuses on the antimicrobial activity of proteinaceous postbiotic substances and bacteriocins, such as Enterocin M. The implications of Lauková’s work are profound for both human and animal health. As the global threat of antibiotic resistance grows, her discovery of autochthonous strains like Enterococcus faecium EF 412—which shows significant activity against methicillin-resistant Staphylococcus aureus (MRSA), provides a viable alternative to traditional antibiotics. Her research into the fortification of dairy products with encapsulated postbiotic active lactococci further demonstrates the commercial potential of her work in the functional food and nutraceutical sectors. 16) Peter Celec: Advancing Molecular Biomedicine Professor Peter Celec, head of the Institute of Molecular Biomedicine at Comenius University, is a central figure in Slovakian medical research. His work is characterised by a high degree of inter-disciplinarity, involving molecular biology, biophysics and clinical medicine. Celec’s current research on the biology of extracellular DNA and the role of neutrophil extracellular traps in gastrointestinal autoimmunity is at the cutting edge of biomedical science. His leadership in training a new generation of PhD students in experimental and laboratory medicine ensures that the "talent pipeline" for the Slovakian HealthTech sector remains robust. 17) Juraj Beniak: Innovation in Additive Manufacturing for Medicine At the Slovak University of Technology (STU), Professor Juraj Beniak has emerged as a leader in the field of additive manufacturing, receiving the Technologist of the Year 2024 award. His work in developing innovative composite materials and design solutions for 3D printing has direct applications in MedTech, particularly in the creation of customized implants and medical equipment. During the COVID-19 pandemic, Beniak’s research was instrumental in the rapid production of respirators using antibacterial nano-composite materials. His work illustrates the strategic importance of technical universities in providing the "hard engineering" capabilities required for medical device manufacturing. 18) 19) Aleksander Kasprzak and Martin Michalko: Building the Trial Ecosystem Aleksander Kasprzak and Martin Michalko, the founders of Biogenesis Trials, are creating a new clinical trial ecosystem in Slovakia. Their mission is to accelerate drug development by fostering deeper collaboration between researchers and clinicians. In a region that is often a preferred location for clinical trials due to its high-quality medical infrastructure, Biogenesis Trials is providing the connective tissue that allows domestic research to reach global standards. This is a critical factor for the retention of medical talent, as it provides clinicians with opportunities to engage in high-level international research without leaving Slovakia. 20) Vlado Beňo: Revolutionising Sensor Technology Vlado Beňo, alongside Michal and Rastislav Beňo, founded RVmagnetics to push the boundaries of sensor technology.Their miniaturised magnetic sensors have diverse applications in healthcare, ranging from smart orthopedic implants to real-time physiological monitoring. By integrating sensors directly into medical devices, RVmagnetics enables the "Internet of Medical Things" (IoMT), where devices can provide continuous feedback to clinicians. This is a foundational technology for the next generation of smart prosthetics and remote monitoring tools. Academic Leader Institution Recognition Research Specialty Andrea Lauková SAS Scientist of the Year 2025 Postbiotics / Antimicrobials Juraj Beniak STU Technologist of the Year 2024 Additive Manufacturing Peter Celec Comenius Univ. VEGA Grantee Molecular Biomedicine Roman Gardlík Comenius Univ. Dept. Head (IMBM) Molecular Biology The Role of Ecosystem Enablers and Strategic Funding The success of these 20 leaders is not an isolated achievement but the result of a supportive ecosystem that includes international accelerators, regional venture capital, and European innovation programs. The EIT Health InnoStars and RIS Innovation Calls have been pivotal in providing early-stage support for Slovakian innovators. Programs like the EIT Health Catapult, which provides 360° training and exposure to over 450 investors, have served as a "launchpad" for companies like Powerful Medical and Sensible Biotechnologies. Furthermore, the emergence of domestic funds like ZAKA VC, which recently unveiled a €15 million fund to support early-stage startups across Europe and the US, provides the necessary local capital for initial scaling. The strategic importance of Slovakia’s technical education is also evident in the ranking of the Slovak University of Technology (STU) as the best technical university in Slovakia by EngiRank 2024. STU’s participation in the EULiST alliance of European universities facilitates the international mobility of researchers and students, ensuring that the local talent pool remains competitive with global benchmarks. Strategic Synthesis and Future Trajectory The collective work of these 20 leaders indicates that Slovakia is carving out a distinct niche in the global HealthTech market. This niche is characterised by: AI-Driven Cardiovascular Diagnostics: A dominant cluster led by Powerful Medical that is setting new European standards for acute care coordination. Advanced Molecular Screening: A focus on non-invasive diagnostics using glycomics and RNA sequencing to eliminate clinical errors in oncology. Biological Platform Technologies: The development of cell-based manufacturing systems for mRNA, addressing the foundational supply chain challenges of modern medicine. Decentralised Health Data: A shift toward blockchain-backed, patient-centric data ecosystems that facilitate global research collaboration. The transition of Slovakian MedTech from a domestic curiosity to a global competitor is nearly complete. The next phase, beginning in 2025, will be defined by the successful penetration of these technologies into the North American and Asian markets, and the continued integration of domestic academic research into commercial pipelines. The leaders identified in this report are not just the "future" of Slovakian healthcare; they are the present force driving the modernisation of medicine across the European continent. Their success serves as a blueprint for how a small, technically proficient nation can leverage its academic heritage to solve the most pressing challenges in global health. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Hungarian HealthTech and MedTech Leaders The Evolution of Hungarian Life Sciences: 20 Future Leaders in HealthTech and MedTech The landscape of Hungarian healthcare innovation has transitioned from a historical foundation of pharmaceutical excellence into a dynamic, multi-disciplinary ecosystem defined by medical deep tech, artificial intelligence and sophisticated biotechnology. This transformation is anchored by a strategic shift in the country’s academic and financial infrastructure, moving toward a "fourth-generation" research model where knowledge transfer and commercialization are prioritized alongside academic inquiry. Between 2015 and 2025, over €925 million in venture capital flowed into the Hungarian startup ecosystem, with the life sciences sector, encompassing pharmaceuticals, biotechnology and MedTech, securing a significant portion of this investment. This growth is not accidental but is the result of a coordinated effort by state agencies, university-led technology transfer centers, and a new generation of scientists-turned-entrepreneurs who are bridging the gap between the laboratory bench and the patient's bedside. The Institutional and Economic Framework of Innovation The maturation of the Hungarian HealthTech sector is facilitated by a robust institutional framework. The National Research, Development and Innovation Office (NRDIO) has launched successive programs aimed at fostering the startup ecosystem, while the Hungarian Innovation Agency (HIA) has focused on developing "Deep Tech" capabilities. A critical component of this framework is the emergence of university-owned Technology Transfer Companies (TTCs), such as the Semmelweis Technology Transfer Company Ltd (SE TTC), established in 2024. These entities act as conduits between academic researchers and market players, translating scientific breakthroughs into commercially viable products. Furthermore, the University of Szeged (SZTE) has established a comprehensive innovation incubation environment, including the Science Park Szeged and various "Advanced Core Facilities" (ACF) ranging from pharmaceutical research to 3D materials science. This institutional support is complemented by the presence of large-scale research infrastructures like the ELI-ALPS Laser Research Centre and the Szeged Biological Research Centre (HUN-REN BRC). Ecosystem Component Primary Function Key Participating Entities State Agencies Policy, Funding, Infrastructure NRDIO, HIA, Hungarian Innovation Hub Venture Capital Seed to Series C Funding Hiventures, PortfoLion, Oktogon Ventures Academic Pillars Research, Clinical Trials, Spin-offs Semmelweis (SOTE), SZTE, Pázmány Péter Accelerators Mentorship, Validation, Scaling EIT Health InnoStars, Health Venture Lab The economic profile of this sector is characterized by increasing deal sizes and more frequent funding rounds. In the first half of 2025, the top ten Hungarian funding rounds reached a total of €41.2 million, a stark increase from €15.4 million in the same period in 2023. This capital is increasingly directed toward companies that leverage AI to solve complex biological problems, reflecting a global trend toward "TechBio". Profile of Oncology and Personalised Medicine Leaders The most advanced segment of the Hungarian HealthTech market is oncology, where the integration of computational modelling and molecular biology is revolutionising drug discovery and clinical decision-making. 1. Szabolcs Nagy (Turbine AI) Szabolcs Nagy, the CEO and co-founder of Turbine AI, represents a new breed of leadership that balances biological complexity with computational scalability. Under his guidance, Turbine has emerged as a global leader in "in silico" drug discovery. The company’s core technology is a Simulated Cell platform that models how cancer cells respond to various treatments at the molecular level, allowing researchers to test millions of drug combinations before entering a physical laboratory. The implications of Nagy’s leadership are profound for the pharmaceutical industry. By identifying the most effective drug combinations early in the development cycle, Turbine significantly reduces the probability of clinical trial failure. This approach is particularly critical in oncology, where the heterogeneity of tumors often renders standard-of-care treatments ineffective. Turbine’s success, highlighted by a $30.7 million Series A round in late 2022 from investors like Accel and Mercia, positions Nagy as a central figure in the European "TechBio" revolution. 2. Kristóf Szalay (Turbine AI) As the CTO and co-founder of Turbine AI, Kristóf Szalay is the technical architect behind the Simulated Cell platform.His work focuses on translating the intricate signaling networks of cancer biology into a predictive mathematical framework. The challenge he addresses is the sheer scale of biological data; a single human cell contains thousands of interacting proteins, and understanding how a specific mutation or drug affects this network requires immense computational power. Szalay’s contribution lies in the development of algorithms that can accurately simulate these interactions, providing a "digital twin" of a cancer cell. This enables a level of precision in drug screening that was previously impossible. The partnership between Nagy’s strategic vision and Szalay’s technical depth has allowed Turbine to partner with major pharmaceutical companies to accelerate their oncology pipelines. 3. István Peták (Genomate Health) István Peták, the founder of Genomate Health, is a pioneer in the field of precision oncology. His work addresses the "N-of-1" challenge: the need to tailor cancer treatment to the specific genetic profile of an individual patient. Genomate Health develops AI-driven computational models that standardise clinical decision-making by automating the synthesis of vast amounts of genomic and clinical data. Peták’s vision is to make precision medicine the standard of care globally. His company’s flagship product assists physicians in identifying the most effective therapeutic options for patients who have exhausted traditional treatments. With a total funding of approximately $10.03 million and a presence in both Budapest and Cambridge, Massachusetts, Peták is bridging the Hungarian research tradition with the world’s most advanced biotech markets. 4. Zalán Péterfi (VRG Therapeutics) Zalán Péterfi, a Harvard-trained scientist and former McKinsey consultant, serves as the Chairman and Managing Director of VRG Therapeutics. His background uniquely positions him to lead a company focused on the intersection of scientific excellence and business execution. VRG Therapeutics specialises in miniprotein-based biopharmaceuticals and cell and gene therapy. Péterfi’s leadership is defined by the use of an AI-powered miniprotein platform that can discover validated hit molecules within six months—a process that typically takes years using traditional screening methods. This efficiency is a critical competitive advantage in the high-stakes world of biotech. VRG's recent expansion into the Netherlands and its participation in major international gene therapy forums illustrate Péterfi’s ambition to scale Hungarian innovation on a global stage. 5. Péter Horváth (HCS-3DX / HUN-REN BRC) Péter Horváth, a researcher at the HUN-REN Szeged Biological Research Centre, has developed a system that could revolutionize the scale of personalized medicine. The HCS-3DX technology integrates artificial intelligence, light-sheet microscopy, and automated sample handling to analyze up to one hundred patient cell samples simultaneously. Horváth’s work addresses the bottleneck in personalized medicine: the slow and manual evaluation of 3D cell samples (spheroids). By automating the selection and handling of these samples using the "SpheroidPicker" micromanipulator, his system brings industrial-scale speed to cell analysis. The goal is to use a patient’s own 3D cell model to determine which treatment will work best for them in real-time, effectively bringing the laboratory's precision directly to the patient's bedside. Leaders in Biotechnology and Life Science Systems The broader biotechnology sector in Hungary is being redefined by leaders who are applying biological principles to solve systemic problems in drug safety, environmental sustainability, and cellular manipulation. 6. Attila Csikász-Nagy (Cytocast) Attila Csikász-Nagy, the CEO of Cytocast and a professor at Pázmány Péter Catholic University, is a visionary in computational systems biology. Cytocast, a spin-off from the university, focuses on "whole-cell simulation," a technique used to predict how drugs will affect cellular networks and to anticipate potential side effects. The significance of Csikász-Nagy’s work lies in its potential to de-risk drug development. Many drugs fail in clinical trials because they interact with non-target proteins, leading to toxicity. By simulating the entire cell, Cytocast can identify these risks before a drug ever enters a human subject. This systemic approach is essential for the next generation of safe and effective biopharmaceuticals. 7. Terje Wimberger (Cellectric Biosciences) Terje Wimberger is the Managing Director and co-founder of Cellectric Biosciences, a company that is pioneering the use of electromagnetic fields for cell manipulation. Following the unexpected passing of co-founder Klemens Wassermann in 2025, Wimberger has led the company as it commercialises its "electrome manipulation" technology. The core innovation of Cellectric is the ability to selectively rupture specific cell types—such as human cells in a blood sample—while leaving others, like bacteria, intact. This has profound implications for the rapid diagnosis of sepsis and other life-threatening infections. By "upgrading" traditional laboratory techniques with electromagnetic precision, Wimberger and his team are creating tools that allow for instant diagnosis and more efficient bioprocessing. 8. Liz Madaras (Poliloop) Liz Madaras, a pharmaceutical chemist engineer and CEO of Poliloop, has gained international recognition for her work in environmental biotechnology. Along with co-founder Krisztina Lévay, she developed a bacterial cocktail capable of degrading single-use plastics into biomass and valuable end-products within weeks. While primarily an environmental startup, Poliloop represents a critical advancement in biological engineering. Madaras’s work demonstrates how nature’s own metabolic processes can be harnessed to solve industrial waste problems. Her leadership has secured investment from prestigious accelerators like Techstars and recognition on the Forbes 30 Under 30 list. As the healthcare industry grapples with the immense volume of plastic waste generated by hospitals, Poliloop's technology offers a path toward a circular bio-economy. 9. Krisztina Lévay (Poliloop) Krisztina Lévay, the CTO and co-founder of Poliloop, is the technical mastermind behind the company’s bacterial degradation process. With a background in pharmaceutical engineering and chemistry, she led the two-year research effort to create the "bacterial cocktail" that integrates the carbon from fossil-based plastics into its metabolism. Lévay’s role is essential for scaling the technology from the laboratory to industrial testing. Her expertise in research design and team management has allowed Poliloop to navigate the complexities of microbial biodegradation. Together with Madaras, she is proving that Hungarian biotech can address some of the world's most pressing environmental and logistical challenges. 10. Tamás Martinek (University of Szeged) Professor Tamás Martinek at the University of Szeged is a leader in the development of targeted drug delivery systems.His research focuses on enabling biologically derived therapeutic agents, which typically act only on the cell surface—to enter the human cell and exert their effects internally. Martinek’s breakthrough solution uses a high-affinity oligopeptide tagging sequence that mimics the entry mechanisms of certain viruses, allowing macromolecules to access the cell via the caveolar pathway. This technology platform has the potential to unlock a new class of intracellular biologics. A spin-off company has already been established to advance this technology into the next phase of development and clinical trials. 20 Future Hungarian HealthTech and MedTech Leaders MedTech Leaders: Redefining Diagnostics and Rehabilitation The Hungarian MedTech sector is particularly strong in the development of hardware-software hybrids that utilise sensors and AI to monitor vulnerable populations and assist in physical recovery. 11. Péter Földesy (NICOWL) Péter Földesy is the CEO of NICOWL, a MedTech startup that is transforming care in Neonatal Intensive Care Units (NICUs). NICOWL’s AI-powered intelligent video surveillance system automatically assesses infant positioning, detects crying episodes, and monitors sleep-wake states in premature babies. The clinical relevance of Földesy’s work is significant. Every hour a premature infant spends in the wrong position or is disturbed during sleep can result in neurological damage. NICOWL’s technology allows for 24/7, non-contact monitoring that reduces nurse workload while improving the developmental outcomes for newborns. With clinical validation data approaching human-level agreement, Földesy is leading the company through the rigorous MDR certification process to deploy this innovation across Europe. 12. Krisztina Katalin Puskás (GraphoPen) Krisztina Katalin Puskás and her team developed the GraphoPen, a tool that has won numerous awards for its role in stroke patient rehabilitation. The device uses neural stimulation and precise measurement to assist patients in regaining motor control and evaluating their progress during the rehabilitation process. The GraphoPen exemplifies the Hungarian focus on "Medical Device Innovation" that combines hardware with sophisticated data tracking. By providing a measurable and interactive way for patients to engage with their therapy, Puskás is addressing a critical need in long-term neurological care, where consistency and accurate tracking of progress are key to successful outcomes. 13. Bertalan Jászkuti (Syreon Research Institute) As the CEO of Syreon Research Institute, Bertalan Jászkuti is a leader in health economics and outcomes research, which are increasingly vital for the adoption of new MedTech solutions. His work involves evaluating the cost-effectiveness and clinical impact of new medical technologies, ensuring that they can be integrated into public healthcare systems. Jászkuti’s role is critical because innovation in MedTech is not just about a functioning device; it is about proving to insurers and governments that the device improves patient health at a sustainable cost. His expertise helps Hungarian startups navigate the complex path from clinical validation to market access and reimbursement. 14. Gábor Orbán (Richter Gedeon) While Richter Gedeon is a large, established pharmaceutical company, its CEO Gábor Orbán has been recognized as the "Most Inspiring Leader of the Year" for his role in modernizing the firm and fostering a culture of innovation. Under his leadership, Richter has increasingly focused on the development of biologics and biosimilars, a high-growth area that requires sophisticated biotechnological capabilities. Orbán’s leadership is significant for the broader ecosystem because Richter Gedeon acts as a major anchor and potential partner for smaller HealthTech startups. By steering one of Hungary’s most successful companies toward a more innovative and collaborative future, Orbán is ensuring that the traditional strengths of the Hungarian pharma industry are leveraged in the new digital and biological age. 15. András Sápi (Verdant Catalyst) Dr. András Sápi, a researcher at the University of Szeged, received the SZTE Innovation Award for the commercialization of his "catalytic brick" technology through the spin-off Verdant Catalyst Kft. While the invention targets environmental pollution, its primary impact is on public health, specifically the reduction of respiratory diseases caused by wood-burning and mixed-fuel heating systems. Sápi’s work represents a practical, market-ready solution to a widespread environmental health problem in Central Europe. The catalytic brick integrates into furnaces and fireplaces, reducing carbon monoxide and particulate matter emissions while improving heating efficiency. His successful journey from laboratory research to a commercially available product serves as a model for other academic innovators in the Hungarian ecosystem. Leaders in Digital Health and Behavioural Science The digital transformation of healthcare in Hungary is being driven by leaders who understand that technology must be paired with human behaviour insights and accessible platforms. 16. Tamás Petrovics (XUND) Tamás Petrovics is a co-founder of XUND, a health-tech company that provides an API-first medical device to connect patients to the appropriate care. XUND's platform uses sophisticated algorithms to analyse symptoms and guide patients through the entire journey from prevention to diagnosis. The success of Petrovics’s vision is evident in XUND’s funding history, which includes a €6 million seed round in 2025 from a diverse group of international and local investors. By providing a structured and medically validated way for patients to interact with their health data, XUND is helping to reduce the burden on primary care physicians and ensure that patients receive the right care at the right time. 17. Rachel Altmann (BeHive Consulting) Rachel Altmann is the CEO and co-founder of BeHive Consulting, a behavioral science firm based in Budapest. Along with her co-founders, she applies insights from psychology and neuroscience to design science-backed solutions that influence human behaviour in the healthcare sector. Altmann’s leadership has been particularly impactful in public health. BeHive has worked with the World Health Organization (WHO) to design EU-wide strategies to reduce alcohol consumption and has optimised hospital vaccination processes during the pandemic. By addressing the "human factor" in healthcare, such as patient adherence and medical professional burnout, Altmann is providing a missing piece in the innovation puzzle. 18. Noémi Molnár (BeHive Consulting) Noémi Molnár, the Chief Behavioural Scientist at BeHive Consulting, is responsible for the academic rigor and scientific methodology of the firm’s interventions. Her work involves diving deep into the nuances of human interaction to deduce insights that organizations can use to optimize their products and processes. Molnár’s contribution is essential for ensuring that behavioral interventions are predictable and data-driven. Her expertise in Behavioural Science and Neuroscience allows BeHive to map out complex systems, such as a patient’s journey through a hospital, and identify the "frictions" that prevent optimal health outcomes. 19. Anna Nyvelt (BeHive Consulting) Anna Nyvelt, a co-founder and Commercial Director at BeHive Consulting, focuses on the application and scaling of behavioral science know-how within organizations. She bridge the gap between scientific insights and the practical needs of clients in the healthcare, banking, and telecommunications sectors. Nyvelt’s work helps organizations build their own internal capabilities in behavioral science, ensuring that innovative interventions are sustainable in the long term. Her leadership has helped BeHive achieve significant commercial success, with $544,000 in revenue in 2024, demonstrating the market demand for "human-centred design" in high-stakes industries. 20. Adewunmi Akingbola (Cambridge Public Health / Research ties to Hungary) Adewunmi Akingbola is a researcher at Cambridge Public Health who has been recognized on the Forbes 30 Under 30 Europe list for his work in developing public health playbooks to improve data reliability. While his primary work is international, his research into Hepatitis C and health biases is highly relevant to the Hungarian scientific community, where data-driven public health is a growing priority. Akingbola’s inclusion as a future leader reflects the increasing global integration of Hungarian science. His focus on addressing biases in health studies and improving the reliability of real-world data is crucial for the development of equitable healthcare solutions. His work serves as an inspiration for young Hungarian researchers who are increasingly looking beyond national borders to solve global health challenges. Comparative Analysis of Funding and Maturity The maturity of the Hungarian HealthTech ecosystem can be quantified by examining the funding status and strategic focus of its leading companies. There is a clear progression from early-stage, university-backed spin-offs to more mature firms capable of raising significant international capital. Leader/Company Primary Vertical Maturity Stage Key Funding/Support Turbine AI Oncology / In Silico Series A $30.7M (Accel, Mercia) Genomate Health Precision Oncology Seed $10.03M Total (Oktogon Ventures) VRG Therapeutics Cell & Gene Therapy Series A $5.47M (Szechenyi Funds) XUND Digital Diagnostics Seed €6M round (Lead Ventures) NICOWL Neonatal MedTech Pre-Seed / Seed EIT Health InnoStars Finalist Cytocast Whole-Cell Simulation Pre-Seed €1.9M round (University spin-off) Poliloop Biotech / Sustainability Seed $2.1M (Techstars) MEROVA Health Chronic Care (Diabetes) Seed HUF 100M (Hiventures) This table illustrates the diverse range of funding sources, including traditional VC firms, state-owned funds like Hiventures, and international accelerators. The presence of both early-stage (Pre-Seed) and more established (Series A) companies suggests a healthy "pipeline" of innovation that will sustain the sector in the coming years. Technological Trends: AI, Spheroids and the Electrome The 20 leaders identified are at the forefront of several key technological trends that are reshaping the healthcare industry. These trends are not isolated but often interact to create more powerful solutions. The Rise of In Silico and AI Diagnostics The most dominant trend is the shift from physical to digital testing. Companies like Turbine AI and Cytocast are leading the way in "in silico" modeling, which uses AI to predict biological outcomes. This is mirrored in diagnostics, where firms like XUND and NICOWL use AI to analyse patient symptoms and behaviour, providing insights that were previously hidden in the data. Scaling Personalised Medicine through Automation A second critical trend is the automation of high-throughput analysis. Péter Horváth’s HCS-3DX system is the primary example of this, bringing industrial speed to the evaluation of 3D cell samples. This trend is essential for making personalised medicine accessible to the general population, as it reduces the manual labor and cost associated with tailoring treatments to individual patients. Biophysical Manipulation and Targeted Delivery Finally, there is a growing interest in the physical and chemical manipulation of cells. Terje Wimberger’s work with electromagnetic fields at Cellectric Biosciences and Professor Martinek’s caveolar entry sequences represent a movement toward highly targeted interventions. These technologies allow for the selective treatment of specific cells or the delivery of drugs directly to intracellular targets, minimising the systemic side effects that plague current therapies. Conclusion: A Sustained Trajectory of Innovation The Hungarian HealthTech and MedTech sectors have evolved into a sophisticated engine of innovation, driven by a new generation of leaders who possess a unique blend of scientific depth and entrepreneurial ambition. The transition from traditional pharmaceuticals to medical deep tech is supported by a robust infrastructure of state funding, university technology transfer, and international collaboration. The 20 leaders identified in this report are not merely building companies; they are redefining the boundaries of what is possible in oncology, diagnostics, and patient care. As the Hungarian ecosystem continues to mature, and as these leaders scale their innovations to a global audience, the impact on human health will be significant and enduring. The coordinated efforts of researchers, investors and policymakers have positioned Hungary as a vital hub for the life sciences in Europe, with a clear and ambitious vision for the future of healthcare. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Greek HealthTech and MedTech Leaders The Hellenic Healthtech Renaissance: Twenty Future Leaders Redefining the Mediterranean Medtech Landscape The Greek innovation ecosystem has entered a period of structural maturation, characterised by a transition from nascent digital adoption to the creation of globally competitive deep-tech enterprises. As of 2025, the Greek startup ecosystem is valued at approximately $4.2 billion, with Athens emerging as a significant node in the global innovation network, ranking 120th worldwide and 26th in Western Europe. This evolution is underpinned by the "Digital Transformation Bible 2020–2025," a foundational policy framework that has prioritised the modernisation of public health services through the deployment of "digital rails," such as the national e-Prescription system and the MyHealth mobile application operated by IDIKA S.A.. Furthermore, the 2024 National AI Strategy, "A Blueprint for Greece’s AI Transformation," has established a dedicated layer for artificial intelligence in healthcare, fostering an environment where scientific excellence from institutions like the Foundation for Research and Technology-Hellas (FORTH) and the National Centre for Scientific Research "Demokritos" can be commercialised effectively. The financial engine driving this transformation is increasingly robust. In 2025, total capital raised by Greek startups exceeded €732 million, representing a 35% increase over 2024 levels. Within this landscape, HealthTech has emerged alongside AI and SaaS as a primary vertical for investment, attracting over 143 unique investors from around the globe.The rise of growth-stage capital, exemplified by the €130 million Big Pi Growth fund, has begun to address the historical "growth gap," allowing promising Greek ventures to scale their operations internationally while maintaining significant R&D and operational bases within the country. This report identifies twenty future leaders, startups, spin-offs and visionary researchers, who are currently defining the frontiers of Greek healthtech and medtech. The Macroeconomic and Institutional Underpinnings of Innovation The trajectory of the Greek medtech sector is inextricably linked to the broader macroeconomic recovery and the strategic intervention of the Hellenic Development Bank of Investments (HDBI). The Greek economy has shifted toward a model of extroversion, where innovation-driven entrepreneurship replaces traditional consumption as a growth driver. The HDBI currently manages approximately €2.1 billion across more than 30 active venture capital funds, focusing on priority sectors such as digital transformation, life sciences, and green technology. Institutional support through clusters like the Hellenic BioCluster (HBio) and the Hellenic Digital Health Cluster (HDHC) has created a collaborative innovation moderator that connects industry partners, academia and policy makers. HBio, established in 2006, serves as an independent not-for-profit association that has successfully bridged the gap between research institutes such as CERTH and BRFAA and major pharmaceutical players like AbbVie and ELPEN. These clusters facilitate global expansion, scale-up strategies for SMEs, and navigation of complex regulatory frameworks, which are essential for Mediterranean firms seeking to penetrate the Northern European and North American markets. Economic Indicator 2023 Performance 2025 Projection/Status Real GDP Growth 2.5% Stable Positive Trend Startup Ecosystem Value $3.1 Billion $4.2 Billion Total Startup Funding ~$540 Million >€732 Million Active VC Funds ~21 Funds >30 Funds Global Startup Rank (Greece) 46th 49th (Recalibration phase) Biopharmaceutical Process Innovation: The New Digital Layer The biopharmaceutical industry faces a persistent bottleneck in process development, the phase where a discovered molecule is transformed into a manufacturable medicine. Historically, this phase has relied on manual, "wet-lab" experimentation, which is both time-consuming and prohibitively expensive. 1. PolyModels Hub: Standardising the Digital Backbone PolyModels Hub, founded in 2023, is perhaps the most significant recent addition to the Greek-founded biotech software landscape. Led by former GlaxoSmithKline (GSK) scientists Antonio Benedetti and Charalampos Christodoulou, alongside software engineer Antonio Yankey, the company addresses the fundamental inefficiency of biopharma manufacturing. Their flagship platform, ModelFlow, provides a unified digital layer that integrates scientific data with physics-based and AI-driven models to optimise pharmaceutical processes. The economic implications of ModelFlow are profound. Developing a new drug typically costs $2.5 billion, with roughly 25% ($650 million) spent on process development alone. ModelFlow has demonstrated the ability to replace over 80 physical experiments with in-silico simulations, reducing experimental workloads by more than 90%. By turning 100-experiment workflows into fewer than ten while maintaining scientific rigor, PolyModels Hub enables pharmaceutical companies to save hundreds of millions of euros per drug program. This value proposition has allowed the company to secure four of the world’s top ten pharmaceutical companies as customers within just 18 months of its founding. In late 2025, the firm raised €7.9 million ($9 million) in Series A funding led by Molten Ventures to expand its platform into the complex biologics sector. 2. JADBio: Automated Predictive Modelling for Biomedicine Originating as a spin-off from the University of Crete and FORTH-ICS, JADBio (Just Add Data Bio) is a leader in automated machine learning (AutoML) specifically tailored for the life sciences. Under the leadership of CEO Ioannis Tsamardinos and co-founders Vincenzo Lagani and Pavlos Charonyktakis, JADBio empowers researchers to build highly accurate predictive models from complex molecular and clinical data without requiring deep programming knowledge. The platform utilises advanced causal discovery algorithms to identify specific biomarkers that are not just correlated with, but likely cause, particular health outcomes. This capability is critical for precision medicine, where the goal is to tailor treatments to a patient's individual genetic profile. JADBio's ability to automate feature selection and model validation boosts the productivity of data scientists and clinicians by orders of magnitude, transforming "Gnosis Data Analysis" from a university spin-off into a globally recognized predictive analytics provider. Diagnostic Excellence and Molecular Reagents The decentralisation of diagnostic testing is a global healthcare priority, and Greek medtech leaders are at the forefront of developing portable, rapid, and highly accurate molecular tools. 3. BIOPIX-T: The "Pebble" and Field-Ready Diagnostics BIOPIX-T, headquartered in Heraklion and founded by a team including Dr. George Papadakis and Professor Electra Gizeli, focuses on point-of-care (PoC) molecular diagnostics. Their primary innovation, the "Pebble," is a portable device that uses quantitative colorimetric Loop-mediated Isothermal Amplification (LAMP) technology to detect infectious diseases. Unlike traditional PCR, which requires complex thermal cycling and laboratory infrastructure, colorimetric LAMP can be performed at a constant temperature, allowing for rapid results in field settings such as physician offices, clinics, or food production facilities. BIOPIX-T has secured €1.7 million in seed funding from Metavallon VC and Eleven Ventures, positioning it as a critical infrastructure provider for the next generation of decentralised health monitoring. 4. Enzyquest: Foundational Bio-Innovation The growth of any biotech ecosystem requires a reliable supply of molecular biology reagents. Enzyquest, founded in 2019 by Dimitris Koutsioulis, specialises in the development and manufacturing of enzymes for research and diagnostics.Based in Heraklion, the company produces high-quality reagents that are essential for DNA amplification and sequencing. By providing a local source of high-purity enzymes, Enzyquest mitigates the supply chain vulnerabilities exposed during the COVID-19 pandemic and supports the broader Greek R&D landscape. The company has attracted seed funding from Uni.Fund and Horizon Europe and it serves as an industrial partner for academic research projects across the European Union. 5. ResQ Biotech: Addressing the Proteotoxicity Gap ResQ Biotech, a Patras-based R&D firm founded in 2019 by Georgios Skretas and Athina Ikonomidou, focuses on therapeutic solutions for diseases caused by protein misfolding. These "proteotoxicity" conditions include Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS). ResQ Biotech utilizes a proprietary discovery platform to identify compounds that can rescue cells from the toxic effects of protein aggregation. By integrating biological research with drug manufacturing capabilities, the company represents the high-end "deep-tech" segment of the Greek medtech scene. Their progress is supported by the "egg - enter grow go" accelerator, highlighting the role of corporate-backed incubation in nurturing high-risk, high-reward biotechs. Immersive Training and Surgical Engineering As surgical procedures become increasingly complex and minimally invasive, the need for standardised, objective training and precision engineering has never been greater. 6. ORamaVR: The MAGES SDK for Medical Training ORamaVR is a Swiss-Greek deep-tech startup that has revolutionized medical training through its proprietary MAGES SDK (Software Development Kit). Founded by Professor George Papagiannakis, Professor Eleftherios Tsiridis (a world-renowned orthopaedic surgeon), and Professor Panos Trahanias, the company is a spin-off from FORTH-ICS. The MAGES platform allows for the creation of high-fidelity virtual reality (VR) simulations for surgical procedures, addressing the limitations of the traditional "see one, do one, teach one" apprenticeship model. In early 2026, ORamaVR raised a €4.5 million seed round led by Big Pi Ventures to accelerate its mission of providing "medical XR training" globally. The company's technology utilises advanced geometric computational models and computer graphics systems to deliver simulations that are both scientifically validated and immersive. 7. Antonia Agapi Pontiki: Precision in Patient-Specific Care Antonia Agapi Pontiki, recognized in the Forbes 30 Under 30 Europe 2024 Science & Healthcare list, is a teaching fellow at King's College London who specializes in surgical engineering. Her work focuses on the development of patient-specific surgical tools and 3D-printed anatomical models that allow surgeons to plan and practice complex procedures with unprecedented precision. Pontiki embodies the "diaspora talent" that bridges the gap between Greek scientific education and global clinical application, often collaborating with Greek research centres to advance the state of surgical robotics and imaging. Digital Therapeutics and Mental Health: Passive Measurement The transition from reactive to proactive mental healthcare is being driven by the integration of wearable sensors and "Emotion AI." 8. Feel Therapeutics: Digital Precision in Mental Health Feel Therapeutics (formerly Sentio Solutions), co-founded by George Eleftheriou and Haris Tsirmpas, has raised $30 million across ten rounds of funding, including a Series A round in June 2024. The company provides a digital precision medicine platform that leverages passive measurement and objective data for mental healthcare. Their core offering, the Feel Program, combines a wearable biosensors, the Feel wristband, with cognitive-behavioural therapy (CBT) and telehealth services. The wristband contains sensors for skin conductance, skin temperature, and heart rate, which allow it to detect physiological shifts associated with anxiety and depression. By identifying a panic attack or a depressive phase as it occurs, the platform can provide immediate support, potentially preventing emergency room visits and providing insurers with quantifiable data on patient progress. 9. SENSSOS: Advanced Health Sensing Co-founded by Evangelia Athanasiou, SENSSOS is a healthtech startup focused on developing next-generation sensing technologies for health monitoring. Recognised as a top Greek healthtech startup for 2024-2025, SENSSOS aims to provide non-invasive solutions for continuous physiological tracking, filling critical data gaps in chronic disease management. 10. E-mbracelet: Wearable Wellness Solutions Led by CEO Maro Manoli, E-mbracelet is a startup founded by five young entrepreneurs focusing on wearable wellness technology. By prioritising the user experience and the integration of health tracking into everyday fashion, E-mbracelet represents the emerging "Gen Z" segment of the Greek startup ecosystem, which emphasises accessibility and digital-first health management. 20 Future Greek HealthTech and MedTech Leaders Operational Excellence and AI in Acute Care Hospital systems face significant operational pressure, which Greek AI leaders are addressing through automation and real-time clinical intelligence. 11. Keragon: The No-Code Healthcare Automation Hub Keragon is a HIPAA-compliant automation platform specifically built for the healthcare sector. Founded by Panos Papageorgiou, George Makkoulis, George Eracleous, and Conno Christou, the company raised a $7.5 million seed round in early 2025. Keragon addresses the fragmentation of healthcare data by providing over 300 integrations with various Electronic Health Records (EHRs) and AI medical tools. Their no-code editor allows healthcare organisations to automate administrative tasks, patient onboarding, and billing processes, which significantly reduces the administrative burden on clinical staff and improves overall revenue capture. 12. Aisthesis Medical: AI-Driven Acute Intervention Aisthesis Medical, under the leadership of CEO Ioannis Gkouzionis, is focused on transforming acute care through pioneering AI technology. Their solution analyses clinical data in real-time to provide early warning systems for clinicians in high-acuity settings, such as intensive care units. By predicting adverse events before they occur, Aisthesis Medical aims to improve patient safety and optimise the allocation of hospital resources. 13. Zeit Medical: Rapid Neurological Diagnosis Orestis Vardoulis, the founder of Zeit Medical, has developed an AI-based product focused on clinical neurology. The platform enables the quick diagnosis of acute neurological events, such as strokes, which is crucial for timely medical intervention. Vardoulis, a Greek founder who has leveraged ties between Trikala and international research centres, exemplifies the cross-border nature of modern medtech innovation. 14. DeepCure: AI Biotech in Immunology Co-founded by Thrasyvoulos Karydis, DeepCure is an AI-native biotech company focusing on inflammation and immunology. Having recently closed its Series A round, DeepCure uses advanced deep learning models to identify novel drug candidates that can modulate the immune system. The company operates as a Greek-Israeli venture, highlighting the regional synergies becoming increasingly common in the Eastern Mediterranean tech corridor. Consumer-Centric Health Models and Wellness The "consumerisation" of healthcare is driving the growth of subscription-based platforms and personalised wellness solutions. 15. Numan: Personalised Digital Healthcare Numan, founded by Sokratis Papafloratos, is a digital health platform providing subscription-based healthcare and wellness services. Having raised €51.6 million in a Series B round, Numan has expanded from its initial focus on men's health to become a broader provider of personalized treatments, diagnostics, and online consultations. By combining telehealth with direct-to-consumer pharmacy services, Numan represents a new model of convenient, proactive patient management. 16. Ovom Care: AI-Enhanced Reproductive Health Co-founded by Felicia von Reden, Ovom Care is applying machine learning to the fertility space. Recognized in the 2025 Forbes 30 Under 30 Europe Science & Healthcare list, von Reden’s work focuses on personalizing reproductive treatment plans. By using AI to more accurately identify viable eggs and tailor hormonal treatments to individual patients, Ovom Care aims to improve the success rates of IVF and other reproductive procedures, moving away from a "one-size-fits-all" approach to fertility. 17. FoodOxys: The Biologists of Metabolic Wellness FoodOxys, a spin-off from the University of Thessaly led by Fotis Tekos, focuses on metabolic health and the assessment of oxidative stress. By providing specialized services for the food and health sectors, FoodOxys uses biochemical markers to certify the quality of nutritional products and provide personalised wellness advice. Tekos, included in the Forbes 30 Under 30 Greek list for 2025, has successfully commercialised academic research in biochemistry to address the growing global demand for "healthy aging" and "well-being". 18. Purposeful: Leveraging Data for Drug Repurposing Purposeful, co-founded by Georgios Drakakis and Charalampos Chomenidis, uses AI and data analytics to discover new therapeutic uses for existing, off-patent drugs. This process of drug repurposing is especially critical for treating rare diseases, where the cost of de novo drug discovery is often prohibitive. Purposeful's platform identifies alternative effects for existing medications, significantly accelerating the path to clinical application. The company raised $2 million in seed funding from Metavallon VC, underscoring the market's interest in sustainable, high-efficiency drug development. Specialised Research and Bioprinting Frontiers The most advanced segment of the Greek medtech landscape involves the integration of photonics, robotics, and cellular biology. 19. PhosPrint: Laser-Enabled Bioprinting PhosPrint, a member of the Hellenic BioCluster (HBio), is an innovative enterprise active in the field of photonics and bioprinting. By utilizing laser-based technology to "print" biological materials, PhosPrint is pushing the boundaries of regenerative medicine and tissue engineering. Their work allows for the precise placement of cells and biomolecules, which is foundational for the future creation of synthetic tissues and organs. 20. YPSILON Care Tech: Digital Health Telematics The establishment of YPSILON Care Tech as a new spin-off from the Institute of Computer Science of FORTH marks a significant step in the commercial utilization of technological solutions developed in the Computational BioMedicine Laboratory. Dedicated to transferring innovation from research to the market, YPSILON focuses on telematics, AI in healthcare, and software quality assurance. The company is staffed by experienced professionals from the Center for eHealth Applications and Services, aiming to advance the digital transformation of both the Greek and international healthcare sectors. The Impact of AI on the Medtech Workforce and Organisational Structure As Greek startups adopt AI-enabled models, the organizational structures within these companies are undergoing significant shifts. The "FWD Greece: Innovation Pulse 2025-2026" report notes that organisations adopting AI may see a reduction in traditional middle-management responsibilities and an expansion of the C-suite to include AI-focused roles.This technological readiness is a key factor in Greece's emergence as a promising innovation hub in Europe. Technology Area Core Mechanism Causal Health Impact Model-Based Solutions In-silico simulation of bioprocesses Faster access to medicines Emotion AI Sensors Physiological signal passive detection Reduced mental health ER visits Colorimetric LAMP Isothermal DNA/RNA amplification Portable, low-cost molecular dx No-Code Automation Cross-EHR data integration Administrative efficiency/burnout reduction Geometric VR Models High-fidelity surgical simulation Objective surgical competency training The transition toward AI integration is not merely a technological challenge but an organizational one, requiring redrafted governance models and a workforce capable of adapting to redesigned processes. Greek universities continue to produce top-tier talent, which, combined with the maturing investment landscape, positions Greece to compete globally in emerging domains like Defense Tech and HealthTech. Challenges and Barriers to International Scaling Despite the remarkable progress, several barriers continue to pose challenges for Greek healthtech and medtech leaders seeking to scale internationally. These include: Fragmented Regulation: Navigating different healthcare systems and regulatory frameworks within Europe and globally remains a significant hurdle for early-stage firms. Talent Availability: While the academic talent is strong, there is a limited availability of experienced senior personnel in highly specialised technical and commercial roles. Early-Stage Funding: While pre-seed and seed activity has recovered (accounting for 75% of deals in 2025), there is still a perceived lack of "follow-on" capital for startups in the transition between seed and Series A rounds. EHR Fragmentation: In the clinical setting, the low rate (14%) of provider satisfaction with integrated digital health records hinders the seamless deployment of new digital health solutions. However, the "Greek ecosystem value" continues to grow year-over-year, and the number of foreign funds participating in funding rounds is increasing, which provides a dynamic and flexible financial environment for overcoming these barriers. Conclusion: The Trajectory Toward a Global Hub The Greek healthtech and medtech landscape is no longer evolving linearly; it is witnessing a gradual transformation where entrepreneurship, academic research, and policy converge. The emergence of twenty leaders across biopharma, diagnostics, immersive technology, mental healthand AI-driven care demonstrates a resilient and adaptable ecosystem that is addressing both national needs and global market gaps. The "Brain Regain" initiative and the active engagement of the Greek diaspora are providing the necessary mentorship and capital to propel these firms onto the global stage. With the continued support of institutional players like HDBI and the innovative output of research centers like FORTH and CERTH, Greece is well-positioned to become a major hub for medtech innovation in Southern Europe. The strides made in 2024 and 2025 have laid a solid foundation for long-term growth, signalling that the "Hellenic Healthtech Renaissance" is not a temporary surge but a structural shift toward a future-forward, innovation-based economy. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Healthcare Business International interviews Nelson Advisors discussing Healthbridge's acquisition of AI scribe Nora Healthcare Business International interviewed Nelson Advisors partner Lloyd Price discussing Healthbridge's acquisition of AI scribe Nora. “The acquisition highlights a broader shift in the industry, as companies are leaning more toward acquisitions instead of building everything in-house,” Lloyd Price, partner at M&A advisory firm Nelson Advisors told HBI. From an investment perspective, the focus is on clinical AI tools that can “demonstrate productivity and efficiency gains whilst growing their user base month after month.” “Healthtech investors are adapting fast too. AI native startups now command higher revenue multiples (typically 9×–14×) thanks to their proprietary datasets and scalable automation potential. Exit timelines are tightening as well, with many “incubation‑to‑exit” deals wrapping up in under three years,” said Price. “Altogether, valuations are breaking away from speculative tech trends and increasingly rewarding platforms that serve as core clinical operating systems rather than optional add‑ons,” he further added. Investors are increasingly focusing on metrics such as annual recurring revenue per clinician and outcome-based pricing that reflect “tangible clinical improvements” as value creation levers. The acquisition also highlights the rapid growth in South Africa’s healthtech market. The digital health and AI scribe market is quickly “moving from a ‘nice to have’ to an essential tool across both private and public healthcare.” Source: https://www.healthcarebusinessinternational.com/healthbridge-buys-ai-scribe-nora/ Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Estonian HealthTech and MedTech Leaders The Estonian Health Technology and Medical Science Renaissance: A Comprehensive Analysis of Twenty Future Leaders The emergence of Estonia as a preeminent global centre for health technology and medical engineering is a phenomenon predicated on the strategic synthesis of high-fidelity genomic data, a sophisticated digital identity infrastructure and a robust entrepreneurial ecosystem that prioritises clinical validation alongside technological scalability. The transition from traditional reactive medical models, often characterised as "sick-care", toward a proactive, personalised, and predictive health economy is driven by a cohort of leaders who bridge the gap between academic rigour and commercial viability. As the Estonian healthtech sector moves toward its "Vision 2035," which anticipates a high-density environment of science-based startups and a significant increase in healthy life years for the population, twenty specific individuals have surfaced as the architects of this transformation. This report provides an analysis of these twenty future leaders, their technical contributions and the strategic implications of their work for the global healthcare landscape. The Genomic Sovereignty and Pharma-cogenomic Integration Estonia’s competitive advantage in medical technology is inextricably linked to the Institute of Genomics at the University of Tartu and the Estonian Biobank, which houses data for over 212,000 individuals. This repository is not merely a data archive but an active instrument for clinical intervention and precision medicine. Lili Milani: The Vanguard of Biobank Translation Professor Lili Milani, Head of the Estonian Biobank and Professor of Pharmacogenomics, represents the critical link between longitudinal genomic studies and frontline medical application. Her leadership is defined by the objective to "decode health, one genome at a time," moving beyond data collection toward actionable insights that influence drug response and disease prevention. A seminal achievement under her direction was the 2024 launch of the MyGenome portal, a pioneering online platform that allows biobank participants to view their genetic risk assessments and traits directly. This shift toward patient-centric data ownership reflects a broader trend in Estonian digital society where individuals are active participants in their health management. Milani’s academic work investigates the genetics of interindividual variation in drug response, specifically exploring how pharmacogenetics and epigenetics can mitigate adverse events and improve outcomes in psychiatric and cardiovascular conditions. Her research group's ability to pair over 2,300 whole genomes with national electronic health records allows for the identification of rare loss-of-function mutations and their phenotypic consequences. This methodology is fundamental to the "predictive and prescriptive" healthcare model envisioned for the next decade. Triin Laisk: Deciphering the Molecular Basis of Reproductive Health Professor Triin Laisk, Professor of Genomic Epidemiology at the University of Tartu, has fundamentally altered the discourse around women’s health through her research into the genetic mechanisms of reproductive disorders. Recognised with the University’s Research Award in 2025, Laisk’s team utilized large-scale genome-wide association studies (GWAS) to clarify the molecular underpinnings of conditions that have historically been treated based on symptomatic presentation rather than biological causation. Laisk’s approach involves the simultaneous analysis of nearly fifty diagnoses related to female reproductive health, drawing on data from the Estonian Biobank and Finland’s FinnGen project. Her findings, published in journals such as Nature Medicine , enable a shift toward a more holistic and precise view of women’s health, offering insights into DNA repair, cell proliferation, and cell growth in relation to conditions like genital tract polyps and endometriosis. By uncovering these genetic triggers, Laisk provides the clinical foundation upon which future FemTech startups will develop targeted therapies and diagnostic tools. Researcher Key Focus Area Methodology Strategic Impact Lili Milani Pharmacogenomics Whole-genome sequencing paired with EHR data. Reducing adverse drug events and enabling precision medicine. Triin Laisk Reproductive Genetics Large-scale GWAS and phenotypic mapping. Shifting women’s health from symptomatic to causal diagnosis. Kelli Lehto Neuropsychiatric Genomics Investigating adult ADHD through multi-omics. Improving diagnostics and personalized treatment for mental health. Maris Alver Complex Traits Genetic regulation of psychiatric and cardiometabolic traits. Understanding the shared molecular pathways of chronic diseases. Tõnu Esko Data Integration Cross-sectoral governance of health data systems. Strengthening the bridge between research data and clinical implementation. The Precision Oncology and Personalised Diagnostics Vanguard Estonia's oncology sector is characterised by an advanced integration of genetic risk scoring and national data strategy, spearheaded by leaders who prioritise early detection and personalised prevention. Peeter Padrik: Scaling Polygenic Risk Scores in Oncology Dr. Peeter Padrik, an oncologist with over three decades of clinical experience, is the founder and CEO of Antegenes.Padrik’s leadership is rooted in the philosophy that the most effective cancer care is characterized by avoidance and early-stage detection. Antegenes utilises Polygenic Risk Score (PRS) technology to assess cumulative genetic risk for common cancers, providing individuals with clinical recommendations that dictate specific screening schedules. Under Padrik’s guidance, the AnteBC breast cancer risk test has been integrated into several European healthcare systems.The impact of this technology is evidenced by the BRIGHT project, which demonstrated that PRS testing could identify over 41% of participants with an elevated risk of breast cancer, enabling them to start mammography screening earlier than the general population. Padrik’s work represents a successful transition from high-level genetic research to a scalable, CE-marked medical device that directly reduces cancer mortality rates. Kadi-Liis Veiman: Orchestrating the Estonian Cancer Network Kadi-Liis Veiman, the Head of the Estonian Cancer Network (ESTCAN), is a pivotal figure in the national strategy for cancer control. Recognised in 2025 for her contribution to society, Veiman leads a multidisciplinary team that has unified ten founding organisations, including medical, research, and patient groups—to function as a coherent system rather than fragmented entities. Veiman’s leadership is essential for the implementation of the Estonian National Cancer Control Plan (2021–2030), which focuses on reducing cancer incidence and improving the quality of life for those diagnosed. Her role involves managing international research initiatives such as UNCAN-Connect, a €30 million project focused on secure, decentralized cancer data sharing across Europe. By promoting the strategic integration of AI and data technologies, Veiman ensures that Estonia remains a leader in personalised medicine within oncology, facilitating a "borderless" approach to cancer research and innovation. The Medtech Engineering and Material Science Revolution The physical reality of healthcare, wound care, tissue engineering and diagnostics, is being reimagined by Estonian engineers who apply nanotechnology and material science to clinical challenges. Olesja Bondarenko: Engineering Antimicrobial Synergy Dr. Olesja Bondarenko, CEO and co-founder of Nanordica Medical, is a researcher whose work addresses the global crisis of antimicrobial resistance (AMR) through the lens of nanotechnology. Her leadership has transformed a decade of research at the National Institute of Chemical Physics and Biophysics into a medtech company that develops first-in-class wound care products. Bondarenko’s innovation lies in the discovery of synergistic combinations of metal-based nanoparticles, such as copper oxide and silver, which can deactivate antibiotic-resistant bacteria up to six times more effectively than traditional methods. This is particularly critical for the treatment of chronic, hard-to-heal wounds, which Nanordica’s flagship product can heal twice as fast as current leading competitors. Her recognition as a runner-up for the 2025 European Prize for Women Innovators underscores the strategic value of her work in improving patient outcomes while tackling the broader societal challenge of AMR. Märt-Erik Martens: The Industrialist of Nanofibers Märt-Erik Martens, CEO and co-founder of Gelatex, is the architect of a technological shift in the production of nanofibers. Historically, nanofibers have been limited by high production costs and low scalability. Martens’s patented HaloSpin™ technology addresses these limitations by reducing production costs by up to 90%, enabling the industrial-scale use of nano0fibres in medical applications. Under Martens’s leadership, Gelatex has focused on the biotech sector, where its nanofibers serve as scaffolds for scar-reducing wound care and more efficient drug discovery models. The 2024 Innovation Radar Prize in the Health Tech category highlights Martens’s success in moving from deep-tech engineering to a commercially viable platform that can disrupt the global market for biocompatible materials. His work is essential for the next generation of regenerative medicine and tissue engineering. Digital Therapeutics and Accessibility Pioneers Estonia’s digital-first approach to healthcare provides a unique advantage for leaders developing digital therapeutics and remote diagnostic platforms. Liis Narusk: Revolutionising Remote Diagnostics Liis Narusk, co-founder and CEO of Certific, has been a central figure in decoupling clinical diagnostics from physical healthcare facilities. Founded alongside Taavet Hinrikus, Certific utilized the urgency of the COVID-19 pandemic to launch the world’s first certified remote testing service, verifying identity and test results through video recording. Following the pandemic, Narusk has transitioned Certific into a platform for broader chronic disease management, most notably through a partnership with PocDoc to tackle cardiovascular disease. This collaboration allows patients to remotely monitor blood pressure, BMI, and quantitative lipid levels through a unified digital interface. Narusk’s vision is to make healthcare "radically easier, cheaper, and more accessible" by empowering patients to perform medically certified tests—including swabs, blood, and urine tests—at home, thereby reducing the burden on primary care physicians. Andres Mellik: Digital Support for Neurological and Speech Recovery Andres Mellik, the founder of SpeakTX (and previously Cognuse), is a veteran of the digital health industry who has pioneered software solutions for critical disease management and rehabilitation. SpeakTX was developed to address the acute shortage of speech therapy professionals and the resulting long waiting lists for patients. Mellik’s approach combines clinical expertise with engaging technology to create an interactive platform for speech therapy that is currently used in nearly 500 kindergartens, schools, and hospitals in Estonia. By offering personalized therapy plans and video consultation capabilities, Mellik ensures that individuals receive the support they need regardless of their geographic location. His leadership illustrates the power of "blended care," where digital tools enhance rather than replace the role of medical professionals. Leader Company Sector Primary Technological Contribution Olesja Bondarenko Nanordica Medical Wound Care Synergistic metal-based nanoparticles for AMR. Märt-Erik Martens Gelatex Biotech Materials HaloSpin™ technology for scalable nanofibers. Liis Narusk Certific Remote Diagnostics Video-verified remote testing for chronic diseases. Andres Mellik SpeakTX Digital Therapeutics AI-enabled speech and language therapy platform. Katrina Laks Migrevention Digital Therapeutics Evidence-based digital clinic for headache management. The Ecosystem Architects and Strategic Visionaries The Estonian healthtech sector’s growth is not accidental but the result of a deliberate construction of an ecosystem that supports founders from ideation to international expansion. 9 and 10 . Erki Mölder and Siim Saare: The Gatekeepers of Health Innovation As the founders of the Health Founders accelerator, Erki Mölder and Siim Saare have created the first vertical launchpad for healthtech in the Baltics. Mölder, with a background in healthcare management dating back to 1899, and Saare, a corporate CEO turned biohacker, provide early-stage startups with the clinical and regulatory mentorship required to survive the "world's most complex industry". Their mission is to accelerate the growth of 100 health technology companies over the next decade, focusing on moving from "sick-care" models toward personalised, predictive interventions powered by AI and big data. By building an alliance of experts, including clinicians like David Yakobi and AI specialists like Shahab Anbarjafari, Mölder and Saare ensure that Estonian startups have a direct path to international markets and clinical validation. Sandra Särav-Tammus: Crafting the Policy Sandbox Sandra Särav-Tammus, Deputy Secretary General for Economy and Innovation, is a key figure in the governmental push for healthtech excellence. She has articulated a goal for Estonia to produce the highest number of healthtech unicorns per capita by 2035, a target she believes is achievable if the country addresses its workforce shortages and regulatory barriers. Särav-Tammus advocates for a "co-creation" model where the state acts as a partner to startups, helping them navigate regulatory roadblocks and ensuring that Estonia remains a "living lab" for innovation. Her work is central to the national program " Estonia.ai ," which aims to integrate artificial intelligence into all sectors of the economy by 2035, under the advisory leadership of entrepreneurs like Markus Villig and Taavi Madiberk. Clinical Trial Innovation and Data Stewardship The speed at which life-saving technologies reach the market is often determined by the efficiency of clinical trials and the strategic management of clinical data. 12 and 13. Anna-Liisa Parts and Jürgen Lorenz: Automating the Clinical Pipeline Anna-Liisa Parts, co-founder and COO, and Jürgen Lorenz, CEO of Menken Trials, have developed a platform that addresses the chronic inefficiencies in clinical trial monitoring. With Parts’s background in clinical research at Tartu University Hospital and IQVIA, the team recognized that the industry was still hampered by paper-based processes and manual errors. Their AI-enabled tool automates up to 60% of the tasks typically performed by clinical monitors, utilizing error detection algorithms to accelerate the review process. This innovation not only reduces the cost of clinical trials but also shortens the time required for drugs to reach the market, a critical factor for patient health globally. Under their leadership, Menken Trials has gained traction in US and UK markets, participating in prestigious accelerators like Tenity and CDL Estonia. Kelli Lehto: Bridging Genetics and Psychology Dr. Kelli Lehto, Associate Professor of Neuropsychiatric Genomics, leads European Research Council (ERC) funded projects that investigate the causes of complex mental health conditions like ADHD in adults. Her work is indicative of a broader trend in Estonian research that integrates genomic data with psychological and behavioural metrics to improve diagnostics. Lehto’s research into the "Genetic risk and comorbid conditions in mental health" is essential for developing next-generation psychiatric interventions. By uncovering the shared genetic components of ADHD and other chronic diseases, her work provides the data necessary for more accurate risk prediction and personalised treatment strategies. This research is a cornerstone for the future of mental health technology in Estonia. 20 Future Estonian HealthTech and MedTech Leaders FemTech and the New Standard of Hormonal Wellness One of the most rapidly growing segments within the Estonian ecosystem is FemTech, where leaders are addressing unmet needs in women’s health through innovative hardware and software solutions. Kerli Luks: Pioneering Real-Time Hormone Monitoring Kerli Luks, the founder and CEO of Muun Health, has identified a critical underserved area in women's health: continuous, non-invasive hormone monitoring. Founded in 2023, Muun Health has developed a wearable biosensor that tracks female sex hormones multiple times per day, providing real-time data to a mobile application. Luks’s medical background and ten years of experience in clinical settings informed her vision of a "glucose monitor for hormones". This technology is particularly relevant for fertility tracking and the management of hormonal imbalances that affect overall well-being. By securing €545K in pre-seed funding from strategic partners like Greiner Innoventures, Luks is positioning Muun Health as a global leader in hormone health technology, focusing on clinical validation and the expansion of the company’s IP portfolio. Agne Velthut-Meikas: Advancing Ovarian Research and Fertility Assessment Professor Agne Velthut-Meikas of TalTech has been recognized for her extensive research into female fertility and ovarian function. Awarded the title of Young Researcher of the Year, Velthut-Meikas leads studies that examine the effects of digital tools on the entrepreneurial health ecosystem and the biological mechanisms of human ovaries. Her research group’s work on fertility assessment is crucial for developing new diagnostics that can identify reproductive health disorders earlier and more accurately. This academic work is tightly integrated with the clinical and startup community, providing the fundamental science required for products that aim to increase healthy life years and improve reproductive outcomes. Leader Specialty Key Research or Initiative Impact on Sector Kelli Lehto Neurogenomics ERC project on adult ADHD. Improving mental health diagnostics via multi-omics. Kerli Luks FemTech Hardware Continuous hormone monitoring biosensor. Empowering women with real-time hormonal data. Agne Velthut-Meikas Reproductive Bio Ovarian function and fertility assessment. Scientific foundation for infertility diagnostics. Anna-Liisa Parts Clinical Trials AI-automated trial monitoring. Reducing time-to-market for life-saving drugs. Jürgen Lorenz Clinical Trials CEO of Menken Trials. Driving international adoption of trial automation. The Infrastructure of Personalisation: Digital Health and Primary Care The future of Estonian healthtech is defined by the move from descriptive analytics to predictive and prescriptive decision support, a transition enabled by leaders in digital health architecture. Peeter Ross: Educating the Next Generation of Digital Clinicians Professor Peeter Ross, a radiologist and Professor of e-Health at TalTech, is a key figure in the formal education and research programs that sustain the Estonian health ecosystem. Ross is responsible for the Digital Health master’s and PhD programs, ensuring that clinicians and engineers have a shared language for innovation. His research projects, such as NORDeHEALTH, focus on providing patients with online access to their electronic health records and increasing self-management in healthcare. By studying the implementation and adoption of personal e-health services across the Nordic countries, Ross provides the guidelines and frameworks required for successful health technology integration. His work in digital literacy for physicians and nurses ensures that the workforce is prepared for the transition to a more data-driven healthcare system. Ain Aaviksoo: Bridging Policy, Business, and Clinical Practice Dr. Ain Aaviksoo, partner and head of development at the HeBA clinic, has a unique perspective shaped by his experience as the Deputy Secretary General for Innovation at the Ministry of Social Affairs and the head of the Praxis think tank. On the advisory board of the Connected Health Cluster, Aaviksoo represents the business perspective, helping startups navigate the complexities of international health innovation. Aaviksoo’s influence is seen in his work with Guardtime, where he advises on health data security, and his leadership in clinics that integrate digital health solutions into primary care. He is a vocal advocate for the use of digital health to bridge the "implementation gap," ensuring that new technologies are not just developed but successfully adopted by healthcare providers and patients alike. The Convergence of Health and Social Impact The Estonian startup ecosystem is increasingly focused on "Impact" categories, where health and well-being are prioritised as much as economic growth. Katrina Laks: Community Leadership in Headache Management Katrina Laks, CEO and co-founder of Migrevention, is a leader in the development of evidence-based digital therapeutics for chronic conditions like migraines. Migrevention functions as a digital headache clinic, providing patients with tools to manage their symptoms and reducing the need for pharmacological intervention. Beyond her work at Migrevention, Laks serves as the Community Lead for Health Founders Estonia, where she moderates discussions on the future of personalized medicine and ensures that the healthtech community remains cohesive. Her dual role as an entrepreneur and community leader is essential for fostering the "co-creation" culture that defines the Estonian ecosystem. Mihkel Tedremaa: Continuous Body Temperature Monitoring Mihkel Tedremaa, co-founder of TempID, leads a medtech company that provides reliable and reusable solutions for continuous body temperature monitoring. This technology is vital for both home and professional care, particularly in monitoring post-operative patients and the elderly. Tedremaa’s background in engineering and product development allows TempID to offer a robust hardware solution that integrates seamlessly into digital health platforms. As healthcare shifts toward remote monitoring, the work of leaders like Tedremaa provides the necessary physical infrastructure to collect the high-fidelity data required for clinical decision support. Synthesis: The Causal Mechanisms of Estonian Success The collective work of these twenty leaders reveals a set of second-order trends that explain Estonia's outsized influence on the global healthtech stage. First, the "Data Continuity" principle is paramount. By linking genomic data (Milani, Laisk) with real-time monitoring (Luks, Tedremaa) and EHR integration (Ross, Aaviksoo), Estonia creates a continuous digital narrative for each patient. This narrative allows for the development of AI tools (Veiman, Salumaa) that can predict health events before they occur, shifting the focus from cure to prevention. Second, the "Regulatory Partnership" model is a key differentiator. The proximity between government policy (Särav-Tammus), academic research (Esko, Ross), and startup acceleration (Mölder, Saare) creates a feedback loop that accelerates innovation. This model reduces the risk for investors and allows founders to focus on clinical validation rather than bureaucratic survival. Third, the "Exportable Infrastructure" focus ensures global scalability. Whether it is a remote diagnostic platform (Narusk), a clinical trial tool (Parts), or a nanofiber production method (Martens), Estonian leaders are building solutions designed for the world's most complex and valuable markets. This focus on global impact ensures that Estonian medtech is not a local anomaly but a scalable model for the future of European medicine. The casual relationship between Estonia's digital identity and healthtech success is most evident in the work of Certific and SpeakTX. Without a secure, nationwide digital identity, remote diagnostics and verified digital therapeutics would be impossible at scale. These twenty leaders are not just building companies; they are leveraging a unique national infrastructure to define a new paradigm of human health that is personalised, proactive, and radically accessible. Leader Strategic Role Future Focus Area Lili Milani Scientific Lead Implementation of pharmacogenomics at the national scale. Peeter Padrik Clinical Innovator Personalized cancer prevention via PRS. Olesja Bondarenko DeepTech Founder Nanotechnology solutions for AMR and chronic wounds. Sandra Särav-Tammus Policy Architect Regulatory environment for healthtech unicorns. Erki Mölder Ecosystem Builder Acceleration of 100 science-based health companies. The analysis suggests that by 2035, the integration of these technologies, genomics, real-time biosensing, and AI-driven clinical support, will result in a healthcare system that is essentially invisible, operating in the background of daily life to ensure longevity and prevent disease. The twenty individuals identified in this report are the primary agents of this change, ensuring that Estonia remains the epicenter of the global healthtech renaissance. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

This Week in European MedTech and HealthTech: 10th April 2026 Major HealthTech themes this week: fresh EU funding calls (Digital Europe, EIT Health), tightening AI-in-healthcare guardrails under the AI Act, and continued shift toward clinically validated, sovereign‑cloud digital infrastructure. Policy and regulation The Commission has updated guidance on how the AI Act dovetails with MDR/IVDR, raising expectations on data quality, risk management and human oversight for high‑risk AI medical software. The EU Health Technology Assessment (HTA) framework is now fully live, with joint clinical assessments ramping and effectively lifting the evidence bar for pan‑EU market access, particularly for digital and AI‑enabled devices. Recent commentary stresses that the AI Act gives patients an explicit legal basis to demand understandable explanations of AI‑shaped medical decisions, which will force explainability and product‑design changes in clinical AI tools. EU and pan-European funding levers A new round of Digital Europe calls opens 21 April 2026, including topics on AI‑based image screening, digital solutions for regulatory compliance through data, and advanced skills for AI uptake in health, with a 1 October 2026 deadline. EIT Health’s 2026 Innovation Validation Call offers up to €850k per project (50% co‑funding) for late‑stage digital health projects ready for clinical validation and launch; micro and small enterprises must take €400k €500k of the grant at the commercialising entity. The EIC has awarded €118m to 30 deep‑tech projects, with a sizeable share into healthy ageing biotech and modular multi‑robot surgical assistance platforms, reinforcing the robotics and longevity stack in Europe. Market, product and infra moves BD has launched its Pyxis Pro medication dispensing and Incada Connected Care platforms in Europe, hosted on AWS European Sovereign Cloud to square scale with EU data‑sovereignty and localisation requirements. CMR Surgical’s Versius Plus robotic platform has now passed 40,000 procedures and is building out a richer digital analytics suite in Europe alongside a 2026 US commercial push, signalling continued convergence of robotics and data services. Johnson & Johnson has released one‑year data for ICOTYDE, paired with new digital adherence monitoring tools tailored to European payers, highlighting the bundling of therapeutics with digital companions. Capital flows and ecosystem signals Q1 2026 global digital health funding reached about $7.1bn across 216 deals, with Europe second by region at roughly $1.16bn, driven notably by France (~$323m) and Switzerland (~$302m), underscoring a resilient European capital base despite modest YoY softness. Analysts continue to characterise the current phase as a “Great Rationalization” in European HealthTech, with capital and corporate attention shifting from experimental AI to clinically validated, scalable solutions and robust cloud/data infrastructure. Near-term conferences and platforms to watch DMEA (Berlin, 21–23 April 2026) remains the flagship digital health fair in Europe with around 900 exhibitors, 20,500 visitors and hundreds of speakers, and will be a key venue for AI‑in‑EHR and hospital IT announcements. The European Digital HealthTech Conference 2026 in Luxembourg is focusing on real-world adoption of digital medical devices and trusted solutions, drawing startups, corporates, and policymakers around implementation challenges. To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk >>>>  Key MedTech themes this week: MDR/IVDR “smarter certification” reform, the EUDAMED go‑live countdown, and UK moves to lock in long‑term CE reliance, all against a backdrop of EU funding and robotics/healthy‑ageing pushes. Regulatory moves and compliance pressure The Commission’s targeted MDR/IVDR simplification advances, including removal of the rigid five‑year certificate validity cap in favour of continuous, risk‑based surveillance to ease notified‑body bottlenecks. Four key EUDAMED modules (actor, UDI/device, certificates, market surveillance) become mandatory on 28 May 2026; industry bodies are urging manufacturers to complete data validation now given litigation and transparency exposure. The MHRA’s consultation (closing 10 April 2026) proposes indefinite recognition of CE‑marked devices in Great Britain under its International Reliance Framework, materially simplifying dual‑EU/UK strategies if adopted. Strategic industry stance MedTech Europe publicly backed the MDR/IVDR simplification package, framing it as a necessary correction to high compliance costs, unpredictable timelines, and risk‑classification issues that have constrained innovation and availability. Legal and consultancy commentary this week emphasises that the reform aims to restore competitiveness and innovation while maintaining safety, suggesting a more pragmatic risk‑benefit balance for SMEs and niche device players. Funding, innovation and robotics The EIC just awarded €118m Pathfinder funding to 30 breakthrough projects, with a notable share going to biotechnology for healthy ageing and modular multi‑robot surgical assistance platforms, reinforcing the surgical robotics pipeline in Europe. New Horizon Europe HORIZON‑HLTH‑2026 calls are open, with MedTech‑relevant topics including regulatory science for patient‑centred tech, NAMs to replace animal testing in device validation, and scaling cardiovascular innovation (including AI wearables). EU4Health signed three new pre‑commercial procurement framework contracts (ceiling €225m over 98 months) to advance pandemic preparedness and vaccine innovation, signalling sustained device‑adjacent public investment in prevention and emergency tooling. Market, product and infra signals BD’s launch of Pyxis Pro medication dispensing and Incada Connected Care across Europe, built on cloud infrastructure, highlights hospital buyers’ focus on integrated medication management and connected‑care platforms. CMR Surgical’s Versius Plus robotic system has now passed 40,000 procedures and is intensifying its digital analytics offering in Europe while preparing for a 2026 U.S. commercial push, underlining the data‑services layer around capital equipment. Near‑term events and forums MedTech Europe and leading firms are positioning April–June conferences (e.g., MedTech Summit Berlin in June) as key venues to unpack MDR/IVDR reform, EUDAMED implementation, and AI‑related compliance expectations. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Finnish HealthTech and MedTech Leaders The Finnish healthcare technology sector has undergone a profound transformation, evolving from a niche engineering discipline into the nation's most significant high-tech export industry. By early 2026, the sector has established itself as a global paradigm for how a small, digitally advanced nation can leverage longitudinal data and institutional trust to solve systemic global healthcare challenges. This transition is anchored in a unique structural advantage: a century of digitised health data and a legislative framework that permits the ethical, secondary use of this data for research and development.As global healthcare systems grapple with acute staffing shortages, aging populations, and rising costs, the Finnish ecosystem offers a blueprint for data-driven, human-centric innovation. The Macroeconomic Landscape and Structural Foundations The robustness of the Finnish HealthTech ecosystem is evidenced by its significant contribution to national exports, reaching an estimated €856 Million to the United States alone in 2024. This growth is not accidental but is the result of decades of strategic public-private collaboration. Central to this infrastructure is the "Kanta" national platform, which has provided secure, seamless data access for both professionals and citizens for over a decade. Furthermore, the Act on the Secondary Use of Health Data has positioned Finland as a premier global destination for pharmaceutical R&D and clinical trials, allowing for the rapid identification of patient cohorts and real-world evidence (RWE) generation. The investment climate in 2025 reflected this maturity. Finnish deep tech companies, a category that heavily overlaps with MedTech and BioTech, set a record by raising nearly €1.6 Billion, a staggering 170% increase over 2024. While mega-rounds for companies like Oura and IQM dominated the capital inflow, the ecosystem also saw a revitalisation of seed and early-stage funding, supported by a diverse array of domestic and international venture capital firms. Investment and Funding Dynamics in 2025–2026 The following table outlines the leading venture capital entities that have been instrumental in fueling the current wave of Finnish health innovation. Their focus ranges from pre-seed software to capital-intensive deep tech and hardware. Investor Name Focus and Investment Strategy Health-Related Portfolio Strength Butterfly Ventures Pre-seed and seed hardware and deep tech specialists. 17 Investments Lifeline Ventures Early-stage growth across health, tech, and consumer. 16 Investments Business Finland Public R&D funding and internationalization grants. 15 Strategic Programs Finnvera State-owned provider of loans and guarantees for scaling. 15 Growth Packages Voima Ventures Science-based startups and deep tech commercialization. 13 Investments Tesi (Finnish Industry Investment) Late-stage and industrial scaling with social impact. 13 Investments Icebreaker.vc Software-focused pre-seed and team building. 12 Investments Innovestor Life sciences, healthtech, and sustainable innovation. 11 Investments . The data indicates a robust pipeline where early-stage firms (supported by Icebreaker and Butterfly) are increasingly finding follow-on capital from Tesi and international investors. However, analysts note that the link between early and later-stage funding (Series A and B) remains an area for continued development to prevent "innovation leakage" to other European hubs. Regional Clusters: The Engines of Innovation Finland’s health innovation is concentrated in three primary clusters, Helsinki, Oulu, and Turku, each possessing a distinct technological and clinical identity. The Helsinki Metropolitan Cluster: Biopharma and Digital Integration Helsinki acts as the administrative and financial heart of the ecosystem. It is home to the Helsinki University Hospital (HUS), which coordinates the CleverHealth Network. This ecosystem leverages HUS's high-quality clinical data to co-develop solutions with global partners like AstraZeneca, GE Healthcare, and Microsoft. The focus here is on the deep integration of AI into clinical pathways and the development of world-class biopharmaceuticals. The Oulu Cluster: Wireless Connectivity and MedTech Hardware Oulu is globally renowned for its history in telecommunications, a legacy that has pivoted toward "Wireless Health." The OuluHealth ecosystem integrates 5G and IoT expertise into medical devices. Oulu is unique in its "TestLab" environment, where 5G technology is piloted in real-time hospital operations to support remote surgery, real-time patient monitoring, and autonomous hospital logistics. The Turku Cluster: Pharmaceutical Development and Manufacturing Turku remains the stronghold of Finland’s pharmaceutical industry. It serves as a global hub for Bayer’s contraceptive R&D and manufacturing, and it is the home of Orion Corporation, the nation’s largest domestic pharmaceutical company.The region benefits from the "Veturi" program, a challenge competition designed to expand the pharmaceutical innovation ecosystem through large-scale R&D investments. The 20 Future Leaders of Finnish HealthTech and MedTech The companies identified below represent the most promising ventures poised for global leadership in the 2025–2026 period. These leaders have been selected based on their technological sophistication, clinical validation, funding success, and strategic alignment with global healthcare needs. 1. TILT Biotherapeutics: The Vanguard of Oncolytic Immunotherapy TILT Biotherapeutics, founded by Professor Akseli Hemminki in 2013, has emerged as a premier developer of oncolytic viruses for the treatment of solid tumors. The company's proprietary technology involves engineering adenoviruses to deliver immune-stimulating cytokines directly into the tumuor microenvironment. This approach is designed to overcome the "cold" immunosuppressive nature of many solid tumours, making them susceptible to the patient's own T-cells. In early 2025, TILT closed a $25 Million Series B funding round to accelerate its clinical trials. Data presented at the ESMO Congress 2025 demonstrated significant survival benefits and clinical correlations in ovarian cancer patients treated intravenously. The company is actively pursuing partnerships with global biopharma firms and is a regular fixture at major industry summits, including BIO-Europe and the ASCO Annual Meeting. 2. Gosta Labs: Redefining Clinical Workflows with AI Gosta Labs addresses one of the most critical issues in modern healthcare: clinician burnout. Founded by former Kaiku Health entrepreneurs, Gosta Labs has developed an "AI Operating System" for healthcare professionals. The platform uses medical-grade AI to automate clinical documentation, patient data structuring, and the surfacing of real-time clinical insights. By February 2026, Gosta Labs became the first AI OS to be registered as a medical device in the European EUDAMED database. The company has expanded its operations to France and secured €7.5 Million in seed funding led by Voima Ventures. Its ability to reduce administrative pressure is being demonstrated in partnerships with major Finnish private providers like Aava and public wellbeing services in Satakunta and Kirkkonummi. 3. Solid IO: Precision Oncology through Tumour-on-Chip Technology Solid IO is a biotech innovator specialising in patient-specific tumour-immune response modeling. Their "tumour-on-chip" technology replicates an individual patient's unique tumor microenvironment using bioengineering and AI. This allows oncologists to test the efficacy of various immuno-oncology treatments before they are administered, effectively eliminating the trial-and-error approach common in cancer therapy. Founded in 2025, the company has quickly gained international visibility, particularly at the HLTH USA 2025 conference.With €800,000 in early-stage funding, Solid IO is expanding its collaborations with pharmaceutical partners to integrate its platform into drug development pipelines, aiming to improve the success rate of new cancer therapies. 4. Nadmed: Standardising NAD Diagnostics Nadmed provides advanced diagnostic solutions for measuring nicotinamide adenine dinucleotide (NAD) levels—a key biomarker for energy metabolism and cellular health. Low NAD levels are increasingly linked to aging, metabolic disorders, and neurodegenerative diseases. Nadmed’s technology allows for accurate measurement using fresh blood samples, a significant advancement over previous, less reliable methods. The company, led by CEO Jari Närhi, has raised $4 Million and established manufacturing operations in California to serve the US market. Nadmed was a standout participant in the 2025 Business Finland Amplify program, which facilitates direct engagement with the Mayo Clinic. 5. Medicubex: The Autonomous eHealth Station Medicubex has addressed the primary care access crisis with its eHealth Station™, a self-service kiosk that enables patients to perform a comprehensive health check in five minutes. The station measures vital signs including blood pressure, ECG, and blood oxygen, and uses AI to provide immediate risk assessments for cardiovascular and metabolic conditions. In 2025, Medicubex won a €4 million tender to deploy these stations across 15 Finnish wellbeing services counties.Internationally, the company has partnered with the Frankfurt University Hospital and was selected for the German Medical Forge accelerator. With over €3 Million in total funding, Medicubex is scaling rapidly across Europe and the UK. 6. CurifyLabs: Digitalising Personalised Medicine CurifyLabs is transforming the compounding pharmacy sector with its automated "PharmaPrinter Aurum" system. By using 3D-printing inspired technology, CurifyLabs allows pharmacies to manufacture personalised medicines tailored to a patient’s specific dosage, flavour and release profile. The company’s solution ensures digital traceability and compliance, which are major hurdles in traditional manual compounding. In 2025, CurifyLabs conducted a global "World Tour," showcasing its technology at major forums like the APhA in Nashville and the EAHP Congress in Copenhagen. The company is strategically positioned to lead the shift toward mass customisation in pharmaceuticals. 7. Oura Health: The Medical-Grade Wearable Pioneer Oura Health has transitioned from a popular sleep tracker to a foundational tool for population health and clinical research. In 2025, the company raised $900 Million, reaching a valuation of $11 Billion. This funding is being used to enhance Oura’s AI capabilities, moving toward predictive health analytics that can detect the early onset of illness based on biometric deviations. Oura’s success demonstrates the Finnish ability to combine high-end sensor engineering with sophisticated data science.By 2026, the Oura Ring is increasingly integrated into employer-sponsored wellness programs and clinical trials as a validated tool for continuous biometric monitoring. 8. Otos Health: Accelerating Hearing Diagnostics Otos Health addresses the "invisible" epidemic of hearing loss. Their automated hearing diagnostics system enables non-clinical staff to perform gold-standard hearing tests in parallel, reducing the time required by 50%. This "triage-at-the-source" model allows primary care clinics to identify hearing issues earlier and refer patients more effectively. Led by CEO Wycliffe Raduma and CTO Ville Sivonen, Otos Health is a key beneficiary of the Business Finland Health 360 program. The company was selected for the Finland Pavilion at HLTH USA 2025, seeking to enter the US market where hearing aid deregulation and the aging population are driving demand for accessible diagnostics. 9. Buddy Healthcare: Care Coordination and Patient Engagement Buddy Healthcare’s platform automates patient communication and streamlines perioperative care pathways. By digitising forms, pre-operative assessments, and patient-reported outcomes (PROs), the platform reduces the administrative burden on hospital staff while improving patient compliance and recovery outcomes. Hospitals using Buddy Healthcare report a 98% reduction in phone calls and a 30% reduction in surgical cancellations.The company is actively expanding in the US and Europe, focusing on high-volume surgical specialties like orthopaedics and cardiology. 10. Monidor: Intelligent Infusion Monitoring Monidor, based in Oulu, has developed a remote monitoring solution for intravenous (IV) infusion therapy. Their technology allows nurses to monitor infusion rates and fluid levels from a central station, ensuring patient safety and improving nursing workflow efficiency. The system is designed to integrate seamlessly into existing hospital IT infrastructures and has seen strong adoption in Finnish and Nordic hospitals. Monidor’s growth is fuelled by the critical need to optimise hospital resources amid global nursing shortages. 11. Cerenion: AI for Critical Care Brain Monitoring Cerenion provides an AI-powered bedside EEG monitoring solution specifically designed for intensive care units (ICUs).Their "C-Trend" technology translates complex EEG signals into a simple "brain state" index, allowing non-specialists to monitor the neurological status of critically ill patients. Founded in 2017 in Oulu, Cerenion bridges the gap between academic research in clinical neurophysiology and the practical needs of emergency medicine. The company is currently scaling its international presence, targeting ICUs where early detection of neurological complications can significantly improve patient survival rates. 12. Medanets: Empowering the Mobile Clinician Medanets provides mobile solutions that allow healthcare professionals to document vital signs and access patient data directly at the bedside. By integrating with existing electronic health records, Medanets eliminates the need for manual transcription, reducing errors and saving clinicians significant amounts of time. With a history dating back to 2004, Medanets is a mature leader in the Finnish digital health space, serving public healthcare organizations across Europe. The company continues to innovate by adding AI-driven decision-support features to its mobile platform. 13. Ounas Health: Care Connectivity and Workflow Automation Ounas Health has developed a modular, AI-driven care connectivity platform designed to automate clinical workflows.The platform acts as a digital orchestrator, ensuring that clinical data from various sensors and systems is directed to the appropriate clinical team members in real-time. This "connectivity-as-a-service" model is particularly relevant for modern "smart hospitals" that utilize a multitude of disparate digital tools. Ounas Health is part of the high-tech MedTech cluster in Oulu, leveraging the region’s heritage in telecommunications and systems integration. 14. Nucu: Science-Based Sleep for Infants Giving sleep a voice to support growing minds from childhood to young adulthood.At Nucu, we believe that sleep is the most powerful tool for a developing brain. It is the foundation for a child’s growth, focus, and happiness—yet millions of kids and teens struggle with bedtime routines, restless nights, and tired mornings.We are redefining sleep health for children and teenagers aged 4–18 with safe, non-wearable technology that helps them sleep better, grow stronger, and thrive. By giving sleep a voice, we provide families with the insights needed to support growing minds during their most formative years. We offer advanced contact-free sleep monitoring for kids and teens aged 4-18 years, which easily integrates with any bed. In an instant, your kids’ bed becomes a smart bed with Nucu. The Nucu hub also monitors the sleep environment, including temperature, humidity, ambient light, and noise levels. It provides parents and children with AI-powered insights through the Nucu companion mobile app to support better sleep, health, and development. 15. Koite Health: Photodynamic Oral Care Koite Health has gained international attention for its Lumoral device, which uses photodynamic therapy to target the bacteria responsible for periodontitis and dental decay. This non-invasive, non-antibiotic treatment is particularly important in the context of the global rise in antimicrobial resistance. Koite Health participated in the Finland Pavilion at HLTH USA 2025, where it highlighted the systemic link between oral health and chronic conditions like cardiovascular disease and diabetes. The company is scaling its consumer and professional distribution networks across Europe and North America. 16. Sartar Therapeutics: Repurposing Drugs for Rare Cancers Sartar Therapeutics is a biotech firm focusing on soft tissue sarcomas and other difficult-to-treat cancers. The company uses a precision-led approach to repurpose existing drugs, optimising their delivery to specific tumour types where there is a high unmet clinical need. In late 2025, Sartar secured funding alongside Medicubex to advance its clinical pipeline. By utilising the Finnish biobank system and the Fingenious ecosystem, Sartar can rapidly validate its therapeutic targets and move toward late-stage clinical trials. 17. Polku Therapeutics: Targeting Neurodegeneration Founded in 2023, Polku Therapeutics is a discovery-stage biotech company developing small molecule drugs for neurodegenerative diseases like Parkinson’s and Alzheimer’s. The founding team includes leading experts in pharmacology and neurology from the University of Helsinki. Polku has raised $2.3 Million to date. Their research focuses on modulating protein aggregation and neuroinflammation, two key drivers of neurodegenerative decline. As the global population ages, Polku’s science-heavy approach makes it a prime candidate for future acquisition or partnership with major pharmaceutical firms. 18. EpiHeart: Advanced Cardiac Micrograft Therapy EpiHeart is a medical device innovator focused on enabling "Cardiac Micrograft Therapy" during surgical interventions.This therapy involves applying a micrograft of the patient's own tissue to areas of the heart damaged by lack of oxygen (ischemia), promoting healing and preventing heart failure. EpiHeart is currently moving through the clinical validation and commercialization phases for its micrograft processing kits. The company represents the high-end surgical innovation occurring within the Helsinki health ecosystem. 19. Maculaser: Fighting Blindness with Controlled Heat Maculaser has developed a novel medical device for treating retinal diseases, specifically focusing on age-related macular degeneration (AMD). Their technology uses precisely controlled laser-induced heat to stimulate the retinal pigment epithelium, aiming to restore its function and halt the progression of blindness. Maculaser’s approach is a non-invasive alternative to the intravitreal injections that are currently the standard of care for wet AMD. The company is currently engaged in clinical trials to validate the long-term safety and efficacy of its treatment. 20. Moncyte Health: Precision Lipid Diagnostics Moncyte Health provides a "cellular lipid-fingerprint" diagnostic for cardiovascular disease risk. Unlike traditional cholesterol tests, Moncyte’s technology analyses how cells actually process lipids, providing a personalised risk profile that can guide more effective treatment plans. This "lipidomics" approach allows for the elimination of treatment trial-and-error, ensuring that patients receive the most appropriate lipid-lowering therapies early on. Moncyte was featured in the Finland Pavilion at HLTH USA 2025, positioning itself as a leader in the next generation of preventative cardiovascular diagnostics. Strategic Internationalisation: The North American Frontier A defining characteristic of the 2025–2026 period is the Finnish health sector’s aggressive pursuit of the North American market. The United States remains the largest global market for health technology, and Finnish companies are increasingly viewed as stable, innovative partners amid ongoing global geopolitical uncertainty. The Mayo Clinic Partnership and the AMPlify Program Business Finland’s AMPlify program represents a significant strategic bridge between Finland and the Mayo Clinic, which has been consistently voted the world’s best hospital. The program provides Finnish companies with direct access to Mayo Clinic experts, clinical decision-makers, and investors. AMPlify Program Phase Key Activities and Outcomes Curated Workshops Expert-led sessions on U.S. regulatory (FDA) and reimbursement pathways. Mentorship One-on-one sessions with Mayo Clinic key opinion leaders (KOLs). Investor Insights Pitching opportunities to U.S.-based healthcare venture capital firms. On-Site Visit A November 2026 delegation to Mayo Clinic, Rochester, Minnesota. Market Entry Development of scalable collaboration and commercialization pathways. . Of the 25 companies that applied for the 2025 AMPlify cohort, 11 were selected, including leaders like Nadmed, Otos Health, and MultivisionDx. This program has already resulted in seven term sheet offers, demonstrating the high level of American interest in Finnish innovation. The Global Outreach Missions In March 2026, a high-level Finnish government delegation is scheduled to visit the major healthcare hubs of New York and Boston. This visit targets influential institutions such as Memorial Sloan Kettering, Pfizer, and the Broad Institute.The goal is to solidify Finland’s reputation as a world-class health innovation partner and to facilitate high-level connections for companies in the oncology, imaging, and health data sectors. Analysing Sector Trends: The Future of Global Health The leaders identified in this report are navigating a landscape defined by several transformative trends that will dictate the next decade of healthcare. 1. AI as the Stabilizing Force for the Workforce The global healthcare staffing crisis has reached a breaking point, with burnout affecting nearly 48% of employees worldwide. Finnish companies are responding by positioning AI not just as a tool for clinical insight, but as a "daily workhorse" that stabilizes the workforce. By automating documentation (Gosta Labs) and routine checks (Medicubex), these technologies provide clinicians with the "gift of time," allowing them to focus on high-value patient care. 2. The Resurgence of MedTech M&A Following a surge in deal value to $97.6 billion in 2025, the MedTech M&A market is entering 2026 with strong momentum. Acquirers are increasingly seeking targets that offer "connected-care" ecosystems and AI-driven analytics.Finnish companies, with their strong focus on data integration and interoperability, are highly attractive targets for global strategics looking to modernise their portfolios. 3. Sustainability as a Core Metric In 2025, 87% of transactions within the Business Finland Health 360 program met stringent responsibility and sustainability objectives. This reflects a broader trend where healthcare companies are increasingly rewarded for demonstrating their commitment to environmental, social, and governance (ESG) goals. This is particularly evident in sectors like remote monitoring and digital health, which naturally reduce the carbon footprint of healthcare delivery. Conclusion: Finland's Role in the Global Healthcare Renaissance The Finnish HealthTech and MedTech ecosystem is currently at an inflection point. The combination of a robust domestic testbed environment, unparalleled health data resources and a strategic focus on internationalization has created a unique launchpad for high-impact innovation. The 20 leaders identified in this report, from the biopharmaceutical pioneers like TILT Biotherapeutics to the digital health innovators like Gosta Labs, are not only building successful businesses but are also providing scalable solutions to some of humanity's most pressing health challenges. As the industry moves through 2026, the success of these companies will be measured by their ability to navigate the complexities of the US and European markets while maintaining the "sisu", the uniquely Finnish characteristic of resilience and determination, that has brought them to the global stage. The future of healthcare is increasingly human-centric, digital, and data-driven, and in this future, Finland is poised to lead. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Czech HealthTech and MedTech Leaders The healthcare technology and medical device sectors in the Czech Republic have reached a critical inflection point in 2026, transitioning from a regional innovation hub into a sophisticated global contender. This evolution is defined by a shift in capital allocation strategies, moving away from fragmented, early-stage experimentation toward a disciplined focus on profitability, clinical validation and scalable business models. As of early 2026, the European healthtech market, valued at approximately $96.68 billion, is navigating a period of strategic evolution influenced by a reorientation of investor priorities. Within this context, the Czech ecosystem, centred largely in the innovation corridors of Prague and Brno, has distinguished itself through a high concentration of deep tech expertise, robust academic spin-off frameworks, and a successful navigation of the rigorous European Medical Device Regulation (MDR). The resilience of the Czech sector is evidenced by its ability to secure significant funding rounds despite a 7.7% year-on-year decline in total investment for Czech founded startups in 2025, which totalled approximately €540 million. Notably, the healthtech vertical remained a cornerstone of this activity, with high-conviction "mega-deals" and strategic pre-seed rounds signaling a maturation of the ecosystem. This report identifies and analyses 20 pivotal leaders whose vision and technical execution are shaping the future of Czech healthtech and medtech, categorised by their impact on diagnostic intelligence, chronic disease management, advanced biotechnology and the burgeoning field of digital resilience. The Vanguard of Artificial Intelligence in Radiology and Diagnostics The integration of artificial intelligence into clinical workflows represents the most significant technological shift in Czech healthcare between 2024 and 2026. The focus has moved beyond the mere detection of pathologies to the creation of "unified AI platforms" that address the systemic issue of physician burnout and administrative overload. 1. Matěj Misař: Orchestrating the Unified AI Portfolio at Carebot Matěj Misař, as CEO and co-founder of Carebot, has transformed a startup focused on pneumonia detection into a leading European provider of comprehensive AI solutions for hospitals. Misař’s background in media and news hosting provided a unique skill set for navigating the complex public and regulatory dialogues surrounding AI adoption in medicine. In late 2025, Misař led the launch of the "Horizon by Carebot" portfolio, a strategic move designed to eliminate the technical barriers hospitals face when integrating multiple separate AI vendors. Under Misař’s leadership, Carebot secured MDR Class IIa certification, a critical milestone that validates the technology for use across the European Union. The company’s focus on "incidental detection", identifying early-stage lung cancer or other pathologies in routine imaging, has provided the clinical and economic justification necessary for widespread adoption. By 2026, Carebot has expanded its footprint beyond the Czech Republic into Southeast Asia (Vietnam) and the Middle East, demonstrating Misař’s ability to scale Czech innovation onto the global stage. 2. Daniel Kvak: The Scientific Architect of AI-Driven Clinical Practice Daniel Kvak, Carebot’s CTO, represents the next generation of Czech medical scientists who bridge the gap between complex machine learning and actual bedside utility. Kvak’s expertise in developing algorithms for chest X-ray analysis, mammography, and CT scans has earned him international recognition, including a place on the Forbes 30 Under 30 list and the " Personality.AI 2024" award. Kvak’s technical philosophy emphasises "explainable AI" and rigorous clinical validation. He has co-authored numerous award-winning scientific studies and serves as a reviewer for prestigious journals like European Radiology . By 2026, Kvak’s focus has shifted toward the development of the AI Bones module, which automates fracture detection, and the AI Head CT application for rapid identification of critical brain abnormalities. His work ensures that the Czech Republic remains a leader in the development of tools that reduce the diagnostic burden on radiologists while improving patient outcomes. Core Leader Primary Affiliation Key Achievement (2025-2026) Global Impact Area Matěj Misař Carebot Launch of Horizon Portfolio Hospital Workflow Optimization Daniel Kvak Carebot MDR Class IIa Certification for Multiple Modules Diagnostic Accuracy & Safety Marek Řehoř Carebot Scaling operations to 40+ European hospitals Operational Scalability Daniel Dufek Carebot Leading development of AI Head CT systems Emergency Radiology Cardiovascular Innovation and the Long-Term Monitoring Revolution The cardiovascular segment is undergoing a paradigm shift from acute care to continuous, AI augmented monitoring. This shift is necessitated by the high prevalence of heart arrhythmias that go undetected during standard clinical observation windows. 3. Vlastimil Hrabal: Scaling Cardiac Diagnostics into the DACH Region Vlastimil Hrabal, appointed as CEO of Kardi AI in April 2025, has been instrumental in the company’s transition from a promising Czech startup to a Series A-ready international medtech leader. Hrabal’s strategic focus on the DACH region (Germany, Austria, Switzerland) addresses the fundamental challenge of procurement and reimbursement in Western European healthcare systems. Kardi AI’s core product, an AI-powered chest strap that detects arrhythmias, addresses the "monitoring gap" where traditional 24-hour Holter monitors fail to capture rare or transient events. Hrabal has successfully positioned the company as a provider of "physician-ready outputs," reducing the review burden for cardiologists by delivering evaluated signal reports in an average of five minutes. This technical efficiency, combined with Hrabal’s leadership, has led to a doubling of sales and the launch of pilots across Bulgaria, Poland, Slovakia and Romania. 4. Prof. Tomáš Skála: Bridging Clinical Science and Wearable Technology As Chief Science Officer and co-founder of Kardi AI, Prof. Tomáš Skála provides the clinical gravitas necessary for a startup to be trusted by national healthcare providers. Skála, a practicing cardiologist, identified the inherent limitations of standard diagnostic tools and sought to create a "globally accessible, medically trusted" solution. Skála’s work focuses on the clinical validation of the AI layer, which evaluates ECG signals from a long-term chest strap.His research indicates a 30% detection rate for Kardi AI, which is roughly six times higher than traditional short window testing. By 2026, Skála is overseeing clinical trials at university hospitals in Olomouc and Ostrava, further strengthening the evidence base for continuous heart monitoring. His vision extends to making cardiac screening as routine and accessible as checking one's blood pressure, potentially preventing thousands of strokes and heart failure cases annually. Cardiovascular Leader AFFILIATION CORE INNOVATION FUNDING/STAGE Vlastimil Hrabal Kardi AI International scaling to DACH/CEE €1.1M Seed+ (2025) Prof. Tomáš Skála Kardi AI AI-driven long-term ECG analysis Series A Ready (2026) Stephen Burke Kardi AI Co-founder and Executive Director 3 Rounds Raised The New Frontier of Oncology and Genomic Medicine The Czech Republic’s biotechnology sector is increasingly defined by university spin-offs that target the fundamental molecular pathways of resistant diseases. These leaders are navigating the longest R&D cycles with high levels of strategic patience and technical precision. 5. Alexander Scheer: Leading the Global Charge Against Resistant Tumors Alexander Scheer, PhD, is the CEO and CSO of Casinvent Pharma, a Masaryk University spin-off that has become the leading Czech drug discovery company in 2026. Scheer brings over 25 years of international experience in the life science industry, having previously served as CSO for biotech companies in Belgium and France. At Casinvent, Scheer is advancing a unique "pan-isoform" approach to inhibiting the Casein Kinase 1 (CK1) family of enzymes. While many competitors focus solely on the alpha isoform, Scheer’s team has developed small-molecule inhibitors that simultaneously target the alpha, delta and epsilon isoforms. This approach is designed to bypass the adaptation pathways that cancers use to develop resistance to standard targeted therapies. By mid 2026, Scheer is preparing the company for its IND (Investigational New Drug) filing and entry into clinical Phase Ia/b trials, supported by a Series A funding target of €10-12 million. 6. Tomasz Radaszkiewicz: The Biological Engine Behind Next-Generation Inhibitors Tomasz Radaszkiewicz serves as the Head of Biology at Casinvent Pharma and is a central figure in the identification of novel therapeutic strategies for Wnt-driven malignancies. Radaszkiewicz’s work involves the rigorous screening of over 500 candidates to select lead compounds with exceptional in vivo efficacy in treating acute myeloid leukemia (AML), melanoma, and pancreatic cancer. Radaszkiewicz’s role is critical for providing the biological evidence that supports the company’s intellectual property claims and attracts institutional investors like KHAN-I and JIC Ventures. His leadership in biological research has led to significant publications in journals like Cell Reports Medicine , positioning Casinvent as a scientifically superior alternative to current targeted degraders. 7. Petr Cigler: Pioneering Advanced Lipid Nanoparticle Technology As Chief Scientific Officer of Adalid Sciences, Petr Cigler is addressing the global "delivery bottleneck" for genomic medicines. Adalid, founded in 2024, focuses on the development of lipid nanoparticle (LNP) systems that transport nucleic acids, such as mRNA and gene-editing tools, into human cells. Cigler’s strategic innovation lies in the company’s "integrated IP portfolio," which focuses on new ionizable compounds and lipid-polymer conjugates. This technology eliminates the need for pharmaceutical companies to source delivery components from multiple vendors, streamlining the development of RNA therapeutics. Under Cigler’s scientific guidance, Adalid has built a diverse library of several patent families focused on flexible and constrained lipids, providing precise control over particle design for specific payloads. 8. Andrea Brazdova: Validating the Future of RNA Delivery Andrea Brazdova, PhD, is the Head of Biology at Adalid Sciences, where she leads the biological validation of next-generation LNPs. Brazdova is a senior immunologist with postdoctoral training in cellular therapy and immuno-regulation. Her work at Adalid involves linking formulation design with in vitro functionality and in vivo validation, ensuring that nucleic acid medicines reach their clinical impact. Brazdova’s expertise in immune response characterization is particularly relevant as the industry moves toward localized and systemic delivery routes for complex gene editing. Her leadership in screening LNP candidates against human primary cells ensures that Adalid’s solutions are optimised for safety and efficacy before they reach clinical trials. Biotech Leader Affiliation Technology Focus Role in Ecosystem Alexander Scheer Casinvent Pharma CK1 $\alpha/\delta/\epsilon$ Inhibitors Global Strategic Leadership Tomasz Radaszkiewicz Casinvent Pharma Wnt-driven Malignancy Research Clinical Strategy & Biology Petr Cigler Adalid Sciences LNP Structural Differentiation IP Development & Chemistry Andrea Brazdova Adalid Sciences Biological Validation of RNA Delivery Preclinical Translation Digital Resilience and the Evolution of Mental Health Technology Mental health has emerged as one of the most attractive investment targets in 2025-2026, with total M&A value in the CNS (Central Nervous System) segment reaching over $30 billion. Czech leaders are pioneering a new category of "digital resilience" that uses AI to mitigate the negative psychological impacts of the digital environment. 9. Jan Romportl: The Visionary Behind "Cognitive Antivirus" Dr. Jan Romportl, co-founder and CEO of Elin.ai , is a leading expert in cybernetics and AI ethics who has pivoted his expertise toward the growing mental health crisis among Generation Z. Elin.ai , founded in 2023, develops an AI-powered assistant designed to support users in challenging digital environments. Romportl’s "cognitive antivirus" concept works as a protective layer for the brain, helping users recognise digital overload and algorithmic pressure before they lead to "brainrot" or anxiety. Under Romportl’s leadership, Elin.ai raised a €1 million pre-seed round to further develop its empathetic dialogue LLMs (Large Language Models), which are trained in close collaboration with clinical experts to detect distress signals and provide proactive interventions. His work represents a shift from reactive therapy to preventive digital well-being. 10. Soňa Sikorová: Scaling Digital Therapeutics for Chronic Psychiatry Soňa Sikorová is the CEO and co-founder of Mindpax, a digital therapeutics company that has become a global leader in the management of bipolar disorder. Mindpax utilises a combination of long-term symptom monitoring (via actigraphic sensors) and targeted digital therapy to improve the clinical condition of patients. Sikorová has been instrumental in securing large-scale commercialization partnerships, most notably with EVERSANA in the United States, to launch Mindpax’s solution as a regulated digital therapeutic. Her leadership focuses on evidence generation; Mindpax has conducted years of clinical studies to develop the world's largest dataset of its kind for bipolar patients. By 2026, Sikorová is steering the company toward full integration with U.S. and European healthcare systems, utilizing AI-powered data insights to optimize treatment outcomes in real-time. 20 Future Czech HealthTech and MedTech Leaders 11. Jiří Horáček: The Bridge Between Neuroscience and AI Startups Professor Jiří Horáček is a psychiatrist, neurobiologist, and co-founder of both Elin.ai and Mindpax. His influence in the Czech medical community is profound; he has published over 200 scientific articles and is recognized as one of the "TOP 50 Doctors" in the Czech Republic. Horáček’s leadership provides the scientific legitimacy required for AI startups to operate in the highly regulated field of clinical psychiatry. He specialises in brain imaging and the use of biomarkers to understand affective disorders. Within Elin.ai , he oversees the training of AI models to ensure they remain non-toxic and empathetic, while at Mindpax, his research into circadian rhythms and suprachiasmatic nuclei (SCN) functioning forms the basis of the company’s monitoring algorithms. Mental Health Leader Project Key Concept Impact Goal Jan Romportl Elin.ai Cognitive Antivirus Digital Resilience for Gen Z Soňa Sikorová Mindpax Digital Therapeutics (DTx) Long-term Bipolar Management Jiří Horáček Elin.ai/Mindpax Empathetic AI Dialogue Scientifically Validated Well-being Lukas Krcil Hedepy Accessible Online Therapy Stigma-free Mental Healthcare Precision Medicine, Longevity and Data Aggregation The "longevity" market focused on extending the healthy human lifespan is moving from wellness hype toward data-driven precision medicine. Czech leaders are building the platforms that unify disparate health data into actionable insights. 12. Petr Štěpánek: The Entrepreneurial Force Behind Macromo Petr Štěpánek, CTO and co-founder of Macromo, is a serial entrepreneur who founded his first project at the age of 16 and has since become a central figure in the Prague startup community. Macromo serves as a health data aggregator, providing users with a holistic view of their health by combining DNA results, blood biomarkers and lifestyle data from wearables. Štěpánek’s vision is to use AI to provide everyone with a "personal health coach" that transforms raw data into clarity. His technical leadership led to the creation of the Macromo Engine, a cloud-based bioinformatics system that contextualises biomarkers over time to identify unique health risks and opportunities. Štěpánek’s proactive approach to fundraising, including independent trips to Silicon Valley to build investor networks, underscores his ambition to take Czech precision medicine technology global. 13. Michal Pohludka: Driving the Clinical and Commercial Bridge Michal Pohludka, PhD, MBA, is a biochemist with a background in molecular pathology and the CEO of GeneSpector and co-founder of Macromo. Pohludka represents the "business scientist" archetype, capable of navigating the extremely regulated pharmaceutical and medical fields. Under Pohludka’s leadership, GeneSpector succeeded in the COVID-19 diagnostic market (generating over $25 million in sales) and subsequently pivoted to global diagnostics for kidney disease and other chronic conditions. His strategy focuses on technology transfer, moving projects from the laboratory to the market through licensing or spin-offs. At Macromo, Pohludka leverages this commercial expertise to build partnerships with certified laboratories and ensure that personalised healthcare is both accessible and actionable. Medtech Infrastructure, Hardware and Biomimetic Innovation Hardware and physical medical devices remain critical for surgical advancement and patient safety. Czech leaders in this segment are using nanotechnology and biomimetic principles to revolutionise traditional procedures. 14. Markéta Hujerová: Revolutionizing Surgery with Nanofiber Patches Markéta Hujerová (née Klíčová) is the founder of Nanoflexion, a spin-off from the Technical University of Liberec.Hujerová’s work centres on the development of a nanofiber surgical patch designed to prevent serious complications after intestinal surgery, such as anastomotic leakage and adhesions. Hujerová’s innovation addresses a critical clinical need: sepsis following colon surgery currently kills up to 22% of affected patients. The nano-patch acts as a biological barrier and carries drugs to suppress inflammation and promote healing. In late 2025, Hujerová signed a pivotal incubation agreement with i&i Prague and Charles University to commercialise the technology and move toward human clinical trials. Her journey from academic research to presenting her project at the World Expo in Osaka illustrates the potential for Czech female scientists to lead global medtech ventures. 15. Miroslav Svoboda: The Snail-Eye Inspiration for Patient Comfort Miroslav Svoboda, MD, is the CEO and project initiator of Riocath Global, a company that has developed a revolutionary technology for tubular medical devices. The RIOCATH® mechanism, inspired by the unfolding of a snail’s eyestalk, allows for a double-skinned catheter that extends from the inside out. Svoboda’s invention significantly reduces the risk of infection and tissue damage during catheterisation, a major issue in hospitals worldwide. By virtually eliminating the friction between the catheter casing and the urethra wall, the technology makes for safer and more comfortable patient care, potentially saving healthcare systems millions in antibiotic costs for urinary tract infections. Svoboda’s ability to raise over two million euros from private investors and secure global patents through the European Patent Office marks him as a leader in Czech bio-mechanical innovation. 16. Jiří Kuchyňa: Advancing Scalable AI in Ophthalmology Jiří Kuchyňa is the CEO of Aireen, a startup that has developed a fundus-camera-agnostic AI system for chronic disease screening through retinal analysis. Under Kuchyňa’s leadership, Aireen achieved a strategic partnership with Optomed to integrate its AI algorithm into handheld fundus cameras, making diabetic retinopathy screening more accessible than ever. Kuchyňa’s focus on scalability addresses a major public health challenge: the need for sensitive and accurate screening of chronic diseases without requiring a visit to a specialist. By 2026, Kuchyňa is positioning Aireen as a critical component of primary care, enabling early detection of diseases that would otherwise lead to permanent blindness. Medtech Infrastructure Leader AFFILIATION CORE TECHNOLOGY IMPACT Markéta Hujerová Nanoflexion Nanofiber Surgical Patch Post-Surgical Sepsis Prevention Miroslav Svoboda Riocath Global Double-skinned Catheter Infection Risk Reduction Jiří Kuchyňa Aireen Retinal AI Screening Accessible Ophthalmology Pavel Rozsíval Viderai High-speed Retinal Analysis Mass-Screening Populations Emerging Disruptors and the Institutional Backbone The long-term success of the Czech healthtech ecosystem is contingent upon leaders who build the infrastructure for innovation and venture capital, as well as those who pivot established tech success into the medical field. 17. Jan Studnička: Leading the Mass-Screening Effort at Viderai Jan Studnička, PhD, is a vitreo-retinal specialist and a core leader at Viderai, an innovative startup aimed at making retinal screening affordable for the general population. Studnička’s clinical expertise in age-related macular degeneration and diabetic retinopathy ensures that Viderai’s AI algorithms deliver specialist-level sensitivity (99%) in routine scans. Viderai’s mission, supported by Studnička’s clinical leadership, is to lower public healthcare expenses by detecting disorders early through mass-screening applications. By automating the routine work of analysing eye scans, Studnička and his team are increasing the examination capacity of clinics, allowing ophthalmologists to focus on complex surgical cases while the AI handles the bulk of the population screening. 18. Otomar Slama: The Catalyst for Science-to-Business Transfer Otomar Slama is a co-founder of GeneSpector and a key figure in the Czech "spin-off" ecosystem. His work focuses on the commercialisation of academic research, bridging the gap between discovery and market-ready clinical diagnostics. Slama’s leadership within GeneSpector has helped create a portfolio of solutions for nucleic acid extraction and PCR-based diagnostics that compete with global giants like Natera and GeneDx. Slama’s influence extends beyond a single company; he is a model for how technology transfer offices and university funds can successfully navigate the complexities of patents, licensing and venture building. His work ensures that the Czech scientific output in biomedicine is not just academic, but industrially viable and beneficial to the national economy. 19. Karel Kubias: Navigating the Venture Capital Life Science Wave Karel Kubias, MBA, is a Founding Partner at the i&i Biotech Fund (i&i Bio), one of the few VC funds in Central Europe focused exclusively on life science ventures. With over 20 years of leadership experience in pharma and diagnostics (including roles at Merck), Kubias is a critical gatekeeper and accelerator for Czech healthtech leaders. Under Kubias’s guidance, the i&i Biotech Fund, established in cooperation with the European Investment Fund (EIF), is investing over €45 million into academic spin-offs in drug discovery, medical devices and digital health. Kubias’s role is to identify founders with a "clear edge" and provide the capital and strategic guidance required to take Czech innovations global. His leadership at the fund level is what enables leaders like Alexander Scheer and Markéta Hujerová to move from proof-of-concept to clinical reality. 20. Barbora Šumová: Identifying the Next Wave of Medtech Success Barbora Šumová, PhD, is a Partner at i&i Bio and a specialist in innovative biotech and medtech ventures. With a PhD in Immunology, Šumová brings deep technical understanding to the investment process, allowing the fund to vet complex biological and technical claims that traditional VCs might miss. Šumová’s leadership in portfolio management and board leadership is vital for the growth of companies like Casinvent Pharma. She represents a new generation of Czech female investment leaders who are shaping the national landscape by focusing on high-tech innovations that fundamentally improve patient care. Her work ensures that the Czech Republic remains competitive in the European healthtech scene through 2026 and beyond. Strategic Market Dynamics: The 2026 Narrative The Czech healthtech landscape is being reshaped by several overarching trends that dictate the strategies of these 20 leaders. The first is the acceleration of digital transformation and AI, with 48% of life science leaders identifying this as the most substantial trend for 2026. The proliferation of generative AI is no longer a peripheral experiment but a core driver of clinical operations and research efficiency. Furthermore, the rise of MDR as a competitive moat cannot be understated. While the regulation is often viewed as a burden, for Czech leaders like Carebot and Kardi AI, achieving MDR Class IIa certification has become a mark of quality that facilitates market entry into the conservative DACH region and beyond. This regulatory hurdle has effectively filtered out less disciplined competitors, leaving a concentrated group of high-impact players. The third major trend is the rise of defence-linked biotech and dual-use innovation. The selection of Czech-linked technologies for the NATO DIANA 2026 cohort underscores a new geopolitical reality: biotechnology is now a core pillar of national and regional security. Funding for "human resilience" and "trauma diagnostics" through NATO and EU instruments provides a new, non-dilutive capital source for Czech medtech leaders that was largely absent five years ago. Investment Landscape and Regional Competitiveness The distribution of capital in 2025 and 2026 favours those who can demonstrate a "right to grow" through effective capital allocation and the integration of high-growth acquisitions. Although total venture funding in the CEE region remains heavily influenced by a handful of large transactions, the steady flow of seed and seed+ deals in the Czech Republic highlights an ecosystem that is deep and resilient. Fund/Investor FOCUS AREA NOTABLE INVESTMENT i&i Biotech Fund Academic Spin-offs, Biotech, Medtech Casinvent Pharma JIC Ventures Deep Tech, SaaS, CEE Early Stage Casinvent Pharma Presto Ventures Early-stage B2B and AI Elin.ai Rockaway Ventures AI-driven Disruptors ValkaAI (Interactive Video) DEPO Ventures Angel-led early-stage medtech Kardi AI The emergence of Brno as a secondary but equally powerful hub for life sciences, particularly in oncology and university-driven medtech, complements Prague’s dominance in software-centric healthtech. This regional synergy creates a diverse national portfolio that can weather shifts in specific technological sub-sectors. Conclusion: The Horizon of 2027 and Beyond By 2027, the Czech healthtech and medtech sectors are poised to move from "market expansion" into "market leadership" in several niches, specifically AI-enabled radiology and cardiac monitoring. The 20 leaders profiled in this analysis are not just building companies; they are constructing the "AI factories" and "biotech hubs" that will define European healthcare for the next decade. The core challenge for these leaders moving forward will be navigating the fragmented global landscape. While optimism remains high, with 75% of medtech executives confident in their financial outlook for 2026, this confidence is tempered by geopolitical tensions and pricing pressures. The successful Czech leader of 2027 will be one who adopts an "agile operating model," builds "robust external partnerships," and continues to unite technical discovery with patient care. As the industry matures beyond the initial AI hype toward measurable productivity, the Czech Republic’s commitment to scientific rigor and regulatory compliance positions it as one of the most promising tech hubs in Europe. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Portuguese HealthTech and MedTech Leaders Evolutionary Dynamics of the Portuguese Healthtech Ecosystem: A Comprehensive Analysis of 20 Emerging Leaders and Technological Frontiers The Portuguese healthtech and medtech landscape has reached a state of systemic maturity, transitioning from a localized cluster of academic spin-offs to a formidable international player in precision medicine, digital surgery, and biotechnology. By the mid-2020s, the national startup ecosystem recorded a 16% increase in active ventures, totalling over 4,700 companies, of which nearly 70% were founded within the preceding five-year window. This acceleration is not merely numerical but represents a qualitative shift toward high-complexity "Deep Tech" and "Fusion Research," where the barriers between laboratory investigation and clinical implementation are systematically dismantled. The influx of venture capital, reaching €886 million in 2024, a 55% increase over previous years, has provided the necessary liquidity for Portuguese leaders to compete on a global stage, particularly in AI-driven care and sustainable biotechnology. The Strategic Macro-Environment of Portuguese Life Sciences The transformation of Portugal into a European health innovation hub is underpinned by several structural factors. First, the decentralisation of innovation beyond Lisbon and Porto has created a "vibrant innovation corridor" encompassing Coimbra and Aveiro supported by academic anchors and regional funding initiatives. Second, the "Startup Visa" and national funding schemes have established a fertile ground for international talent and capital. Third, the role of institutional "anchors" such as the Champalimaud Foundation and the Institute for Research and Innovation in Health (i3S) has provided the infrastructure for high-risk, high-reward medical breakthroughs. In this environment, leadership is defined by the ability to navigate the "valley of death" between research and commercialisation. The current vanguard of Portuguese healthtech leaders is characterized by a high degree of technical expertise, often holding advanced PhDs or clinical backgrounds, and a strategic focus on export-driven growth. The following sections analyse 20 of these leaders, categorising their influence by technological domain and institutional impact. The Vanguard of AI-Driven Care and Digital Infrastructure The most significant capital injections in the Portuguese healthtech sector have concentrated on Artificial Intelligence (AI) solutions that address clinical labor shortages and diagnostic inefficiencies. Virgílio Bento: Scaling the AI-First Care Paradigm Virgílio Bento, the founder and CEO of Sword Health, represents the apex of Portuguese healthtech entrepreneurship. As of early 2026, Sword Health reached a Series Junior post-money valuation of $4.36 billion, positioning it as one of the most valuable private healthtech companies globally. Bento’s strategic vision centers on shifting healthcare from a "human-first" to an "AI-first" model, a transition necessitated by the global shortage of clinical professionals. Under Bento's leadership, Sword Health has expanded its scope from musculoskeletal (MSK) therapy to comprehensive mental health support with the launch of "Mind" in 2025. This platform utilises a proprietary wearable device, the M-band, to detect early biomarkers of depression and anxiety, enabling proactive outreach by clinicians. Bento’s execution has successfully attracted major international investors, including General Catalyst and Khosla Ventures, and the company has reportedly saved clients nearly a billion dollars in unnecessary healthcare costs by preventing avoidable surgeries. His stated goal of pursuing an initial public offering (IPO) by 2028 reflects a long-term commitment to rebuilding care delivery through foundational AI research. Tiago Cunha Costa: Revolutionising Diagnostic Interpretation Tiago Cunha Costa, founder and CEO of BloodFlow, is addressing a systemic bottleneck in hospital workflows: the interpretation of laboratory results. Founded in 2024 and based in Lisbon, BloodFlow utilises an AI-powered platform for automated blood test interpretation. Costa, a former high-performance swimmer, identified the inefficiency of manual data analysis during his athletic career, where raw data often lacked the clinical context necessary for immediate action. BloodFlow’s "FlowCore" technology is distinguished by its native integration within Electronic Health Record (EHR) systems using HL7 FHIR standards. This approach ensures data sovereignty, as clinical data is processed entirely on-premise without transferring patient information outside the provider's infrastructure, a critical factor for regulatory compliance and physician trust. In 2025, Costa secured a €1.2 million seed round from 3xP Global, enabling the company to scale its "invisible automation" across European markets. José Bastos: Defining the Digital Front Door José Bastos, co-founder and CEO of knok healthcare, has been a central figure in the maturation of Portuguese telemedicine. knok operates a "Digital Front Door" strategy, connecting patients, providers, and healthcare professionals through a seamless digital interface. Supported by Armilar Venture Partners, Bastos has steered the company toward late-stage VC rounds, focusing on the integration of digital health solutions into the current frameworks of major healthcare providers. His leadership at knok reflects a broader shift toward patient-centric platforms that prioritise accessibility and motivation throughout the recovery journey. Henrique Martins: Architect of Digital Health Strategy Professor Henrique Martins, associated with ISCTE-IUL and UBI, is a pivotal leader in the policy and management of digital health in Portugal. As a digital health consultant and a key voice in the Portuguese eHealth Strategy, Martins bridges the gap between technological possibility and regulatory reality. His work emphasizes the "democratisation of access" and the need for scalable implementation of AI and digital tools in everyday clinical practice. Martins’ influence extends to European policy, where he contributes to discussions on health data hubs and the secondary use of healthcare data. Leader Company/Institution Core Technology Recent Milestone Virgílio Bento Sword Health AI Physical/Mental Therapy $4.36B Valuation (Jan 2026) Tiago Cunha Costa BloodFlow AI Diagnostic Analysis €1.2M Seed Round (July 2025) José Bastos knok healthcare Telemedicine Platform Late VC Round backing (May 2025) Henrique Martins ISCTE-IUL / UBI Digital Health Strategy Lead voice in Portuguese eHealth Strategy Pioneers of the Surgical Metaverse and Advanced Oncology The Champalimaud Foundation has emerged as a global leader in "Fusion Research," particularly in the development of augmented reality (AR) and digital twin technologies for oncology. Pedro Gouveia: Architect of the Surgical Metaverse Dr. Pedro Gouveia, a breast surgeon and researcher at the Champalimaud Clinical Centre, is the primary visionary behind the "MetaBreast" project. Gouveia’s work centres on the "Surgical Metaverse," where AR goggles connected to a health data cloud allow surgeons to superimpose 3D digital twins of tumors directly onto a patient's body in the operating room.This non-invasive, image-guided precision surgery aims to ensure clear surgical margins and reduce the need for repeat operations. Supported by approximately €1.4 million in funding from the Portuguese Resilience and Recovery Plan (PRR), Gouveia has established a Digital Surgery Lab that combines AI, computer vision, and immersive visualization. His leadership is characterised by a focus on "technological literacy" and the removal of cognitive burdens for surgeons, facilitating better-informed decision-making at scale. Markus Büchler: Transforming Pancreatic Cancer Care Professor Markus W. Büchler, an internationally renowned pancreatic surgeon with a record of over 3,000 surgeries, was appointed Director of the Botton-Champalimaud Pancreatic Cancer Centre in April 2023. Büchler’s arrival in Lisbon signifies Portugal’s ability to attract top-tier global talent to lead multidisciplinary teams of surgeons, scientists, and computational biologists. The Centre, funded by a €50 million partnership with the Mauricio and Charlotte Botton couple, is the first in the world to simultaneously integrate research and treatment for pancreatic cancer. Under Büchler’s direction, the Centre utilises a BSL-2-compliant cGMP Gene Therapy Facility to produce CAR-T cells for clinical trials, embodying a translational methodology that brings innovations swiftly into clinical practice. Tiago Marques and João Santinha: Leading Deep Learning in Radiology Within the Marques-Santinha Lab at the Champalimaud Foundation, Tiago Marques and João Santinha lead the development of AI algorithms designed to enhance the accuracy of screening and diagnosis. Their research leverages deep learning to segment fat and fibroglandular tissue in MRIs, which is essential for creating the precise 3D digital twins used in Gouveia's surgical metaverse. By focusing on the "generalisability and robustness" of AI models, Marques and Santinha are accelerating the clinical adoption of these tools across diverse healthcare settings. Albino Oliveira-Maia: Integrating AI into Neuropsychiatry As the Director of the Neuropsychiatry Unit at the Champalimaud Foundation, Albino Oliveira-Maia is at the forefront of applying AI to mental health diagnostics. His work involves exploring how digital neuro-therapeutics and AI virtual assistants can revolutionise medical practice and research in neuropsychiatry. Oliveira-Maia’s leadership is critical in bridging the foundation's strengths in neuroscience with the emerging capabilities of generative AI and medical imaging. Leaders in Biotechnology and Sustainable Nutrition The Portuguese biotech sector is experiencing a renaissance in "Blue Biotechnology" and precision fermentation, addressing global challenges in nutrition and resource sustainability. Ali Osman: Driving Precision Fermentation for Human Health Ali Osman, founder and CEO of PFX Biotech, is a central figure in the development of human milk proteins via precision fermentation. Based in Porto and incubated at UPTEC, PFX Biotech uses engineering biology to produce functional ingredients such as lactoferrin, which is associated with immune system support and iron regulation. In mid-2025, Osman secured a total of €5 million in funding, including a €2.5 million seed round led by Buenavista Equity Partners and a matching €2.5 million grant from the EIC Accelerator. Osman’s team combines deep operational know-how with scientific depth, aiming to make precision fermentation commercially viable at scale. PFX Biotech’s proteins provide a safer, allergen-free alternative for infant formulas and advanced nutrition for the elderly and athletes. 9. Vítor Verdelho: Pioneering Cellular Aquaculture Vítor Verdelho, CEO of Cell4Food, is leading the first Portuguese company dedicated to cellular aquaculture. A spin-off from the University of Porto, Cell4Food is developing technologies to produce cell-based seafood, beginning with octopus cells ( Octopus vulgaris ). Verdelho’s strategy centers on a B2B model, creating and licensing technological platforms for the agri-food industry to support more sustainable and resilient food systems. In early 2026, Cell4Food secured €1.5 million to advance its cell-based seafood innovation, utilizing AI-powered bioprocess modeling to reduce trial-and-error experimentation by 80%. Verdelho’s vision positions Portugal as a relevant player in the European blue transition, dissociating food production from the direct exploitation of marine resources. Bruno Sarmento: Advancing Nanomedicine and Drug Delivery Professor Bruno Sarmento, a researcher at i3S and co-founder of the spin-off Inovapotek, is a global leader in controlled drug delivery systems. In 2026, Sarmento will assume the presidency of the Controlled Release Society, the largest international scientific society in the field. His research focuses on the development of functionalised nanomedicines for diabetes, cancer, and infectious diseases, as well as three-dimensional tissue engineering models for the in vitro validation of these medicines. Sarmento’s leadership at i3S and his involvement in global pharmaceutical nanotechnologies highlight Porto's role as a major hub for translational drug delivery research. Innovators in Immunotherapy and the Fight Against AMR The challenge of Antimicrobial Resistance (AMR) has spurred the development of novel immunotherapies by leaders who are redefining how we treat infectious diseases. Bruno Santos and Pedro Madureira: Neutralising Bacterial Virulence Bruno Santos (CEO) and Pedro Madureira (CSO) are the co-founders of Immunethep, a biotechnology company that originated as a spin-off from the University of Porto. Immunethep’s innovation is based on Madureira’s discovery of a virulence mechanism shared by life-threatening bacteria, such as E. coli and K. pneumoniae . The bacteria release a protein variant called bGAPDH, which shifts the host’s immune response toward an anti-inflammatory state, making the body more susceptible to infection. Under their leadership, Immunethep has developed the "Paragon Novel Vaccine" (PNV), the first in the world to simultaneously prevent infections from five critical bacteria. In 2025, the company received $2 million from CARB-X and additional funding from PACE to advance its monoclonal antibody program. Santos’s background in biological engineering and MBA training complements Madureira’s scientific discoveries, moving Immunethep toward human clinical trials and international partnerships with top pharma companies. Leader Company Focus Area Impact Metric Ali Osman PFX Biotech Precision Fermentation €5M Seed/Grant (2025) Vítor Verdelho Cell4Food Cellular Aquaculture €1.5M Portugal 2030 (2026) Bruno Santos Immunethep AMR Immunotherapy $2M CARB-X Funding (2025) Bruno Sarmento i3S / Inovapotek Nanomedicine President-Elect Controlled Release Society Leaders in Medtech and Bioengineered Materials Materials science and bioengineering in Portugal are producing leaders who are developing autonomous, battery-free medical devices and advanced diagnostic tools. 12 Andreia T. Pereira: Pioneering Batteryless Medical Devices Andreia T. Pereira, a junior researcher at i3S, is at the vanguard of "BioTribo," a research line focusing on energy-harvesting systems for biomedical use. Her work involves using the human body as an inexhaustible energy source to power smart medical devices, such as pacemakers, through triboelectric nanogenerators. Pereira’s research also includes developing graphene-based composites for blood-contacting devices that prevent thrombosis and bacterial adhesion. Her contributions have been recognized with the Maria de Sousa Prize and the L'Oréal Portugal Honor Medal for Women in Science. Alexandre Barros: Advancing Biodegradable Medtech Alexandre Barros, the CEO and Business Development Manager at Hydrumedical (Hydrustent SA), has led the commercialisation of biodegradable urological stents. Hydrumedical's patented technology allows for the creation of the first 100% biodegradable ureteral stent, which avoids the need for a second surgery and reduces treatment costs by 60%. Under Barros’s leadership, the company has expanded into stoma care and infection control lines, achieving international certifications (ISO 13485) and establishing a certified production site in Guimarães. Ricardo Moura: Scaling Anthropometric Ecosystems Ricardo Moura, co-founder and CEO of Wisify Tech Solutions, has built a measurement ecosystem trusted by sports nutritionists and performance teams globally. Wisify’s products, Lipowise and Gripwise, are digital devices for evaluating body composition and muscle strength, connecting hardware and software to monitor frailty and sarcopenia. Moura’s leadership has focused on creating a complete clinical workflow that makes precision measurement accessible and actionable for professionals in five markets. Diana S. Nascimento: Innovating Cardiovascular Regeneration Diana S. Nascimento, an investigator at i3S and professor at ICBAS, is a leader in bioengineered therapies for cardiovascular disorders. Her research focuses on heart repair using piezoelectric materials to drive cardiac regeneration and inhibit fibrosis. Nascimento’s work bridges fundamental and applied research, addressing the formation of fibrosis and the aging of the extracellular matrix after injury, contributing significantly to the field of regenerative medicine in Portugal. Strategists in Digital Health and Professional Efficiency The broader digital health ecosystem in Portugal is shaped by leaders focused on clinical efficiency, professional networking, and long-term ecosystem development. Joana Pinto: Gamifying Physiotherapy Joana Pinto, co-founder and CEO of Clynx, is redefining physiotherapy delivery through gamification. A participant in the 2018 EIT Health InnoStars Awards, Clynx improves the patient experience by supporting flexible, motivating care. Pinto has been recognised as one of Europe's most influential women in the startup space, highlighting the potential of gamified digital health tools to ease pressure on healthcare systems. José Paulo Carvalho: Scaling Remote Patient Monitoring José Paulo Carvalho, founder and board member of Hopecare, is a pioneer in remote patient monitoring in Portugal. His work focuses on integrating digital health into current clinical frameworks, helping patients manage chronic conditions from home. Carvalho’s role as an executive board member at TICE.PT highlights his influence in the Portuguese information and communication technology cluster for health. Cláudio Costa: Leading Clinical Research and Intelligence Cláudio Costa, CEO and founder of ActOne Intelligence & Research, is a key figure in the application of intelligence and data analytics to clinical research. ActOne focuses on providing deep insights that drive decisions in the life sciences sector, reflecting the growing importance of analytics in the Portuguese healthtech landscape. David Magboulé: Facilitating Technology Transfer David Siqueira Magboulé, CEO at LabtoMarket, is a leader in bridging the gap between academic research and commercial applications. LabtoMarket works with researchers and institutions to identify market-ready technologies and facilitate their transition into the healthcare ecosystem. His leadership is essential for the continuous flow of innovation from Portugal's strong academic base to the global market. Filipa Fixe: Steering Corporate Health Innovation Filipa Fixe, as an executive leader at Glintt Global, oversees one of the largest technology and consulting groups in the Iberian Peninsula focused on healthcare. Her work involves managing digital health solutions for hospitals and pharmacies, ensuring that large-scale clinical institutions can adopt and integrate the innovations coming from the startup ecosystem. Fixe’s role is critical for the "robustness and transparency" of healthcare processes at the corporate level. Technical Foundations: A Comparative Analysis of Medtech Innovations The leadership demonstrated by these 20 individuals is deeply rooted in the technical superiority and unique mechanisms of their respective technologies. The following table provides a comparative overview of the core technological drivers for selected leaders. Leader Primary Platform Technical Mechanism Strategic Implication Pedro Gouveia MetaBreast / AR 3D-Digital Twin Superposition Precision surgery; zero repeat procedures Tiago C. Costa FlowCore / AI HL7 FHIR Native EHR Processing Data sovereignty; zero external data transfer Pedro Madureira Immunethep / PNV bGAPDH Neutralization Anti-bacterial therapy without AMR risk Andreia T. Pereira BioTribo / Nanogen Triboelectric Energy Harvesting Battery-free, autonomous implants Vítor Verdelho Cell4Food Cellular Blue Biotechnology Sustainable seafood; resource dissociation Virgílio Bento Sword AI Multi-modal Deep Learning Unlocking $MSK$ and mental health access Institutional Synergy and the "Fusion Research" Model The emergence of these leaders is not an isolated phenomenon but the result of a deliberate "Fusion Research" model adopted by Portuguese institutions. The Champalimaud Foundation and i3S exemplify this by housing surgical services, research labs, and clinical trials under one roof. The Champalimaud Centre for the Unknown: A Catalyst for Metaverse Surgery The architecture and mission of the Champalimaud Centre for the Unknown (CCU) are designed to "bridge the gap between laboratory and clinic". This environment allows leaders like Gouveia and Büchler to test digital surgery solutions in "Immersive Surgical Arenas" that mimic real operating rooms. The creation of a health data cloud infrastructure by CCU scientists ensures that medical data can be transferred and stored securely, virtually via the internet, which is a prerequisite for the commercialisation of medical devices in the surgical metaverse. i3S: A Porto-Based Hub for Bioengineering Similarly, the Institute for Research and Innovation in Health (i3S) in Porto merges three founding institutes (IBMC, INEB, and IPATIMUP) to face aging, infectious diseases, and regenerative medicine. This integrative nature provides leaders like Bruno Sarmento and Andreia Pereira with access to state-of-the-art facilities and a multidisciplinary team of clinicians and researchers. The "Nanomedicines & Translational Drug Delivery" group at i3S, led by Sarmento, is a testament to how institutional solidity fosters international leadership in complex fields like pharmaceutical nanotechnology. The Investment Landscape: 2025 and Beyond The funding trajectory for Portuguese healthtech in 2025-2026 indicates a shift toward "Endurance and Adoption". While previous years focused on rapid digitisation, the current phase prioritises "sustainable technology" and "clinical validation". The Role of Portugal Ventures and 3xP Global Portugal Ventures, the national venture capital company, remains a foundational supporter, managing a portfolio of 20+ life sciences companies and offering pre-seed funding through initiatives like "Call INNOV-ID". The appointment of new leadership for the 2025-2027 triennium focuses on making the institution a "closer and more agile partner" for health and biotechnology startups. Concurrently, private equity firms like 3xP Global are launching dedicated "Health Innovation Funds". Their investment in BloodFlow highlights a focus on "infrastructure-level solutions" that turn routine diagnostics into real-time decisions.This strategic alignment between institutional support and focused private capital is essential for the global expansion of Portuguese healthtech leaders. Ecosystem Maturation: Regional Hubs and Decentralization The decentralisation of the startup scene is a hallmark of Portugal's maturing ecosystem. While Lisbon and Porto are the primary centres, the growth of cities like Coimbra and Aveiro signals a national trend where innovation is no longer confined to the capital. The Porto-Coimbra-Lisbon Corridor The "Porto Region" saw a significant increase in investment volume in 2025, driven by a mix of early-stage activity and scale-up rounds for companies like PFX Biotech and Immunethep. The Biocant Park in Cantanhede (near Coimbra) has provided the ideal conditions for Immunethep to expand its R&D facilities independently. This regional specialisation, Porto for bioengineering and drug delivery, Lisbon for digital surgery and AI, and the Coimbra region for immunotherapy and vaccines—creates a diversified and resilient national healthtech portfolio. Future Outlook: Indicators of Sustained Leadership As we look toward 2027, the success of these 20 leaders will be measured by their ability to achieve several key benchmarks: Clinical Adoption at Scale: Transitioning from research projects (e.g., MetaBreast) to widely implemented medical devices in everyday clinical practice. Regulatory Clearance (CE-marked and FDA-cleared): Achieving medical device certification is a critical goal for leaders like Tiago Costa (BloodFlow) to become the "invisible standard layer" of diagnostics worldwide. Global Commercial Readiness: For biotech leaders like Ali Osman (PFX Biotech), accelerating the path to commercial launch for allergen-free human milk proteins is the next "defining moment" Successful IPOs and Record Exits: Virgílio Bento’s target of an IPO by 2028 will serve as a bellwether for the entire Portuguese healthtech sector, signalling its ability to produce global health leaders at scale. The Portuguese healthtech and medtech ecosystem is no longer in its infancy. It is characterized by leaders who combine scientific depth with entrepreneurial drive, supported by institutions that prioritize translational impact. The integration of AI, augmented reality and precision biotechnology into the clinical landscape is not just a future possibility, it is a transformation currently being enacted by these 20 leaders. As visibility and reliability outperform novelty, the Lusitanian life sciences sector is positioned for long-term endurance on the global stage. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Swiss HealthTech and MedTech Leaders The Macroeconomic and Academic Foundations of Swiss Innovation The Swiss life sciences sector has entered a transformative era in 2025 and 2026, characterised by a fundamental shift from traditional pharmaceutical dominance toward a highly integrated "deep tech" health ecosystem. This evolution is underpinned by a robust venture capital environment that saw high-tech investments rise by 23.9% to CHF 2.9 billion in 2025, despite broader global economic uncertainties and sluggish growth in export-oriented industries. Within this capital influx, the medtech and biotech sectors have emerged as the most resilient pillars, driven by the unparalleled efficiency of the Swiss academic engine, specifically the Swiss Federal Institutes of Technology in Zurich (ETH Zurich) and Lausanne (EPFL). The record-breaking creation of 46 new ventures from ETH Zurich in 2025 serves as a testament to the maturation of the university spin-off model. This model is no longer merely about patent licensing but represents a comprehensive institutional commitment to commercializing research through formalized pathways like the ETH Pioneer Fellowship and the newly launched "Express Licensing" procedure. This procedure, which provides a standardized, negotiation-free license within six to eight weeks in exchange for a modest 2% equity stake, has drastically reduced the barriers to entry for scientific founders. Consequently, Swiss academic institutions now rank among the top ten globally for spin-off value creation, outperforming larger economies on a per-capita basis. However, the ecosystem faces a structural "late-stage gap," where approximately 96% of late-stage capital originates from international sources. This has necessitated a strategic focus on global expansion, particularly into the United States market. The Venture Leaders Medtech program, which selects the "Swiss National Startup Team" for an intensive roadshow in Boston, serves as a critical bridge for these 20 leaders as they transition from pre-clinical prototypes to market-ready clinical solutions. Comparative VC Funding Landscape 2025 The following data illustrates Switzerland's leading position in venture capital efficiency relative to its European peers, highlighting the concentration of capital available for high-growth healthtech ventures. Country VC-Funding (EUR) Inhabitants VC per Capita (EUR) Finland 2,200,000,000 5,621,739 391 Switzerland 3,100,000,000 9,007,798 344 United Kingdom 22,000,000,000 69,931,528 315 Ireland 1,600,000,000 5,356,950 299 Sweden 2,200,000,000 10,701,047 206 Denmark 1,200,000,000 6,023,520 199 Netherlands 3,300,000,000 18,448,775 179 Germany 7,700,000,000 83,644,258 92 The Robotics Renaissance in Interventional Medicine At the forefront of the Swiss medtech revolution is a new generation of surgical robotics companies that leverage soft materials and magnetic control to overcome the physical limitations of traditional rigid instruments. These leaders are addressing high-stakes clinical scenarios, particularly neuro-vascular interventions and complex brain surgeries, where precision at the millimetre scale is non-negotiable. 1. NanoFlex Robotics: Magnetic Navigation for Neurovascular Health NanoFlex Robotics, an ETH Zurich spin-off founded in 2021, represents a paradigm shift in the treatment of stroke and other neuro-vascular diseases. The company's technology is rooted in over 20 years of research from the Multi-Scale Robotics Lab, led by co-founder Bradley Nelson. Under the leadership of CEO Matt Curran, NanoFlex has developed a soft robotic system that enables surgeons to steer specially adapted catheters and guide wires through the intricate vasculature of the brain using remote magnetic fields. The core innovation lies in the transition from manual, friction-dependent catheter manipulation to a magnetic steering system that minimises trauma to the vessel walls. This technology not only simplifies complex procedures but also potentially reduces the radiation exposure for physicians, as the system can be operated from a distance. In 2023, NanoFlex secured USD 12 million in Series A funding, which has facilitated the installation of their first demo systems and the progression toward first-in-human clinical trials. 2. Distalmotion: Democratising Robotic Surgery in Outpatient Settings While giants like Intuitive Surgical dominate the hospital-based soft-tissue robotics market, Distalmotion has identified a critical underserved segment: the Ambulatory Surgery Center (ASC). Their DEXTER® Robotic Surgery System is designed for a high-volume, cost-effective environment, offering a smaller footprint and seamless integration into existing operating rooms. Distalmotion, led by CEO Greg Roche, a medtech veteran with over 20 years of experience, successfully closed a USD 150 million Series G round in 2025. This was followed by a strategic investment from Johnson & Johnson Innovation in early 2026, aimed at accelerating the US adoption of DEXTER for general surgery, gynecology, and urology. The DEXTER system’s unique value proposition is its "hybrid" approach, allowing surgeons to switch between robotic and manual laparoscopic modes instantly, thereby optimizing clinical efficiency in outpatient settings. 3. Clee Medical: Advancing Real-Time Vision in Neurosurgery Clee Medical addresses the "dynamic uncertainty" of the neurosurgical operating room. Traditional neurosurgery relies heavily on static, pre-operative imaging (MRI/CT), which does not account for the "brain shift" that occurs during surgery. Clee Medical’s flagship platform, Neuro Access, integrates ultra-high-resolution real time intra-operative Optical Coherence Tomography (OCT) imaging with AI-powered anatomical navigation. The Geneva-based startup, emerging from the Wyss Center in 2024, is led by CEO Matt Lapinski, who brings extensive experience in building Class III medical device startups in the United States. In early 2026, the company raised seed funding to accelerate its clinical validation program, with the goal of making minimally invasive brain surgery safer and more scalable. Leadership Profile: Surgical Robotics Leader Company Background Strategic Focus Matt Curran NanoFlex Robotics University of Edinburgh; Medical device commercialization Stroke treatment via magnetic soft robotics Greg Roche Distalmotion Sociology and Law; 20+ years in MedTech (Stryker, etc.) ASC expansion and purpose-built robotics Matt Lapinski Clee Medical Engineer; Class III device expert (Medtronic background) Real-time OCT imaging for neurosurgery The Digitalisation of Diagnostics and Preventive Health A major theme in the 2025–2026 cohort is the decentralization of clinical-grade diagnostics, moving specialized testing from centralized hospital labs directly to the point-of-care or even into the patient's home. This trend is powered by sophisticated AI algorithms that democratise expert-level interpretation of medical data. 4. QUMEA: Redefining Patient Safety with Radar-Based AI QUMEA, the winner of the Swiss Medtech Award 2025, has become a benchmark for digital health implementation in institutional care. The company’s technology, developed under CEO Cyrill Gyger, utilizes a contactless 3D radar sensor to monitor patient movement patterns around the clock. Unlike camera-based systems, QUMEA’s approach is entirely anonymous, respecting patient privacy while using AI to analyse movement in real-time. The clinical impact of the system is quantifiable: somatic hospitals implementing QUMEA have reported an average reduction in falls of 74%. This proactively preventative standard of care has led to broad implementation across over 130 institutions in the DACH region and the Nordics. In October 2025, the private equity firm GRO made a strategic investment in QUMEA to accelerate its international expansion, signalling the maturity of the company's business model. 5. Scanvio Medical: AI-Assisted Ultrasound for Endometriosis Scanvio Medical is addressing one of the most significant diagnostic gaps in women's health: endometriosis. Currently, the average delay for an endometriosis diagnosis is 8 to 12 years, primarily because identifying the condition via ultrasound requires rare, high-level expertise. Scanvio, an ETH Zurich spin-off founded in 2024, is developing a real-time AI assistant that guides clinicians through standard pelvic ultrasound examinations to identify signs of the disease. Led by CEO Stefan Tuchschmid—who previously scaled VirtaMed into a global leader in surgical training—Scanvio secured USD 3.4 million in a seed round in 2025. The platform leverages algorithms developed during CTO Dr. Fabian Laumer’s PhD research, aiming to democratise expert-level ultrasound diagnostics for gynaecology practices worldwide. 6. Testmate Health: Democratizing Sexual Health Testing Testmate Health is positioned to tackle the "silent epidemic" of sexually transmitted infections (STIs) by providing a product aligned with urgent public health initiatives. Their diagnostic solution offers a low-barrier, rapid testing platform that can be used outside of traditional clinical settings, encouraging regular screening and faster treatment cycles. By combining molecular diagnostic accuracy with consumer-grade ease of use, Testmate Health represents the vanguard of "home-first" clinical diagnostics in Switzerland. 7. Avelo: Breath-Based Pathogen Collection Avelo is revolutionizing the diagnosis of lower respiratory tract infections through its innovative breath collection device.Traditional methods for diagnosing pneumonia often involve invasive procedures or the collection of sputum, which can be difficult for many patients. Avelo’s hand-held device captures pathogens directly from a patient’s breath, enabling a non-invasive and rapid pathway to identifying the cause of infection. This technology is critical for antimicrobial stewardship, as it allows clinicians to differentiate between viral and bacterial infections at the point-of-care, ensuring that antibiotics are only prescribed when necessary. 8. IMAI MedTech: Automated 3D Histology IMAI MedTech, a Schlieren-based startup founded in 2024 by CEO Francesca Catto and Robert Axelrod, is bringing three-dimensional visualisation to the field of pathology. Conventional histology relies on thin 2D slices of tissue, which can miss critical diagnostic markers and lead to misinterpretation. IMAI has developed an automated platform for fast tissue processing and 3D visualisation, vital for both clinical and research use in oncology diagnostics. The team, which includes CTO Sascha Brun, plans to use their CHF 150,000 Venture Kick award to finalise their hardware prototype and scale AI features for automated cell counting and cancer mass measurement. Key Performance Indicators: Diagnostic Leaders Startup Metric Impact/Result QUMEA Fall Reduction 74% average reduction in falls Scanvio Medical Diagnostic Delay Aims to reduce 8-12 year wait for endometriosis Evismo Network 1,500+ specialists using remote diagnostics IMAI MedTech Market Size Targeting USD 16B histology/cytology market Neuro-technology and the Restoration of Sensation The Swiss neuro-technology sector has moved beyond simple diagnostic tools toward therapeutic devices that interface directly with the nervous system to restore lost functions. These "bio-digital" leaders are combining material science with artificial intelligence to treat disorders ranging from epilepsy to peripheral neuropathy. 9. Neurosoft Bioelectronics: Soft Stretchable Brain Interfaces Neurosoft Bioelectronics is pioneering the use of soft, stretchable materials for neural implants. Led by CEO and co-founder Dr. Nicolas Vachicouras, the company addresses the mismatch between rigid electronic electrodes and the soft tissue of the brain. In February 2025, Neurosoft achieved a major milestone with the successful testing of its high-channel-count interface in human patients during epilepsy surgery at University Medical Center Utrecht. The company's primary focus is the restorative treatment of tinnitus, epilepsy, and other neurological disorders. In early 2026, Neurosoft entered a multiyear partnership with Science Corp, granting them access to a world-class clinical-grade neural engineering platform. This collaboration is expected to aggressively accelerate the clinical adoption and commercial scaling of their pioneering neural data platform. 20 Future Swiss HealthTech and MedTech Leaders 10. MachineMD: Neuro-Ophthalmology via VR and Ocular Biomarkers MachineMD, a Swiss-American medical device company based in Bern, is revolutionizing brain diagnostics using ocular biomarkers. Their platform, Neos, is a VR-based neurodiagnostic tool that enables fast, scalable, and non-invasive brain assessments by tracking eye movements. CEO Dominic Senn leads a team that includes medical director Mathias Abegg and CTO Dominik Brügger. In October 2024, Neos became the first VR headset to obtain EU MDR Class IIa certification for the assessment and diagnosis of ophthalmic and neurological disorders. This certification is a significant enabler for precision medicine, supporting research and diagnosis for people with Parkinson's, multiple sclerosis (MS), and other rare diseases.MachineMD’s technology addresses the shortage of neuro-ophthalmologists by providing highly reproducible, objective data that can be interpreted by a wider range of healthcare professionals. 11. Mynerva: Tactile Restoration for Peripheral Neuropathy Mynerva, an ETH Zurich spin-off, won the Venture Awards Grand Prize in June 2025 for its work in restoring the sense of touch. Led by CEO Greta Preatoni, the company focuses on medical technology for patients suffering from sensory loss, particularly those with diabetic peripheral neuropathy. By providing artificial tactile feedback, Mynerva’s technology helps patients regain balance and reduce the risk of falls, a critical complication of neurodegenerative diseases. 12. Biped Robotics: AI-Powered Mobility for the Visually Impaired Biped Robotics has developed an AI-powered wearable that assists blind and visually impaired individuals in navigating safely in real time. The device uses 3D cameras and spatial audio to identify obstacles and provide directional guidance, essentially acting as a "co-pilot" for human mobility. Ranked 95th in the 2025 Top 100 Swiss Startup Award, Biped represents a broader trend of applying computer vision and edge-AI to enhance the quality of life for those with physical or sensory impairments. Advanced Therapeutics, Vaccines and Bio-Engineering The Swiss life sciences sector continues to push the boundaries of biotechnology, with a specific focus on antibacterial resistance, targeted drug delivery, and orthopedic restoration. These future leaders are leveraging synthetic biology and advanced material science to create treatments that were previously impossible. 13. Baxiva: Leading the Fight Against E. Coli Baxiva, an ETH Zurich spin-off incorporated in 2025, is developing a first-in-class vaccine designed to prevent diseases caused by Escherichia coli (E. coli), such as urinary tract infections. Led by CEO Dr. Giorgia Greter and CSO Dr. Tim Keys, the company combinesScientific innovation in bacterial vaccines with industrial experience in conjugate development. In early 2026, Baxiva joined the CARB-X portfolio, receiving USD 3 million to advance its vaccine candidates toward clinical development. Their multivalent glycoconjugate platform addresses a critical unmet need in infection prevention, offering a viable alternative to the overuse of antibiotics. Baxiva’s success highlights the power of Swiss glycobiology research in addressing global health threats like antimicrobial resistance. 14. Flowbone: Strengthening Bones with Injectable Hydrogels Flowbone addresses the massive public health burden of osteoporosis through its injectable, "bone-seeding" gel. The technology, which provides a local strengthening of fragile bones, is designed to prevent fractures before they occur.Under the leadership of project leaders like Peyman Karami and Valérie Malfroy Camine, Flowbone exemplifies the trend toward "minimally invasive preventative orthopaedics," where early intervention can prevent the catastrophic consequences of hip and spinal fractures in the elderly population. 15. Positrigo: Decentralized Nuclear Imaging for Brain Health Positrigo is democratizing advanced functional brain imaging through its ultra-compact PET system, NeuroLF. Founded in 2018 as an ETH Zurich spin-off by CEO Jannis Fischer and COO Max Ahnen, Positrigo aims to make precision brain scanning available to everyone at a fraction of today's cost. In 2025, the company raised CHF 7 million in a round led by HealthCap to boost production and commercialization. In early 2026, Positrigo was named a finalist for the Swiss Medtech Award 2026. Their "BrainPET Accelerator Program," launched in the US in 2026, enables neurology practices to offer advanced PET imaging directly within their offices, significantly improving access to diagnostics for Alzheimer's disease and other neurodegenerative conditions. 16. Myria Biosciences: GEMMS for Transformative Small-Molecules Myria Biosciences, led by CEO Steven Schmitt, is an ETH Zurich and HZI/HIPS spin-off that pioneers drug discovery through Genetically Engineered Modular Molecule Scaffolds (GEMMS). Their platform integrates high-throughput synthetic biology with AI-driven design to develop therapies that exceed the constraints of nature. Myria represents the "tech-bio" frontier, where synthetic natural products are smartly engineered for biological production, paving the way for next-generation small-molecule therapies. Scientific Leadership Profile: Therapeutics and Bio-Engineering Leader Company Domain Expertise Core Innovation Giorgia Greter Baxiva Microbiology/Vaccines E. coli glycoconjugate vaccine platform Steven Schmitt Myria Biosciences Synthetic Biology GEMMS for AI-driven drug discovery Jannis Fischer Positrigo Particle Physics (ETH PhD) Compact NeuroLF PET system Valérie Malfroy Camine Flowbone Orthopedic Bio-Engineering Injectable "bone-seeding" hydrogel Systems of Care and Structural Medtech Innovation The final group of future leaders focuses on the hardware and software "infrastructure" of healthcare, optimising existing clinical workflows and improving the accuracy of standard surgical procedures. 17. Evismo: Intelligent Remote Diagnostics for the Heart Evismo is a Zurich-based healthtech company that has combined state-of-the-art sensor technology with AI-based software to revolutionise remote cardiac diagnosis. A finalist for the Swiss Medtech Award 2025, Evismo provides a suite of diagnostic services: CardioFlex for cardiac arrhythmias, RespiFlex for sleep apnea, and StressCheck for analyzing stress and burnout. Their model facilitates early detection directly in the general practitioner's practice, ensuring that patients receive timely interventions before condition escalation. 18. Bonebridge: Quality-Driven Musculoskeletal Trauma Solutions Bonebridge focuses on high product quality and ease of clinical application in the field of musculoskeletal trauma. As a finalist for the Swiss Medtech Award 2025, Bonebridge addresses various clinical challenges related to trauma surgery through innovative hardware and a focus on "Swissness" in manufacturing. Their collaborative approach with globally recognised partners ensures that their developments contribute sustainably to the improvement of patient care in high-stress surgical environments. 19. HeroSupport: Personalizing Radiotherapy with 3D Printing HeroSupport, founded in 2023, specializes in patient-specific immobilization for radiation therapy. Their flagship product, VENUS SHELL, is a 3D-printed immobilization shell designed for breast radiotherapy in a prone position. This patient-specific approach ensures that the target tissue is precisely positioned during every treatment session, improving clinical outcomes and patient comfort. HeroSupport was awarded the "most investable startup" title at the Swiss-Italian Startup Award 2025, reflecting the high market interest in personalised oncology support tools. 20. PeriVision: AI-Driven Visual Function Assessment PeriVision, ranked 69th in the 2025 Top 100 Swiss Startup Award, combines AI, VR, and cloud technology to build next-generation systems for understanding visual function. Their solution allows for the fast and objective assessment of the visual field, which is critical for monitoring chronic conditions like glaucoma. By utilising portable VR headsets, PeriVision enables testing outside of the traditional darkened clinical room, making diagnostic screening more accessible and efficient for both patients and providers. The Future Roadmap for Swiss Medtech and HealthTech As the Swiss ecosystem moves toward 2030, several macro-trends will define the success of these 20 leaders. The first is the integration of "Foundation Models" and "Multimodal AI" into clinical workflows. This involves combining electronic health records (EHR), medical imaging, and sensor data from wearables like those of QUMEA or feedback intuitive to provide a holistic, predictive view of patient health. Secondly, the "Late-Stage Gap" will continue to drive M&A activity. The acquisitions of Araris Biotech for USD 1.1 billion and OBaris by Johnson & Johnson in 2025 serve as a powerful validation of the Swiss academic spin-off model, yet also highlight the reality that most Swiss high-tech ventures will ultimately be scaled by international giants. Finally, the focus on "Modernizing the Mechanics of Care" will remain a priority. This includes the rollout of digital hospitals and smart infrastructure, such as the smart hospital platforms being developed by Stryker and others, which will serve as the host environment for many of the Swiss robotic and AI innovations discussed. Anticipated Milestones (2026–2030) Year Company Milestone Type Description 2026 Positrigo Award/Finalist Swiss Medtech Award Ceremony (June 10, 2026) 2026 Clee Medical Clinical Initiation of first-in-human neurosurgery studies 2026 Distalmotion Regulatory Expected FDA gynecology/general surgery expansion 2026 Baxiva Preclinical Advance vaccine project toward clinical phase with CARB-X 2027 Roche Regulatory Planned filing for afimkibart (bowel disease) Conclusion: Synthesising the 2025-2026 Swiss Leadership The 20 future leaders profiled in this report represent a sophisticated synthesis of Switzerland’s long-standing excellence in precision engineering and its rapid ascent in the fields of artificial intelligence and biotechnology. The recurring theme across these companies, whether in the soft robotics of NanoFlex, the AI-diagnostics of Scanvio, or the glycobiology of Baxiva, is the translation of deep scientific insight into tangible patient benefit. The robust support system provided by institutions like ETH Zurich, EPFL, Venturelab, and Venture Kick has created a uniquely reliable signal for global investors. While the path to global scale often leads through the United States, as evidenced by the 2025 Venture Leaders Medtech Boston roadshow, the intellectual and technological "Swissness" of these ventures remains their primary competitive advantage. By 2030, the innovations of these 20 companies are poised to be integrated into the standard of care worldwide, solidifying Switzerland’s position as a global epicentre for the future of healthcare. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk